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Abstract 
Radiotherapy has been used to treat meningiomas for decades, both in the 
primary setting when resection is not possible and as an adjunct to surgery in 
recurrent/ high grade disease. Newer radiotherapy planning and delivery 
techniques aim to optimise tumour control and minimise long-term toxicities. 
The purpose of this thesis was to explore the feasibility and potential for the use 
of advanced radiation planning and delivery techniques to treat meningiomas.  
In a prospective observational study of intensity modulated radiotherapy (IMRT) 
in fifty patients I demonstrated that IMRT is feasible and provided excellent 
dosimetric parameters. Medium term meningioma control rates were >90% in 
benign disease. Objective measures of toxicity were low. Visual symptoms 
improved in 38.5% of patients.   
In a pilot study of ten patients I showed that simultaneous 68Ga DOTATATE 
PET/MRI can be utilised in meningioma radiotherapy planning. Baseline levels 
of interobserver variability in target volume definition between three Observers 
using CT/MRI alone were very high (mean target volume conformity levels of 
0.31-0.34). Levels of agreement improved only 4-5% with the addition of PET 
and there was negligible difference in contouring between standard PET(CT) 
and simultaneous PET(MRI). 
In a planning study of ten meningiomas I did not find a notable advantage for 
proton therapy (non-intensity modulated) over IMRT. The high quality of the 
IMRT plans left little room for improvement and range uncertainty restricted 
exploitation of proton dose deposition characteristics.  
In my review of the first six patients treated with the radionuclide 177Lutetium 
DOTATATE for advanced progressive meningioma, tumour growth rates were 
found to slow, but there was generally disease progression during treatment.  
In conclusion, advanced radiation techniques for meningioma treatment are 
feasible and can confer clinical benefit. However, advances in technology do 
not necessarily translate into therapeutic gains. Careful prospective evaluation 
is required to ensure their optimal use. 
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1 Chapter 1: Introduction 
 
 
1.1 Background 
Meningiomas are the most common non-glial brain tumour. Although the 
majority are benign, they can cause significant morbidity by pressure effects on 
critical structures and high grade disease limits life expectancy. Whilst surgery 
is the mainstay of therapy, radiotherapy is often used to treat the more 
challenging cases where resection is not possible or the tumour has recurred. 
Newer radiotherapy planning and delivery techniques aim to optimise tumour 
control whilst minimising long-term toxicities. However, the evidence base for 
radiotherapy use is largely based on retrospective case series.    
This thesis describes my research methodology and results obtained during my 
MD(Res) studies into advanced radiation techniques to treat meningioma. It 
begins with a comprehensive overview of meningiomas and describes the 
current role of radiation therapy in their management. In particular the many 
controversies surrounding radiotherapy due to the lack of prospective study are 
highlighted. The lack of available treatment options for progressive disease and 
targets for study are also discussed.   
 
1.2 Epidemiology 
Meningiomas constitute approximately 25% of all histologically diagnosed 
primary intracranial neoplasms[1]. In a United States (USA) population-based 
study new symptomatic tumours were encountered annually in 2.0/100000 of 
the population and found incidentally on neuro-imaging in 5.7/100000, giving an 
overall incidence of 7.7/100000[2]. Prevalence of histologically-confirmed 
meningioma in the USA is 97.5/100000[3]. Screening and autopsy studies have 
reported that 1-3% of the adult population have a meningioma[4, 5] highlighting 
that most remain “silent” and asymptomatic. Incidence is increasing, but this 
may reflect increasing identification of hitherto silent disease with an increase in 
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the frequency of neuro-imaging for other reasons, advances in imaging quality 
and more robust reporting rather than a true increase in tumour frequency. 
 
1.3 Pathology 
 
1.3.1 Anatomical Features and Grade 
Meningiomas arise from arachnoidal cap cells that are usually present in small 
clusters in the leptomeninges. They are firmly attached to the dura, usually in 
the skull base, convexity, and parasagittal regions or occasionally in 
intraventricular regions.  Approximately 90% are intracranial and the other 10% 
arise in the spine[6]. Most commonly, meningiomas are superficially based 
globular masses that compress rather than invade adjacent brain tissue. 
Extension of the meningioma itself into dura and bone is not unusual – a feature 
that is not necessarily indicative of higher grade tumours. Conversely, brain 
invasion does indicate non-benign disease. 
Meningiomas represent a diverse group of tumours with a range of subtypes 
and behaviours. Since the first World Health Organisation (WHO) classification 
of meningiomas in 1979, three grades (I-III) represent the spectrum of benign to 
increasingly malignant behaviour. Histological grade indicates the likelihood of 
disease recurrence and prognosis. As such, tumour grade has significant 
implications for patient management.  
Morphological subtype is one aspect of the grading system. Initially seven 
morphological subtypes were recognised, but further subtypes have been 
identified in the intervening period and the current 2007 classification 
recognises 15 distinct classes as shown in table 1.1.  
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Table 1-1 WHO Classification of Meningioma Subtypes 
Grade 1 Grade 2 Grade 3 
Meningothelial Clear cell Rhabdoid 
Fibrous (fibroblastic) Choroid Papillary 
Transitional (mixed) Atypical Anaplastic (malignant) 
Psammomatous Brain-invasive  
Angiomatous   
Microcystic   
Secretory   
Lymphoplasmocyte-rich   
Metaplastic   
 
A new feature in the 2007 grading system is that the presence of brain invasion 
in an otherwise benign meningioma automatically raises it to grade 2 
classification.  Additionally, any one or more of the following characteristics 
identify higher grade meningiomas: 
Atypical meningiomas (grade 2): 
 ≥4 mitoses/10 high powered field (HPF) 
presence of at least 3 of the following characteristics:  
 sheeting architecture 
 hypercellularity 
 macronuclei 
 small cell formation 
 spontaneous necrosis (not induced by embolisation or radiation) 
Anaplastic meningiomas (grade 3): 
 ≥20 mitoses/ 10HPF 
 Focal or diffuse loss of meningothelial differentiation at light microscopy 
resulting in sarcomatous, carcinomatous or melanoma-like appearance 
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The automatic upgrading of otherwise benign meningiomas to grade 2 disease 
if there is brain invasion has substantially increased the proportion of tumours 
that are classified as grade 2. Such meningiomas have the same rates of 
recurrence and mortality as other grade 2 meningiomas[7]. Using the 2007 
classification approximately 75% of meningiomas are grade 1(previously 
approximately 90%), 18-22% are grade 2 and <5% grade 3[7].  
 
1.3.2 Proliferation Markers 
Although not currently a feature of the WHO grading system, markers of 
proliferation are often assessed on pathology specimens. MIB-1 is a 
monoclonal antibody directed at Ki-67, an important cellular marker of 
proliferation. Immunohistochemical staining for MIB-1 correlates with 
meningioma grade: 0.7%-2.2% for benign, 2.1%-9.3% for atypical and 11.0%-
16.3% for anaplastic meningiomas [8]. Several studies have advocated the use 
of such proliferation markers as predictive markers of tumour recurrence [9-12], 
whereas others have found limitations in using these mitotic markers to indicate 
likelihood of recurrence [13-15]. Among completely resected benign 
meningiomas, a MIB-1 index ≥3% was associated with a significantly shorter 
time to recurrence and the authors suggested that this could potentially identify 
a group who would benefit from post-operative radiotherapy [16]. 
 
1.4 Genetic Abnormalities 
 
1.4.1 Tumour Initiation 
The most common genetic abnormality in sporadic meningioma involves the 
NF2 tumour suppressor gene on chromosome 22 [1]. This encodes the tumour 
suppressor protein merlin (also known as schwannomin) that is found 
predominately in Schwann cells and plays a role in controlling cell shape, 
movement and communication between cells. Loss of heterozygosity of the NF2 
gene occurs in 40-70% of spontaneous meningiomas and almost all NF2 
associated meningiomas. NF2 gene mutations in the form of small insertions, 
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deletions or nonsense mutations affecting splice sites are present in up to 60% 
of meningiomas [17-20]. Certain pathological subtypes are more likely to carry 
particular NF2 abnormalities, for example, bi-allelic inactivation of NF2 is less 
common in meningothelial meningiomas than transitional or fibroblastic types 
[19]. There is considerable variation in NF2 inactivation between subtypes 
within the same grade: NF2 abnormalities are present in approximately 80% of 
grade 1 fibroblastic and transitional meningiomas but <1% of grade 1 secretory 
meningiomas. Moreover, as the frequency of NF2 mutations across all grades 
of meningioma is generally equal, such mutations appear to be an important 
initiating event in meningioma tumorigenesis rather than acquired with disease 
progression [21]. DAL1, a gene of the same family as merlin, found on 
chromosome 18p has also been implicated in the early development of 
meningioma with reduced expression in approximately 60% of meningiomas 
regardless of grade [20]. There has only been one genome wide association 
study on meningioma and this identified a new susceptibility locus for 
meningioma at 10p12.31 [22]. 
 
1.4.2 Tumour Progression 
Deletion of 1p is the second most common genetic mutation in meningiomas 
and appears to be acquired at disease progression rather than initiation as it is 
associated with higher grade tumours, disease recurrence and progression[23]. 
Loss of 1p is associated with a 30% recurrence rate compared to a 4.3% 
recurrence rate when 1p is intact [17]. 
The question of whether higher grade tumours develop from a lower grade 
precursor continues to generate debate.  From a clinical point of view, most 
recurrent tumours retain the same grade as the original tumour -  large series 
suggest that only fairly rarely are tumours upgraded [24, 25]. This suggests that 
most high-grade meningiomas occur de novo, at least when they are 
macroscopically detectable. However, at a cytogenetic level, malignant 
progression appears to be associated with a stepwise cumulative acquisition of 
chromosomal aberrations which creates a more aggressive subclone with a 
greater growth advantage [26, 27]. Grade 2 meningiomas generally maintain 
the genetic abnormalities found in grade 1 disease, whilst commonly showing 
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additional chromosomal losses (1p, 6q, 10, 14q, 18q) and gains (1q, 9q, 12q, 
15q and 20). Similarly, the aforementioned abnormalities are usually present in 
anaplastic tumours with additional loss of 9p and 17q amplification [28, 29].  
The overall number of chromosomal irregularities as detected by FISH 
correlates to invasive growth potential, tumour recurrence, and MIB-1 
proliferation index [30].  
Inactivation of various tissue inhibitors of matrix metalloproteinases, 
upregulation of several oncogenes including c-sis (22q) and STAT3 (17q), and 
signalling dysregulation of pathways such as the wingless (Wnt) pathway with 
alterations of E-cadherin and beta-catenin proteins, and the hedgehog pathway 
have been have all been found to play important, and perhaps complementary 
roles in meningioma development, progression, and recurrence [23, 20]. Figure 
1.1 depicts the proposed genetic evolution of meningiomas. Considerable work 
is required to establish whether an individual’s genetic tumour profile and 
proliferation indices should be incorporated into management decisions and 
whether targeted therapeutic strategies have a role in the treatment of 
progressive disease.   
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Figure 1-1 Proposed stepwise progression of meningioma [29] 
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1.5 Prognosis 
 
1.5.1 Recurrence 
Recurrence rates at 5 years after complete removal are approximately: 3-20% 
for grade 1, 38-50% for grade 2 and 33-78% for grade 3 meningiomas[31, 6, 32, 
3]. These figures correspond to the pre-2007 grading system and therefore we 
may see a grade migration effect with lower recurrence rates in grade 1 
tumours and higher recurrence rates for grade 2 disease. 
 
1.5.2 Survival 
Despite being the most common type of brain tumour, registry data regarding 
survival in patients with meningioma is obscured because they are largely 
considered benign. As a result they are often poorly coded and excluded from 
registries. Data from the SEER database (2004-2007) for 6737 patients with 
histologically confirmed benign meningiomas showed 3 year overall survival 
rates of 92.4% [33]. Most of these deaths are likely unrelated to the meningioma 
as a negligible death rate at 3 years in relation to a benign disease would be 
expected. Longer outcome data and disease-specific survival would provide 
more valuable information. For higher grade tumours, in the US National 
Cancer Database (1985-1992), five year overall survival rates of 75% for 
atypical (grade 2) and 55% for malignant (grade 3) meningiomas were recorded 
[31]. In this analysis, disease recurrence was a clear adverse prognostic factor 
for morbidity and mortality [31].  
Other reports are from institutional case series. Yang et al reported a mean 
overall survival of 142.5 months and a mean progression-free survival of 138.5 
months for atypical meningiomas compared with a median overall survival of 
39.8 months and a median progression-free survival of 32.2 months for 
malignant meningiomas. They also reported that 1.8% of 1098 patients in total 
experienced progression of tumour grade from their original tumours and that 
these recurrent higher grade tumours carried a worse prognosis than de novo 
higher grade disease [34]. Pasquier et al reported 5-year survival rates of 
67.5% and 60% for grade 2 and 3 meningiomas respectively with corresponding 
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5-year progression-free survival rates of 62% and 48% [35]. Durand et al 
reported 5- and 10-year overall survival rates of 78.4% and 53.3%, respectively, 
for patients with grade 2 meningiomas and 44.0% and 14.2%, respectively, for 
patients with grade 3 meningiomas. Increased age is reproducibly 
demonstrated as an independent adverse prognostic feature in various studies 
[31, 36]. 
 
1.5.3 Metastases 
Distant metastases from meningiomas are extremely rare, occurring in an 
estimated 0.1% of meningiomas and almost always in association with very 
large intracranial tumours [37]. The rarity of extracranial metastases in 
meningiomas may be due to the strong cohesiveness of meningioma cells, and 
extracranial organs may not supply a fertile soil for these tumours. However, the 
reported rate of metastatic spread may underestimate true prevalence as 
meningioma-related metastases are usually asymptomatic and systemic staging 
is not routinely performed. Discovery of metastasis often occurs after 
recurrence of the primary tumour, perhaps on a pre-operative chest x-ray, and 
the interval from first cranial surgery to discovery of metastasis ranges from 4 
months to 15 years [38-41]. The most common secondary site is the lung 
(61%), followed by liver, lymph node, bone, pleura, and mediastinum [42-46]. 
Blood-borne passage of meningioma cells through venous channels is the most 
likely mechanism for distal spread of tumours as even benign tumours 
commonly invade the dural venous sinuses. Alternatively metastases could 
spread to the neuroaxis through the cerebrospinal fluid [47].  It has been 
postulated that surgical manipulation could release tumour from its normally 
cohesive state into the bloodstream or CSF. On the other hand, there is a very 
low incidence of metastasis associated with surgical management and 
metastases have been reported in non-operated cases [46, 48].  
 
Traditional histological markers of malignancy do not appear to reflect 
metastatic potential in meningiomas and metastases often behave in a benign 
nature pursuing a very slow course [43, 45, 49, 50]. Surgical resection of 
metastasis can be curative [51]. 
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1.6 Spinal and Primary Extradural Meningioma 
 
Spinal meningiomas account for 7.5-12.7% of all meningiomas[6, 52]. The 
majority are located within the thoracic region[53]. In women, meningiomas are 
the most common type of spinal tumour, accounting for over 50%, while in men, 
gliomas and nerve sheath tumours are more common[54]. The tumour is 
located completely intradurally in 80-90% of cases, extradurally in 5-14% or 
both in approximately 5%[52, 55]. Unlike cranial tumours, the most common 
histological subtype of spinal meningioma is the psammomatous subtype[52, 
56]. Pain is the most common initial symptom, usually proceeding neurological 
signs by several years and signs of myelopathy are present in most patients at 
diagnosis, with 64% having weakness and 32% nonambulatory [55].   
 
To differentiate from metastatic disease, primary extradural meningioma/ 
ectopic meningioma refers to cases where there is no identifiable primary dural-
based meningioma. However, the lack of consistency across case series in the 
precise definition of such cases obscures accurate incidence evaluation 
(variously quoted at 0.4-2% of meningiomas [57]).  The vast majority occur in 
the orbit, paranasal sinuses, eyelids, parotid or facial bones [58]. Primary 
pulmonary meningioma has also been described in case reports where no 
central nervous system meningioma has been identified, although the exact 
origin such tumours is debated.  Different theories have been advocated, such 
as intrathoracic differentiation of meningocytes/ arachnoid cells or ectopic 
proliferation of arachnoid cells [59-61, 41].  
 
Detailed discussion of non-cranial meningiomas is outwith the scope of this 
thesis. In general, the pathology and natural history of these meningiomas is the 
same as for intracranial lesions with the vast majority being benign in nature. 
Management strategies follow the same principals as for intracranial 
meningioma. 
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1.7 Cranial Meningioma Location and Symptoms 
Meningioma related symptoms relate to tumour location. If close to critical 
structures, morphologically benign tumours can cause devastating disability. 
Table 1.2 details the intracranial sites and frequency within the brain along with 
potential symptoms[62]. In addition to site-specific symptoms, meningiomas can 
also cause seizures, headaches and other symptoms of raised intracranial 
pressure. Multifocality occurs in approximately 2.5% of cases (particularly in 
patients with neurofibromatosis) and meningiomas can grow “en plaque” in a 
diffuse flattened manner [58]. 
 
Table 1-2 Meningioma Site, Frequency and Symptoms 
Site Approximate  
Frequency (%) 
[63] 
Potential Symptoms 
Parasagittal/ falcine 
Anterior 1/3:   (49%) 
Middle 1/3:     (29%) 
Posterior 1/3: (22%)  
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Memory and behaviour changes 
Motor and sensory deficits 
Homonymous hemianopia 
Convexity 19 Motor and sensory deficits, skull 
defect 
Sphenoid ridge 17 Medial – visual loss, cavernous 
sinus related cranial nerve deficits 
Lateral – motor and sensory deficits 
Parasellar 9 Visual field defects (Bitemporal 
hemianopia), hormonal deficits, 
cavernous sinus cranial nerve 
deficits  
Posterior Fossa 8 Drowsiness, ataxia, ocular palsies, 
dizziness, hydrocephalus symptoms 
Olfactory Groove 8 Anosmia, change in mental status  
Meckel’s cave 4 Trigeminal neuralgia 
Tentorium 3 Ataxia, visual loss, diplopia 
Peri-torcular 3 Homonymous hemianopia, 
cerebellar symptoms 
Lateral ventricle 1-2 Hydrocephalus symptoms 
Foramen Magnum 1-2 Nausea, ataxia, dysphagia, motor 
and sensory deficits 
Orbit/ Optic Nerve 
Sheath 
1-2 Visual loss, proptosis 
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1.8 Aetiology 
 
1.8.1 Population Statistics 
Meningiomas show a female preponderance. The male-to-female ratio is 
approximately 1:2 overall, but this varies across age ranges with a maximum of 
3.15:1 in the 35-44 year age group[3, 64]. Female predominance is not evident 
with grade 3 tumours [63]. In a Los Angeles study there was a slightly higher 
incidence of meningioma in African Americans than in other races [65], but 
overall there does not appear to be significant differences in risk according to 
race [58]. The incidence of meningioma significantly increases with age. In the 
over seventies, meningioma comprises 50% of reported brain tumours - a 3.5 
times higher incidence than in those below seventy [66]. Meningiomas can 
occur in children, but comprise only 2.2% of child/ adolescent CNS tumours and 
are associated with neurofibromatosis type 2 (NF2) in approximately 10% of 
cases [67]. In a recent large meta-analysis, there were more grade 3 tumours 
(10%) in the childhood population versus adults [67]. 
 
1.8.2 Genetic 
Meningiomas occur in around 50% of patients with the syndrome of 
neurofibromatosis type 2 (not to be confused with the NF2 gene aberrations 
commonly found in all meningiomas). Approximately 30% of patients with NF2 
have multiple meningiomas [68]. As such, it is important to consider the 
possibility of this syndrome in patients with multiple meningiomas. NF2 is an 
autosomal dominant syndrome caused by inactivating mutations of the NF2 
tumour suppressor gene on chromosome 22q12 that predisposes to multiple 
benign tumours of the CNS. The prevalence of NF2 is approximately 
1/56000[69].  In 50% of cases there is no family history and the condition is due 
to a de novo mutation [68]. The proportion of non-benign meningiomas is higher 
in patients with NF2 syndrome than general. However, there is in-built treatment 
bias in this statistic as only tumours displaying more aggressive features on 
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serial imaging will be removed; the majority of NF2 meningiomas are managed 
conservatively with a surveillance approach [70].  In contrast, the syndrome of 
neurofibromatosis type 1 (NF1) is not associated with an increased incidence of 
meningioma [71]. 
 
There are little data regarding family history of meningioma and risk outwith 
NF2 families. One study reported a standardised incidence ratio of 2.2 for the 
development of meningioma in first degree relatives of patients with 
meningioma [72]. However, there will be an effect of screening bias in families 
where one member has a meningioma. Nevertheless, spouses were unaffected 
and increased risk to first degree relatives was more evident in younger 
meningioma patients suggesting this may be a true finding.   Another registry 
study demonstrated a five-fold increase in risk for persons with two affected first 
degree relatives [73]. No linkage or segregation analysis has yet been 
published for non-NF2 families. 
 
1.9 Environmental 
 
1.9.1 Radiation 
The only clear environmental risk factor for the development of meningiomas is 
exposure to ionising radiation. An Israeli population-based study followed 
patients who had received radiotherapy for tinea capatis between 1948 and 
1960 and found a relative risk of developing meningioma of almost 10[74]. Data 
from atomic bomb survivors showed an increased risk of meningioma but this 
was not found to be statistically significant. However, relative risk did increase in 
patients who had been closer to the site of the explosion [75]. In the Israeli 
study, a higher proportion of meningiomas had malignant characteristics, 
whereas the grade of tumour in the atomic bomb survivors reflected that found 
in the general population.   
The actuarial risk of developing a meningioma after radiation therapy in 
childhood has been reported as 0.53% at 5 years and 8.18% at 25 years [76]. 
The use of radiotherapy to treat head and neck and intracranial tumours has 
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been shown to increase future risk of meningioma [77, 74] with a median time 
from radiotherapy to meningioma diagnosis of 19 years [78]. Whether 
diagnostic level irradiation increases meningioma risk is less clear with studies 
(mainly focusing on dental x-rays) showing conflicting results [79-81].  
 
1.9.2 Hormones 
The female preponderance to meningioma, particularly within the reproductive 
years, suggests a potential hormonal influence. Receptors for oestrogen and 
progesterone are present on many meningiomas, although the functional 
activity of these receptors is not clear and there is no difference in their 
expression between sexes. There are several population studies addressing the 
relationship between meningioma risk and exogenous hormone exposure [82-
86], but there is little data about hormonal drug composition or length of 
exposure. The data available does suggest a small increase in meningioma risk 
in those taking hormonal replacement therapy (HRT): three out of four studies 
that have addressed this question found a positive association with maximum 
odds ratio of 2.2. An association between hormonal contraception use and 
meningioma development was found in only one of three studies that reported 
on this. Conversely, one study found a protective association between hormone 
use and meningioma risk[86]. Conclusions cannot be made regarding whether 
there is an association between meningioma risk and pregnancy/ menstrual 
factors from available data. Again, several population and case-control studies 
have tackled the question [86, 83, 82, 85, 87] but outcomes are inconsistent 
and future research into hormonal associations should link associations with 
different hormonal receptor expression profiles to assess whether certain 
subtypes of tumour may be associated. 
There appears to be an association between breast cancer and meningioma 
risk. A review of the literature reported a relative risk of 1.5-2.0 across studies 
[88]. The studies included were unable to control for potential hormonal risk 
factors and it is likely that, rather than a causal relationship, the association 
between the two illnesses is driven by shared hormonal risk factors. 
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1.9.3 Head Injury 
An association between head trauma and meningioma has been postulated. 
Studies are generally small and results conflicting – positive associations may 
be a result of detection bias as patients who have experienced head trauma are 
more likely to undergo neuro-imaging. The largest cohort of over 200,000 
patients followed up for an average of eight years after hospitalisation for head 
injury showed no statistically significant association after the first year[89]. 
 
1.9.4 Mobile Phone Use 
Whether mobile phone use is associated with increased meningioma risk 
continues to be debated and multiple studies have investigated the question – 
all with methodological deficits [90-92]. Currently, little evidence exists to 
support an association, but there are caveats to this conclusion: meningioma 
event numbers are quite low, follow-up time since mobile phone usage became 
widespread is still relatively short in view of the slow-growing nature of most 
meningiomas and measurement of the degree of phone usage is challenging.  
 
1.10 Diagnosis 
 
1.10.1 General 
Patients may undergo imaging to investigate any of the symptoms detailed in 
Table 1.2 or the meningioma may be found incidentally whilst investigating 
unrelated symptoms. 85% of grade 1 meningiomas exhibit classical imaging 
characteristics [93] and, when combined with their select intracranial dural-
adherent locations, there is usually relative certainty in the diagnosis of 
meningioma without histology.  The majority of patients undergo computed 
tomography (CT) initially followed by magnetic resonance imaging (MRI). 
Current imaging protocols cannot reliably predict the grade of tumour, which is 
only an issue if a non-surgical approach is to be followed. However, even a 
biopsy will not identify small regions of non-benign disease or brain invasion.  
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1.10.2 Computed Tomography 
Meningiomas are extra-axial and usually appear as sharply circumscribed 
lesions with a well-defined tumour/ brain interface. They are usually spherical or 
lobulated but can appear as “en plaque” lesions and can have a broad or 
narrow dural attachment appearing either sessile or pedunculated. They are 
isodense relative to the adjacent brain on nonenhanced images and dense, 
homogenous enhancement is typically seen following intravenous contrast [94]. 
Occasional heterogeneity can be due to the presence of blood products, 
necrosis or other tissue elements. Peritumoural oedema and calcifications have 
been reported in 25-60% of cases [94]. CT is more useful than MRI in 
identifying adjacent bone erosion or associated hyperostosis [95].  
 
1.10.3 Magnetic Resonance Imaging 
MRI is far better at showing soft tissue detail than CT. Meningiomas are 
typically iso- to slightly hypointense compared to the adjacent gray matter on 
non-enhanced T1 and T2-weighted imaging (T1W, T2W) and mildly 
hyperintense on fluid-attenuated inversion-recovery (FLAIR) sequences. 
Following gadolinium contrast, meningiomas typically exhibit homogenous 
enhancement.  
The “dural tail” sign is a term used to describe thickening of the dura adjacent to 
an intracranial neoplasm. It is best seen on T1W post-gadolinium sequences, 
but can also be identified on non-enhanced FLAIR sequences. It was originally 
described in relation to meningioma [96] and was initially thought to be 
pathognomic. However, subsequently it has been demonstrated in the context 
of numerous other pathologies, although is still most commonly associated with 
meningioma [97].  
In addition to routine MRI sequences, MR perfusion images may be useful in 
differentiating between meningioma and schwannoma. Meningiomas are 
generally rapidly perfusing, hypervascular tumours (no blood-brain barrier), 
whereas schwannomas are hypovascular or avascular lesions [98]. Differentials 
in relative cerebral blood volume of a dural-based tumour may distinguish 
meningiomas from metastases [99].  
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Preliminary work suggests that differential cerebral blood volume or diffusion 
weighted imaging may help to distinguish between atypical and typical 
meningiomas[100, 101], but this requires validation.  
 
1.10.4 Imaging Mimics 
The list of other lesions that may resemble typical meningiomas on imaging is 
long: pituitary macroadenomas, craniopharyngiomas, lymphoma, 
plasmacytoma, ependymoma, primitive neuro-ectodermal tumours, glial 
tumours, granulomatous disease, schwannomas, glomus tumours and 
metastases [93]. However, tumour location and other imaging features usually 
allow differentiation. 
About 15% of grade 1 meningiomas and a higher percentage of non-benign 
meningiomas have uncharacteristic imaging appearances [93]. On CT these 
include intracranial tumour, osteolysis, and extracranial extension of the mass 
[102, 103]. MRI features that may be associated with higher grade 
meningiomas include markedly irregular tumour margins, irregular nodules, a 
mushrooming pattern and inhomogeneous enhancement [104]. Malignant 
meningeal tumours such as haemangiopericytomas, sarcomas and metastases 
are the most common differential diagnoses in these cases.  
In general, standard CT and MRI appearances will reliably diagnose a 
meningioma but, if doubt remains, several other imaging modalities can be used 
to distinguish meningiomas from other brain tumours. 
 
1.10.5 MR Spectroscopy 
Magnetic resonance spectroscopy (MRS) complements MRI. While MRI uses 
the signal from hydrogen protons to form anatomic images, proton MRS uses 
this information to determine the concentration of brain metabolites such as N-
acetyl aspartate (NAA), choline (Cho), creatine (Cr) and lactate in the tissue 
examined. Meningioma spectra lack N-acetyl aspartate, have high choline, 
alanine and glutamine levels and low creatine levels. [105-107] Preliminary 
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results indicate that higher grade tumours may have different metabolic 
parameters compared to grade 1 tumours [108].     
 
1.10.6 Nuclear Imaging 
1.10.6.1 Somatostatin Receptors in Meningioma 
It has been known since the 1980s that meningioma cells strongly express 
somatostatin receptors (sstr)[109]. Somatostatin is a widely distributed 
neurotransmitter with a generally inhibitory and anti-proliferative role [110]. Sstr 
are present in many neuroendocrine tumours, but there has been little 
investigation into the function of these receptors in meningiomas. Many 
pathological studies have reported that 100% of meningiomas express sstr[111, 
109, 112-114], but analysis of only around 120 tumour samples have been 
reported in total and one larger study (n=42) reported only 88% positivity[115]. 
There are various methods of evaluating sstr positivity on tumour specimens 
with some degree of variation in test sensitivity.  
Of the five sstr subtypes, expression of subtype 2 (sstr2) is particularly strong in 
meningiomas[113]. Apart from high receptor positivity in the pituitary gland, sstr 
are not present to any degree in the normal brain, but they can be present on 
most other intracranial tumours, albeit to a far lesser extent (pituitary adenoma, 
high grade glioma, metastasis, lymphoma, sarcoma, abscess, chordoma)[116].  
 
1.10.6.2 Octreotide Scintigraphy/ SPECT 
Naturally occurring somatostatin is metabolically unstable and therefore 
synthetic somatostatin analogues have been developed. Octreotide is a 
selective, high affinity ligand for several sstr subtypes. Scintigraphy or single 
photon emission computed tomography (SPECT) using radiolabelled octreotide, 
usually DTPA chelate of 111Indium or 111In to [D-Phe1]-octreotide, are nuclear 
medicine imaging modalities that have been used to identify meningiomas for 
the past two decades, with a reported sensitivity to correctly identify 
meningioma of 84-100%[116-121]. To investigate whether negative imaging 
results were true or false negatives,  Meewes et al, carried out 
immunohistochemical (ICH) evaluation of sstr in meningiomas that had been 
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negative for sstr on pre-operative scintigraphy (8/47 tumours)[112]. They found 
that all tumours were positive for sstr on ICH indicating that the negative 
scintigraphy results were false negative. Smaller tumours were more likely to be 
false negative. They concluded that although meningiomas are devoid of a 
typical blood–brain barrier as they are durally based, a permeability barrier does 
appear to exist that possibly loses its integrity with tumour growth.  
 
In isolation, a positive sstr imaging result has a much lower specificity for 
meningioma as many other tumour types can display sstr. Specificity was as 
low as 27% in one study [122]. However, in the context of other radiological 
features typical of meningioma, SPECT or scintigraphy may aid diagnosis. 
Furthermore, such imaging may identify residual disease following surgery [123] 
and one study has suggested a possible relationship between a decrease in the 
concentration of sstrs at short-term scintigraphic follow-up after radiosurgery 
and early neurological improvement [124].  
 
1.10.6.3 Positron Emission Tomography (PET) 
A major drawback of SPECT is its difficulty in detecting meningiomas with a 
volume <10 mL[121]. PET imaging uses tracers that generate positron decay 
and captures projections on multiple directions. Compared to scintigraphy/ 
SPECT, PET has increased spatial resolution with a higher sensitivity to detect 
and record emitted events.[125] Furthermore, tracer biodistribution can be 
quantified with standardised uptake values (SUV). Although the experience with 
PET in meningioma is still limited, small scale studies indicate that it may be a 
promising molecular imaging modality and, when combined with CT, PET has 
potential to assist with radiotherapy target delineation (see section 1.15.6.1). 
Several PET tracers may be of use in meningioma.  
 
1.10.6.3.1 68Gallium-DOTATOC/ DOTATATE  
In view of the sensitivity of octreotate scintigraphy to highlight tumours with sstr, 
somatostatin analogues for PET imaging and radionuclide therapy have been 
developed. Three compounds are in use, all of which utilise 68Gallium DOTA 
conjugate peptides (DOTATOC, DOTATATE, DOTANOC). DOTA is the 
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chelating agent and TOC, TATE or NOC the somatostatin analogue. 68Ga is 
produced from a generator and does not require a cyclotron. 
 
Most studies using 68Ga DOTA imaging have been in the context of 
neuroendocrine tumours. There does not appear to be a clinically relevant 
difference between the various DOTA conjugate peptides, although DOTATATE 
has a 10 fold higher affinity for sstr2 than DOTATOC and  DOTATOC may have 
higher SUV[126, 127]. 68Ga-DOTATATE has been shown to be more sensitive 
than 111In scintigraphy to identify neuroendocrine tumours[128]. In meningiomas 
68Ga-DOTATOC has been found to have higher sstr binding affinity than its 
SPECT counterpart and to identify much smaller tumours with a very high 
tumour-to-background ratio[129].  
 
1.10.6.3.2 18F-FDG 
18F-FDG is the most widely used PET tracer in oncology, exploiting the 
hypermetabolic state of most tumour cells. However, the high and regionally 
variable FDG uptake in normal brain often makes the delineation of brain 
tumours difficult and FDG-PET must be interpreted in conjunction with fused CT 
or MRI scans. There are increasing indications for 18-F FDG in malignant 
tumours, but the situation is quite different for meningiomas as the majority are 
benign. Some reports do show 18F-FDG uptake to be as high as in normal gray 
matter, but most demonstrate that meningiomas are hypometabolic resulting in 
low tumour-to-gray matter ratio[130-132] .  
 
Glucose consumption appears to reflect aggressiveness of meningiomas and 
may predict probability of recurrence with only high grade tumours 
demonstrating higher than background FDG uptake[132-134]. In this context it 
is unsurprising that a recent study suggests there is no role for 18F-FDG PET in 
tumour delineation or in monitoring response to radiosurgery, although it may 
be valuable for differentiating benign from malignant meningioma[130]. In 
contrast, another group found that the sensitivity of FDG PET to detect high-
grade meningioma was low but suggested that it may predict recurrence and 
survival[134].  
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1.10.6.3.3 Amino Acid and Membrane Component Tracers 
Several tracers are available that are markers of amino acid transport and 
protein synthesis. These accumulate significantly in meningioma. An advantage 
of using radio-labelled amino acids over FDG is the relatively low uptake of 
amino acids by normal brain tissue. 
 
 18-F Tyrosine 
18F-tyrosine has a half-life of 110 minutes and meningioma-to-cortex activity 
ratio of approximately 2.5. One group evaluated the addition of 18F-Tyr PET to 
MRI in the follow-up of previously irradiated skull base meningioma (n = 11, GI 
= 8, unknown = 3). They found the PET positive region to be the same as the 
MR image in 54%, larger than the MR in 38% and smaller in 8%[135]. 
 
 11C Methionine 
11C Methionine also shows high uptake in meningioma with a comparatively 
low uptake in normal brain and a half life of 20 minutes. It better identifies 
meningioma than 18F-FDG[136]. A heterogeneous 11C-MET uptake has been 
found to significantly correlate with tumour Ki-67 index[137]. Gudjonssen et al, 
evaluated 19 patients with this PET tracer pre and post proton therapy of whom 
15 patients had a reduction in PET uptake at 36 months following treatment with 
a mean reduction of 20%[138]. 
 
 1-11C Acetate 
Acetate is readily taken up by normal cells and activated to acetyl-CoA which is 
converted to carbon dioxide and water or amino acids.  Tumour cells 
overexpress the enzyme that converts acetate into fatty acids and these are 
incorporated into intracellular membrane microdomains that are important for 
tumour growth[139]. A study using 1-11C acetate PET in meningioma (n = 22: 
GI = 8, GII = 2, GIII = 2, unknown grade = 10) showed that it was useful for 
detecting and evaluating the extent of meningioma and it could have a role in 
monitoring the response to radiosurgery[130]. However, 1-11C-acetate did not 
assist with radiological grading. The half life is also 20 minutes. 
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 11C Choline 
11C-Choline is a marker of phospholipid synthesis, which is increased in 
malignant tumours. Experience with meningiomas is very limited. A preliminary 
clinical study including 7 meningioma patients (GI = 5, GII = 2) showed that 
11C-choline may better image meningioma compared to 18F-FDG[140]. Half 
life is 20 minutes. 
 
1.10.7 Clinical Evaluation 
Amidst this myriad of complex imaging options the value of thorough clinical 
evaluation should not be diminished. Baseline documentation of neurological 
examination allows follow-up comparison and, depending on the tumours 
location, ophthalmological and auditory examination may be appropriate. If a 
patient is undergoing surveillance clinical follow-up is particularly important as 
symptoms and signs can develop in the absence of significant change on 
imaging. If a patient has undergone treatment, clinical evaluation is important to 
assess potential side-effects of treatments as well as monitor disease. 
 
1.11 Natural History of Untreated Meningiomas 
 
An understanding of the natural history of meningiomas is essential to guide 
treatment decisions, particularly as increasing numbers of incidental tumours 
are being identified on imaging performed for other purposes. Most studies of 
surveillance (all retrospective) evaluated 40-60 cases with mean follow-up 
periods of 29-67 months. Results across the series are reasonably consistent 
with 22-37% of meningiomas showing disease progression on imaging within 
the study period, although patients usually remained asymptomatic and growth 
was usually in the order of 2.4 - 4mm/ year[141-145].  
In view of the complex shapes of meningiomas, volumetric analysis as opposed 
to linear measurement is a more sensitive measure of growth. The largest 
series of conservative management reported tumour growth rates within four 
years from diagnosis in 244 patients with meningioma followed-up for 1 year or 
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more (mean follow up 3.8 years) [146]. 44% of tumours demonstrated linear 
growth, 74% volumetric growth and 26.3% went on to have treatment in that 
time span. Although the proportion who developed symptoms is unclear, many 
patients did not require treatment despite some tumour growth. The significance 
of varying degrees of growth is largely dependent on tumour proximity to critical 
structures (even minor growth may be important if adjacent to a critical 
structure), therefore, the clinical relevance of volumetric assessment is not 
clear. Another 72 patients were followed-up for less than a year and of these, 
22 (30.6%) required treatment in that period. They found the following factors to 
be associated with tumour growth: younger age, absence of tumour calcification 
on imaging, T2 hyperintensity on MRI and associated oedema. Initial tumour 
diameter >25mm, absence of calcification and younger age were associated 
with a shorter time to progression.  
The majority of studies evaluating conservative management have considerable 
limitations that hamper interpretation. Most have small patient numbers and 
limited follow-up periods. Furthermore, patients who undergo surveillance 
usually have their diagnosis of meningioma made on radiological grounds 
alone. As such the grade of the tumour is unknown and some tumours may not 
be meningiomas at all. There is also significant patient selection bias in that 
only patients who are asymptomatic or are deemed low-risk are selected for a 
surveillance policy.  
 
1.12 Treatment Options 
 
1.12.1 Overview 
The aim of treatment for patients with meningiomas is to achieve local control 
with the least possible morbidity. Whilst improving overall survival is a 
considerable objective for higher grade meningiomas, grade 1 tumours in non-
eloquent areas often do not have a significant impact on survival. The optimum 
treatment strategy for each patient depends on tumour factors (location, size 
and grade) and patient factors (co-morbidity, age, performance status, 
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meningioma-related symptoms). First line management options for 
meningiomas include surveillance, surgical resection or radiation therapy.  
There are no randomised controlled trials (RCT) comparing treatment options 
for meningioma and published literature is largely based on retrospective single 
institution case series. Database studies, on the surface, suggest that surgery is 
associated with improved survival. McCarthy et al, evaluated outcomes for 
patients with meningioma pre-1992 in over 1000 US hospitals using the 
National Cancer Database (NCDB). They reported 5-year OS rates of 75% in 
those who underwent surgery versus 49.9% in non-operated patients [31]. A 
more recent analysis of the SEER database [33] evaluated outcomes for over 
12000 patients classified as having non-malignant meningioma (only 55% had a 
histological diagnosis) and reported that 3 year survival rates were 93.4% for 
those who had undergone surgery versus 88.3% in those who had not. It is 
tempting in the absence of a RCT to draw conclusions about treatment efficacy 
from observational databases, but this is not possible as the lack of data held 
within databases, particularly regarding meningiomas, prevents reliable 
adjustment for confounding factors that may well account for the apparent 
survival differences. Low grade meningiomas are unlikely to impact upon 
survival to any degree at three years, therefore differences in short-term 
survival are unlikely to be associated with the treatment modality (unless there 
was significant treatment-associated mortality). Such differences are far more 
likely to be due to inherent patient factors driving treatment decisions; patients 
with short life expectancies due to severe comorbidity would not have been 
offered surgery. Such factors were not addressed in the multivariate analysis so 
these database studies do not reliably compare treatment modalities. 
The various treatment options are discussed below and the current National 
Comprehensive Cancer Network Guidelines for treatment out-with a clinical 
study are summarised in figures 1.2 and 1.3. 
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Figure 1-2 NCCN Guidelines for Treatment of Meningioma at Presentation 
 
 
 
Figure 1-3 NCCN Guidelines for Follow-up and Treatment of Recurrent Disease 
 
Meningioma
Asymptomatic Symptomatic
Small 
(<3cm)
Large 
(>3cm)
Small 
(<3cm)
Large 
(>3cm)
Observe (preferred) 
or 
surgery if potential 
neurologic consequences 
and accessible, followed 
by RT if G3. Consider RT 
for subtotally resected G2 
or 
RT if potential neurologic 
consequences 
Surgery if accessible, 
followed by RT if G3. 
Consider RT if incomplete 
resection and G1/2 
or 
observe
Surgery if accessible, 
followed by RT if G3 
or 
RT
Surgery if accessible, 
followed by RT if G3. 
Consider RT if incomplete 
resection in G1/2 
or 
RT
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1.12.2 Surveillance 
Most meningiomas are benign, slowly progressive tumours. In asymptomatic 
patients a surveillance approach appears safe with serial neuro-imaging until 
the tumour enlarges significantly, grows closer to critical structures or symptoms 
develop[145, 141]. Surveillance may be the treatment of choice for 
asymptomatic patients with incidental small tumours or in patient with significant 
co-morbidities whose symptoms are minimal and unlikely to progress within 
their lifetimes. Surveillance may also be appropriate in the minimally 
symptomatic patient when the tumour is inoperable and primary radiotherapy 
would be the active treatment option, with the aim of delaying the onset of 
potential radiotherapy-related toxicity (including increased second tumour risk). 
However, growth rates on an individual level are unpredictable and care has to 
be taken not to allow patients to develop significant irreversible symptoms prior 
to treatment or allow tumours to become inoperable. If treatment is likely to be 
required within the foreseeable future, it may be preferable to deliver treatment 
upfront depending on the patient’s wishes. When complete surgical resection of 
a tumour appears possible at diagnosis, the extent of growth that would 
preclude complete excision must be taken into account when considering a 
surveillance policy: tumours close to critical structures may only have to 
increase in size a small amount to become inoperable. The NCCN meningioma 
guidelines suggest repeating MRI imaging at 3, 6 and 12 months in untreated 
patients, then 6-12 monthly for 5 years followed by 1-3 yearly indefinitely [147].  
There is limited data regarding the percentage of patients diagnosed with 
meningioma who initially follow a surveillance program. This will be heavily 
dependent on the patient population and the interventional threshold of the 
department. One group report that approximately half of their patients undergo 
upfront surgery and the majority of the rest undergo primary surveillance (a 
small percentage have primary radiotherapy) [148]. 
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1.12.3 Surgery 
Complete surgical resection may be curative. Therefore surgery is the active 
treatment of choice where meaningful tumour resection can be achieved without 
significant predicted morbidity. The majority of patients undergoing treatment for 
meningioma undergo surgery. Surgical removal may permit reversal or 
improvement in neurological deficits caused by the meningioma, but this may 
not always be the case if permanent damage has already occurred. Surgical 
approach depends on the tumour location. Description of surgical techniques is 
covered in detail by Lee [149]. It should be noted that surgical techniques have 
progressed significantly in recent years including the development of intra-
operative image guidance, microsurgery, endoscopic techniques and pre-
operative embolisation.  
In 1957, Simpson introduced a five-grade classification of surgical removal of 
meningiomas that correlated with tumour recurrence [150] (detailed in table 
1.3). Most authors (including the RTOG and EORTC) classify a gross total 
resection (GTR) as Simpson grade 1-3 (abnormal bone may remain).  The 
extent of surgical removal is the most important factor in predicting tumour 
recurrence after resection although Simpson’s work predated statistical 
evaluation for confounding factors and formal histological grading of 
meningiomas (although there is considerable discussion of histology). 
Nevertheless, many surgical series in the decades following Simpson supported 
his findings, with some going on to recommend even more radical surgery [151, 
152]. Clusters of meningioma cells have been observed within the arachnoid 
membranes in the vicinity of meningiomas and in the dura mater 3cm away, 
prompting some surgeons to favour a “grade 0” surgery where at least a 4cm 
margin of dura mater is removed in all directions. Some groups noted a 
significant difference in recurrence rates with or without extensive arachnoid 
membrane removal [153-155].  
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Table 1-3 Simpson Grading of Extent of Meningioma Resection from 1957 
Simpson Grade Description Recurrence/ 
Progression Rate 
I Macroscopically complete tumour removal 
with excision of the dural attachment and any 
abnormal bone 
9% 
II Macroscopically complete tumour removal 
with coagulation of its dural attachment 
16% 
III Macroscopically complete removal of the 
intradural tumour without resection or 
coagulation of its dural attachment or 
extradural extensions 
29% 
IV Subtotal removal of the tumour 39% 
V Simple decompression of the tumour 89% 
 
 
However, whether Simpson’s criteria remains relevant in the era of microscopic 
neurosurgery and embolisation has been questioned, particularly as sensitivity 
to identify subtotal resections at surgery and on subsequent imaging has 
improved. In Simpson’s work and most reports published prior to the 1990s, 
recurrences were identified by clinical symptoms/ signs (or CT at the end of that 
period). Clearly current imaging techniques will more readily identify 
recurrences, although these may not necessarily be of clinical significance. 
Furthermore, base of skull tumours are now far more accessible than in the 
1950s and the benefit of extensive resection is questionable as it is possible 
that tumour in bone may not behave in the same manner as tumours 
elsewhere. In fact the clinical effect of the advances in neurosurgical techniques 
over recent decades is underlined by the fact that overall recurrence/ 
progression rates have not increased despite imaging advances that more 
readily identify very small regions of tumour [156]. Sughrue et al published 5 
year outcomes for 373 patients with grade 1 meningiomas undergoing primary 
surgery between 1991 and 2008 and found no significant differences in terms of 
recurrence or progression free survival between Simpson grades (I-IV) for 
tumours at all sites, and specifically for the base of skull group. However, they 
did not comment on the use of adjuvant therapies[157].  A recent study of 240 
patients reported that those who underwent Simpson grade IV resections had 
higher recurrence rates than those with Simpson grade I-III resections, but that 
there was no difference in recurrence rates for those with Simpson grade I, II or 
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III tumours. However, in patients who had Simpson grade II or III resections, 
those with a MIB-1index of >3% had shorter times to recurrence[16]. 
Clearly, the degree of resection possible is dependent on tumour location. 
Figure 1.4 depicts the difference in surgical accessibility between meningioma 
sites. Tumours of the convexity are more likely to be totally resected and have 
lower recurrence rates than parasellar or base of skull meningiomas. In one 
retrospective study of 225 patients, total resection rates were 96%, 58% and 
28% for convexity, parasellar and sphenoid ridge tumours respectively which 
corresponded to 5 year progression rates of 3%, 19% and 34%[6]. The highest 
recurrence rates have been quoted in the skull base with 10-year recurrence 
rate post-surgery for tumours which invade the medial sphenoid wing and 
cavernous sinus of 60-100% [158].  
 
 
Figure 1-4 Tumour location and surgical potential. a) large convexity meningioma, 
GTR possible; b) small cavernous sinus meningioma, no meaningful resection possible 
due to proximity of critical vessels/ nerves. 
 
A balance must be struck between the morbidity associated with attempted total 
resection and potential for meningioma-related morbidity associated with 
progressive disease. Even today few would argue with the conclusion of 
Simpson’s 1957 paper: “Surgery should be as radical as is safe”[150]. 
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Several groups have performed retrospective studies to assess whether 
baseline imaging can indicate those grade 1 tumours likely to recur/ progress 
following surgery. Aspects analysed have been: tumour shape and size, relation 
to major sinuses, calcification, clarity of tumour/ brain interface, existence of a 
dural tail or oedema and residual tumour volume. Peritumoural oedema has 
been found to be an indicator of the likelihood of brain invasion – for each 
centimetre of oedema, the probability of brain invasion increased by 
approximately 20%[159]. Furthermore, peritumoural oedema has been shown 
to relate to the aggressiveness of the tumour and correlate with a high 
meningioma MIB-1 index[9, 160].  
 
1.12.4 Radiation Therapy for Meningiomas 
External beam radiotherapy (EBRT) and radiosurgery (RS) are well-established 
treatments for meningioma. The different radiation modalities will be discussed 
in detail in section 1.13. In general, for radical treatment EBRT involves a 
“fractionated” course of treatment with small doses (fractions) of radiation 
delivered on a daily basis (Monday to Friday) for approximately six weeks, 
whilst RS is usually delivered as a large single dose. Protons, heavy ions and 
radio-isotopes are beginning to be studied. Radiation therapy can be employed 
as a primary treatment, post-operatively or at recurrence. A consistent problem 
with the meningioma evidence base is that it is limited to retrospective case 
series, often within a single institution. The radiotherapy evidence base is 
further handicapped by the fact that outcomes are often analysed together 
regardless of treatment setting, technique or dose. Furthermore, many series 
have insufficient follow-up as progression/ recurrence can occur even after ten 
years.  
Local control rates 5-10 years following modern EBRT in benign tumours are 
generally >90% and recent RS series suggest similar results for local control 
[161]. Tables 1.4-1.6 detail outcomes in published EBRT series. Where possible 
results are grouped for benign/ non-benign tumours and according to treatment 
timing, but should be interpreted with caution in view of the small number of 
progressions and non-benign tumours in most series. Only one study was 
prospective in nature. Several are from the same institution and therefore the 
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same patients may have been included in several reports. Many of the studies 
span decades and will incorporate varying levels of sophistication in 
radiotherapy planning techniques. Symptom control following radiation is not 
uniformly reported and analysis is clouded by high rates of previous surgery. 
However, some degree of clinical improvement is reported in 29.3 – 53.5% of 
patients following EBRT/ RS, with symptom stabilisation in most others with 
radiological stable disease [162-167]. 
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Table 1-4 Older Case Series of Radiotherapy Outcomes for Meningioma With Conventional Radiotherapy  
Study   
Year 
Patients 
(n) 
Region Grade Primary 
Tx (n) 
Previous 
surgery % 
Planning 
Method 
Median 
Dose  
(Gy) 
Median 
F/up 
(months) 
Local Control 
(%) 
Late 
Toxicity 
(%) 
Barbaro ∩ 
1987[168] 
54  all N/A 0 100 2D 52.5 78 68 at 10yr 0 
Taylor  
1988[169] 
23 all 1 0 100 2D 50-63 >70 >80 at 10yr 0 
Glaholm ∆ 
1992[170] 
186 all All 32 82.8 2D 50-55 80 53 at 15yr 2 
Miralbell 
1992[171] 
36 all All 0 100 2D/ 
3D+proton 
45-60.4 53-57 78-100 at 8yr 16.7 
Goldsmith ∩ 
1994[172] 
117 all All 0 100 2D/ 3D 53 40 77 at 10yr 3.6 
Peele 
1996 
PROS[173] 
42 SW 1 0 100 N/A 55 48 100 at 4.2yr 5 
Condra* 
1997[174] 
28 all 1 25 75 2D 51.7-53.3 8.2 87 at 15yr 3.5 
Nutting ∆ 
1999[175] 
82 SB 1 0 100 2D/ 3D 55-60 41 83 at 10yr 14 
Vendrely 
1999[176] 
156 all all 49 51 2D/ 3D 50 40 79 at 5yr 11.5 
Maguire 
1999[177] 
28 CS all 0 100 2D/ 3D 53.1 41 81 at 8yr 7 
Dufour 
2001[178] 
31 CS N/A 45 55 2D/ 3D 52 73 92.8 at 10yr 3.2 
Pourel 
2001[179] 
45 All (no 
ONS) 
all 20 80 2D/ 3D 56 30 67 at 8yr 2.2 
SW: sphenoid wing; SB: skull base; CS: cavernous sinus; ONS: optic nerve sheath; N/A: not applicable
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Table 1-5 Fractionated Radiotherapy Outcomes for Meningioma (studies using solely 3DCRT or IMRT), continues on next page 
 
Study   
 
Pts 
(n) 
Region Grade 
(where 
known) 
Primary 
Tx (%) 
Previous 
surgery 
(%) 
Planning 
Method 
Median 
Dose  
(Gy) 
Median 
F/up 
(months) 
Local Control 
By Grade (%) 
Local Control 
By Timing (%) 
Late 
Toxicity 
(%) 
Debus* (2001) [180] 189 SB 1 and 2 31 69 FSRT  56.8 35 G1: 94 at 10yr 
G2: 78 at 8yr 
NS 12 
Jalali (2002) [181] 41 All 1 36.6 63.4 FSRT 55 21 100 at 3yr NS 9.8 
Uy (2002) [182] 40 All (no 
ONS) 
1 27.5 62.5 IMRT 50.4 30 93 at 5yr NS 5 
Pirzkall (2003) [183] 20 SB 1 20 80 IMRT 57 36 100 at 3yr NS 0 
Torres** (2003)[184] 77 All all 35 65 FSRT  48.4 24 G1: 97.2 at mfu 
G2: 60 at mfu 
NS 5.2 
Selch** (2004) [185] 45 CS 1 36 64 FSRT  50.4 36 97.4 at 3yr NS 0 
Milker-Zabel* 
 2005 [186] 
317 All 1 and 2 43 67 FSRT  57.6 67 G1: 89 at 10yr 
G2: 67 at 10yr  
1ry: 4.7 at mfu 
Rec: 10 at mfu 
8.2 
Sajja (2005) [187] 35 All 1 (2 pts 
G2) 
46 54 IMRT 50.4 19.1 97 at 3yr No Difference 5 
Henzel† (2006) [188] 224  All all 42 58 FSRT 
(plus11 
RS) 
55.8 36 G1: 100 at 5yr 
G2:  90 at 3yr 
G3:  83 at 3yr 
NS 0 
Milker-Zabel* 
2007 [162] 
94 All all 28 72 IMRT 57.6 52 G1: 96.3 at 5yr 
G2: 77.8 at 5yr 
NS 4 
Hamm† (2008) [189] 181 SB all 30 70 FSRT  56 36 97 at 5yr NS 8.2 
Litre (2009) [190] 100 CS NS 74 26 FSRT  45 33 93 at 3yr NS 0 
Minniti (2011) [191] 52 SB 1 66 34 FSRT  50 72 93 at 5yr No Difference 5.5 
Tanzler (2011) [192] 146 All 1 60 40 FSRT (3D/ 
IMRT) 
52.7 88 96 at 10yr 1ry:99 at 10yr 
Post-op: 93 at 
10yr 
6.8 
Adeberg* (2012) [193] 85 All 2 and 3 8.3 91.7 FSRT (3D), 
IMRT (+/- 
carbon) 
 
57.6 73 G2: 50% at 5yr 
G3: 13% at 5yr 
No Difference 0-1 
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Study   
 
Pts 
(n) 
Region Grade 
(where 
known) 
Primary 
Tx (%) 
Previous 
surgery 
(%) 
Planning 
Method 
Median 
Dose  
(Gy) 
Median 
F/up 
(months) 
Local Control 
By Grade (%) 
Local Control 
By Timing (%) 
Late 
Toxicity 
(%) 
Compter (2012) [163] 72 All all 64 36 FSRT  54 50 G1: 95 at 3yr 
G2: 40 at 3 yr 
1ry: 94 at 3yr 
Post-op: 71 at 
3yr 
Rec: 58 at 3 yr 
4.2 
 
Maclean (2013)[166] 30 All (vd) all 30 70 IMRT 50.4 28 97 at mfu No difference 
for symptom 
improvement 
3 
Combs* 
(2013)[167] 
507 SB all 54.4 45.6 FSRT or 
IMRT 
57.6 107 Overall: 88 at 
10yr 
G1: 91 at 10yr 
G2/3: 53 at 
10yr 
No Difference NS 
*, **, †: authors from the same institution and potentially the patient cross-over between series   
FSRT is 3DCRT with stereotactic set-up unless specified. 
ONS: optic nerve sheath; FSRT: fractionated stereotactic radiotherapy (with 3DCRT); vd: visual deficits; NS: not specified; SB: skull base;   
mfu: at median follow up time; IMRT:intensity modulated radiotherapy; ND:no difference; Rec: treatment for recurrent disease; CS: cavernous sinus 
1ry:primary treatment 
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Table 1-6 Outcomes Following Radiotherapy for Optic Nerve Sheath Meningioma 
Study Patients 
(n) 
F/up 
Months 
(mean/ median) 
RT 
Method 
Total 
Dose 
(Gy) 
Dose Per # 
(Gy) 
Vision 
Improved (%) 
Vision 
Stable 
(%) 
Vision 
Worse (%) 
Imaging stable/ 
improved (%) 
Late 
Toxicity (%) 
Liu 2002 [194] 5 36 FSRT  45-54 1.8 80 20 0 100 0 
Andrews 2002 
[195] 
30 20.4 FSRT 50-54 1.8 30 63.3 6.7 100 10 
Becker 2002 
[196] 
39 34.8 FSRT 54 1.8 6 94 0 100 10.3 
Narayan 2003 
[197] 
14 51.3 3DCRT 50.4-56 1.8-2 35.7 50 14.3 100 14 
Baumert 2004 
[198] 
23 20 FSRT 45-54 1.8-2 72.7 22.7 4.6 100 4.6 
Richards 2005 
[199] 
4 30 FSRT 43.4 -45 1.67-1.75 100 0 0 100 0 
Landert 2005 
[200] 
7 (eyes) 57 FSRT 50-54 1.7-1.8 85.7 0 14.3 100 0 
Sitathanee 2006 
[201] 
12 34 FSRT 55.7 1.8 60 40 0 100 3 
Litre 2007 [202] 8 27 FSRT 45 1.8 37.5 62.5 0 100 0 
Arvold 2009 
[203] 
22 30 3D or 
proton 
45-59.4 1.8 64 32 4 95 0 
Smee 2009 
[204] 
15 86.4 FSRT/ 
3D/ RS 
50 1.8-2 0 (some slight 
improvements) 
92.3 6.7 93.3 6.7 
Milker Zabel 
2009 [205] 
32 54 FSRT 54.9 1.8 38 59 3 100 0 
Saeed 2010 
[206] 
34 58 3D/ FSRT 45-54 1.8 41 50 9 N/A 35 (mild) 
Lesser 2010 
[207] 
11 89.6 FSRT/3D/ 
IMRT 
45-54 1.8 36 55 9 100 18 
Metellus 2011 
[208] 
8 91.3 FSRT 50.4-54 1.8 75 25 0 100 12.5 
Note: FSRT delivered with 3DCRT 
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1.12.4.1 Radiation as a Primary Treatment  
 
Radiotherapy is the treatment choice when meningiomas are deemed 
unresectable either due to tumour location (most commonly in close proximity to 
the optic apparatus or in the skull base) or when the patient requires treatment 
but is not suitable for surgery[147]. Durable PFS following radiotherapy is 
experienced by the majority of patients, although studies with longer follow-up 
periods tend to show lower progression free survival and most commonly 
symptoms stabilise but sometimes improvements are documented [170, 209, 
210, 174, 179, 211]. One of the most recent large series presented separate 
outcomes for those treated with primary RT (88 patients) or following STR (57 
patients) [192]. Local control rates at 5 and 10 years were as follows: definitive 
RT, 99% and 99%; postoperative RT, 96% and 93%; and overall, 97% and 
96%, respectively. The 5- and 10-year cause-specific survival rates were: 
definitive RT 94% and 94%, postoperative RT, 100% and 96%; and overall 96% 
and 95% respectively. 5- and 10-year overall survival rates were: definitive RT, 
81% and 75%; postoperative RT, 96% and 85%; and overall, 87% and 79% 
respectively. Severe RT complications occurred in 6.8% of RT patients; severe 
surgery-related complications occurred in 17% of patients treated surgically.  
 
Primary RS outcomes for meningioma are also impressive and data are 
available for larger patient cohorts than EBRT. Santacroce et al reported 10 
year PFS rates of 92.7% following RS in nearly 3000 patients with imaging-
defined meningiomas (implying no previous surgery) [164]. Pollock et al found 
no difference in 7 year PFS rates between RS and gross total resection (GTR) 
(>95% for both) [212]. 
Although some reduction in volume can occur, in general, meningiomas do not 
substantially shrink following radiotherapy and treatment should not be delayed 
until symptoms become severe. Some patients can have symptom 
improvement without significant change in tumour dimensions [208, 162, 166], 
probably because only a very small change may be required to relieve nerve 
compression in certain regions or perhaps reflecting vascular changes. If the 
tumour is large, even if GTR is not possible, surgery to relieve mass effect 
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followed by radiotherapy to the inoperable residual may be appropriate rather 
than radiotherapy alone. 
1.12.4.2 Optic Nerve Sheath Meningiomas 
Optic nerve sheath meningiomas (ONSM) provide a considerable body of 
literature regarding outcomes following primary EBRT as this is usually the 
treatment of choice due to high rates of blindness associated with optic nerve 
infarction during surgery [213]. Overall, reported data suggest that ONSM 
remained stable or reduced in size following primary EBRT in 93.3-100% of 
cases (20.4 – 91.3 months median follow-up). Clinical improvement figures vary 
as criteria differ, but ≥85% achieved stable disease in reported studies (table 
1.6). 
 
1.12.4.3 Radiotherapy Following Subtotal resection 
Benign tumours 
Subtotal resection (STR) is associated with inferior PFS [214]. This is improved 
by post-operative radiotherapy. In case series PFS following STR plus EBRT 
appears comparable to GTR (table 1.7). RS rather than EBRT can treat the 
post-surgery remnant if size and location is appropriate. Although no studies 
directly compare the two, overall PFS rates following STR plus RS appear 
equivalent to GTR [161].  
 
Unfortunately, a phase 3 EORTC study comparing observation with 
radiotherapy following STR in benign meningiomas closed due to low accrual 
(EORTC 26021-22021). The ongoing RTOG 0539 study, designed to assess 
dose escalation in non-benign meningiomas, incorporates an observational arm 
for grade 1 meningiomas following GTR or STR, so should provide prospective 
outcome data for those who are not treated with radiotherapy. 
 
Most studies focus on PFS and do not address whether this impacts overall 
survival (OS). McCarthy et al analysed OS according to treatment in >8000 
meningioma patients using the US National Cancer Database [31]. They 
reported equivalent OS in patients with GTR or STR and poorer outcomes in 
those treated with radiotherapy. However, considerable bias was unaccounted 
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for in the database and <5% of patients received radiotherapy. Soyeur et al 
reported no difference in OS amongst those with STR or STR plus up-front 
radiotherapy, suggesting it may be safe to delay radiotherapy until progression 
[215]. In practice, STR of meningioma is usually in locations where tumour 
growth would cause symptoms, hence upfront radiotherapy may still be 
favoured.  
 
Non-benign tumours 
OS does appear significantly shorter for patients with non-benign meningiomas 
who undergo STR as opposed to GTR [216, 217]. As such, post-operative 
radiotherapy is commonly recommended following STR of non-benign 
meningiomas. This is usually EBRT, although some groups support RS in this 
setting [218] [219]. Unfortunately the literature tends to group grade 2 and grade 
3 meningiomas together.   
 
Table 1-7 Meningioma Studies Reporting Outcomes Following GTR, STR and 
GTR or STR plus RT 
Study 
Year 
Patients 
(n) 
Histology 
Grade 
≥5yr PFS 
after GTR 
(%) 
≥5yr PFS 
after STR 
(%) 
≥5yr PFS 
after STR + 
RT (%) 
Adegbite 
1983 [151] 
114 G1* 90 45 82 
Barbaro 
1987 [168] 
135 No 
comment 
96 60 80 
Taylor 
1988 [169] 
132 G1* 96 43 85 
Miralbell 
1992 [171] 
115 G1* N/A 48 88 
Peele 
1996 [173] 
86 G1* N/A 52 100 
Condra 
1997 [174]   
246 G1* 95 53 86 
Soyuer 
2004 [215] 
92 G1* 77 38 91 
 
58 
 
1.12.4.4 Radiotherapy Following Gross Total Resection in Non-benign 
Meningiomas 
Five year PFS following GTR for G2 meningiomas is 40-50% [7, 24]. Such 
patients are therefore commonly offered adjuvant irradiation. However, study 
results are clouded by small patient numbers, combined outcomes for G2/G3 
tumours, and significant variation in radiotherapy technique/ doses. Komotar et 
al reported recurrences in 22% of G2 meningiomas following GTR (median 44 
months follow-up):  8% versus 41% for those with or without post-operative 
radiotherapy [220]. Likewise, Aghi et al described no recurrences in eight 
patients with atypical meningioma (out of 108) who had undergone GTR plus 
radiotherapy versus a 30% recurrence rate with GTR only (mean 3 year follow-
up)[221]. However, modern imaging, highly sensitive to early recurrences, may 
permit a surveillance approach and in some locations repeat surgery in the 
event of re-growth may be preferable to radiotherapy. The largest study (n=114) 
found no benefit for post-operative radiotherapy in patients with G2 meningioma 
following GTR [219].  
 
In practice, many factors are considered when deciding to offer adjuvant RT for 
grade 2 tumours including the fitness of the patient, the extent of the resection, 
the presence of brain invasion, markers of proliferation (mitotic index, MIB-1) 
and the likely morbidity of tumour re-growth or repeat surgery. It should also be 
noted that where there is no residual tumour on imaging defining the target 
volume is challenging. 
 
Database evaluation has not clarified the issue. Stessin et al evaluated post-
operative radiotherapy for G2/G3 meningiomas using the SEER database [222] 
and concluded that adjuvant radiotherapy did not improve survival. However, 
they emphasised that the role of radiation remains uncertain due to selection 
bias, scant radiation and surgical detail and small patient numbers evaluable by 
the WHO 2007 criteria (n=82).  
 
There is a clearer case for post-operative radiotherapy for G3 tumours 
regardless of the extent of resection and a combined treatment strategy is 
generally accepted in the majority of the published literature [223]. Local 
recurrence is reported to be reduced [224] and GTR plus adjuvant radiation for 
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malignant meningiomas has been shown to independently predict improved 
disease-free and overall survival times - five-year disease-free survival 
improved from 15% without radiation to 80% with adjuvant radiation [225]. Coke 
et al reported local disease progression in 65% of patients after surgery alone, 
versus 18% after surgery plus radiation[226]. 
 
1.12.4.5 Radiotherapy for Recurrent Meningioma 
Recurrent meningiomas pursue a more aggressive course than newly 
diagnosed meningiomas (they are a group selected by their propensity to 
recur). Older studies suggest improved salvage rates with surgery plus radiation 
or radiation alone versus surgery alone[171, 169, 227]. PFS with immediate or 
delayed post-operative radiotherapy is similar in some reports[169, 215], whilst 
others suggest that postponing radiation results in less effective tumour 
control[171, 179, 163]. No studies address OS. Again treatment decisions are 
individualised.  
  
Regarding timing of radiotherapy in relation to surgery, some publications show 
similar local control rates for patients treated with immediate or delayed post-
operative radiotherapy[169, 215], whilst others suggest that postponing 
radiation results in less effective tumour control [179, 171]. Overall survival is 
not detailed in the studies and the absence of a randomised trial in this area 
means the question of whether radiotherapy can be safely delayed is 
unanswered; again decisions are taken on a case-by-case basis. Following 
surgery, particularly after a recurrence, patients generally undergo regular 
surveillance imaging and the increased sensitivity of modern imaging to identify 
very early recurrences may allow more leeway to delay radiotherapy. 
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1.13 Radiotherapy Planning and Delivery Techniques 
 
1.13.1 2-Dimensional Techniques 
There have been many advances in recent years in radiotherapy delivery 
techniques. Traditionally, EBRT was planned on orthogonal radiographs in a 
two-dimensional (2D) manner with dosimetric calculations made on the 
isocentre-axial slices of each field. Thus dosimetry was relatively crude and 
reflected dose deposition on a slice of tumour not the whole volume. Doses to 
organ at risk (OAR) were equally rudimentary. Only coplanar beam 
arrangements were possible.  
The majority of patients who received radiotherapy prior to the mid 1990s had 
treatment planned and delivered in a 2D fashion and much of the retrospective 
case series outcome data refers to these techniques. Some geographical 
misses and tumour underdosing were inevitable. Similarly, toxicity rates may 
have been higher with older techniques as doses to OAR were not accurately 
calculated and the ability to shape beams to avoid critical structures was very 
limited. 
 
1.13.2 3-Dimensional Conformal Techniques  
3D conformal radiotherapy (3DCRT) involves the delivery of radiation to a 
defined 3D target volume as opposed to a target area with 2D planning. The 
use of CT or MRI and advanced treatment planning software has enabled more 
accurate delineation of tumour/ OAR and allowed the high dose radiation region 
to be better shaped around the target while minimizing the dose to the adjacent 
OARs, although inevitably high dose will spill outside of the target (figure 1.5). 
Compared to 2D radiation delivery methods, 3DCRT has reduced radiation-
induced toxicity and allowed safe escalation of radiation dose with resulting 
improved local tumour control for many tumour types. Goldsmith et al reported a 
22% improvement in PFS for patients with meningiomas treated with 
immobilisation devices and CT or MRI based target definition in comparison to 
those treated without such techniques (p = 0.002)[172]. In older EBRT series 
that included 2-D planning, ten year PFS rates for benign meningioma were 
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often <80%, significantly lower than modern series [228], although median 
follow-up is generally longer in older studies.  
 
Figure 1-5 A standard 3 field 3DCRT plan for a cavernous sinus meningioma. The 
red line is the PTV, the red colour wash shows how the 100% isodose splashes outside 
of the PTV to include normal brain in the high dose region. The blue/green regions 
represent lower isodoses. 
 
 
1.13.3 Intensity Modulated Radiotherapy 
 
Intensity-modulated radiotherapy (IMRT) takes 3DCRT a step further in that the 
beam intensity can be varied whilst the beam is on. This allows the sculpting of 
complex dose distributions around irregular targets, reduces dose to normal 
tissues and permits delivery of the prescribed dose to regions of tumour 
adjacent to critical structures, potentially permitting dose escalation. 
Theoretically, as doses to OAR will be reduced, the risk of late normal tissue 
toxicity should also reduce, although there is some concern about the long-term 
effects of the “low dose bath” to normal brain and the additional radiation 
exposure associated with the daily image-guidance required to ensure accurate 
patient positioning with IMRT.  
 
In contrast to the iterative approach with older radiotherapy planning methods, 
in IMRT the prescribed dose to the target and maximum permissible doses to 
critical structures are entered into sophisticated planning software. This allows 
the planning physicists to determine the beam arrangement that best meets the 
dosimetry goals. Dose gradients between high and low dose are extremely 
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steep and dose delivered to the tumour and critical structures is much more 
accurately defined.   
 
When IMRT was first introduced a static gantry dynamic multi-leaf collimated 
(SG-DMLC) technique was used where dose would be delivered in 5-9 set 
gantry positions. More recently volumetric arc therapy (VMAT) has become 
available where IMRT dose is delivered continuously through a 360⁰ arc. A 
comparison of techniques is shown in figure 1.6. Multiple arcs can be used as 
required to optimise the plan. Planning studies have shown that both techniques 
are essentially equivalent in the brain in terms of dose to the target and 
avoidance of OAR, but VMAT has the potential advantage of shorter treatment 
times and uses less radiation compared to SG-DMLC [229-233]. 
 
 
 
Figure 1-6 Cavernous sinus meningioma IMRT treatment plans: a) 5 field SG 
DMLC technique b) VMAT technique (1 arc of 270⁰). The red line is the PTV and the 
red colour wash the 100% isodose - conformality of the high dose is very high and 
similar for both plans. There are some differences in the regions of low dose 
distribution, but this can be altered as required. 
 
 
The few series available regarding outcomes following IMRT in patients with 
meningiomas are noted in table 1.5. All are retrospective in nature and have the 
associated methodological drawbacks.  Pirzkall et al. compared conformal and 
IMRT plans used in nine patients and showed that the IMRT technique 
increased dose and target coverage while sparing OAR [183]. Uy et al. 
described treatment outcomes at five years following IMRT for 40 patients with 
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intracranial meningioma (40-56Gy, median 50.4Gy) and reported cumulative 5-
year local control, PFS and overall survival as 93, 88 and 89%, respectively 
[182]. Two patients experienced tumour progression - one locally and one at a 
distance. OAR generally received a significantly lower dose than the target. 
Details on toxicity were limited, but the most commonly reported acute toxicity 
was mild headache. Milker-Zabel et al, reported their experience with IMRT in 
94 patients with complex-shaped skull base meningioma. IMRT was used for 
recurrent disease in 54 patients, as a primary treatment in 26 patients and for 
postoperative residual disease in 14 patients. Overall local control was 93.6% at 
4.4 years median follow up. Pre-existing neurological deficits improved in 39.8% 
and worsened in 4.3%. Two patients developed new clinical symptoms due to 
local tumour progression. [162]  
Of course, any improved outcomes seen in the IMRT era will also relate to 
improvements in imaging quality, treatment planning systems, patient 
immobilisation and set-up verification as well as improved dose distributions. 
 
1.13.4 Fractionated Stereotactic Radiotherapy 
Stereotactic radiotherapy refers to treatment that is delivered with the patient 
immobilised using a stereotactic frame. Such frames position the patient in a 
more reproducible fashion than a standard radiotherapy shell and, as such, the 
margin added to the target volume to account for set-up errors can be reduced 
(usually to 2mm). This may reduce dose to critical structures surrounding the 
tumour. “Stereotactic” does not refer to the technique used to deliver radiation. 
Stereotactic treatment can be fractionated and delivered with 3DCRT or IMRT – 
referred to collectively as fractionated stereotactic radiotherapy (FSRT). In the 
vast majority of case series FSRT in the main refers to treatment delivered by 
3DCRT (certainly for patients treated prior to 2010). In most cases when IMRT 
has been delivered in a fractionated stereotactic manner the treatment has 
been classified as IMRT in publications. 
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1.13.5 Radiosurgery 
Stereotactic radiotherapy can also be given as a large single fraction, often 
described as radiosurgery (RS). As will be discussed in section 1.15.1, RS 
target volumes are generally smaller than EBRT volumes as margins for 
subclinical spread and set up error are usually not added (or are minimal). 
Various technologies exist to deliver RS. It can be delivered by a highly 
advanced linear accelerator or by the Gamma Knife.  The therapeutic radiation 
in Gamma Knife therapy is gamma rays produced by radioisotope decay rather 
than photons, although the biological quality of gamma rays and photons is the 
same. For single-fraction treatments local control rates appear similar whether 
treatment was delivered with a linear-accelerator [234-236] or by the Gamma 
Knife[237-242]. Due to the sensitivity of normal tissue to dose per fraction, a 
meningioma size of >3.5cm mean diameter, optic nerve/ chiasm compression or 
ONSM are cited as contraindications to single fraction RS[239] and EBRT is 
often preferred to single-fraction RS when the tumour is close to sensitive 
critical structures, particularly the anterior visual pathway. 
To complicate the terminology, in recent years linear accelerator based 
technology has been developed to deliver RS with stereotactic accuracy without 
the need for a stereotactic frame due to precise and frequent onboard imaging 
(Cyberknife®). This has allowed “hypofractionated radiosurgery” where radical 
radiotherapy schedules are delivered in ≤5 fractions. Some groups now treat 
larger benign meningiomas or those close to critical structures in ≤5 fractions of 
radiotherapy rather than with EBRT. Published results so far appear equivalent 
to fully fractionated treatments, although again derive from small single 
institution case series with short follow-up [243-245].  
No randomised studies compare EBRT to RS. Overall, five and ten year PFS 
for G1 meningioma following either appear similar: 86-100% with RS [161] and 
89-97% with modern EBRT techniques (table 1.5). Han et al reported equivalent 
outcomes in patients treated with either modality [246] and local control was the 
same for 28 cavernous sinus meningioma patients treated either with EBRT (50 
Gy in 30 fractions) or with SRS (12 to 17 Gy at the 90% isodose) within the 
same centre [247]. 
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If patients are suitable for both EBRT and RS, RS is often favoured for patient 
convenience. In a retrospective multicentre analysis of 3768 patients with 
apparently benign meningiomas treated in 15 gamma-knife centres [164] 5 and 
10 year PFS rates were 95.2% and 88.6% respectively with a permanent 
morbidity of 6.6% (4.8% ≥moderate morbidity) which appears similar to EBRT. 
Symptomatic peritumoural oedema is rarely noted post-EBRT, but is reported in 
6-35% of patients up to 18 months after RS (associated with larger tumours and 
parasagittal/ convexity locations where there is a greater parenchymal interface 
than in the skull base) [248, 161, 249].  
As non-benign tumours are more likely to be infiltrative, subclinical disease may 
not be adequately treated by RS (no margin added to account for subclinical 
disease), and many institutions reserve RS for benign meningiomas. 
Furthermore, there is a theoretical radiobiological advantage of the higher total 
dose delivered in EBRT.  However, some outcomes have been reported for 
higher grade meningiomas treated with RS [250, 242, 251]. The largest study 
(n=50) reported 40% 5 year PFS rates [242], but many patients received RS 
after progression following EBRT [242]. In general, failing EBRT is a negative 
predictor of PFS following RS and complications are more likely [242, 252], but 
treatment may be appropriate in the absence of other options. 
RS criteria is dependent on a centre’s experience, one centre even reports use 
of single fraction RS to treat ONSM, although reported visual deterioration rates 
of 20% are higher than in most fractionated EBRT papers [253].  
 
1.14 Radiation Toxicity  
 
Historically radiotherapy was often avoided as it was felt to carry considerable 
toxicity. Concerns were raised regarding the rare circumstance of malignant 
degeneration as well as the more common relationship between irradiation and 
the development of meningiomas [223, 76]. The data available suggests that 
toxicity is substantially less than previously feared, particularly with modern 
techniques although limiting long-term toxicity remains of paramount importance 
as meningioma patients usually have long life expectancies. Data regarding 
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radiotherapy toxicity in the treatment of meningiomas mainly stems from the 
case series summarised in tables 1.4-1.6. However, accuracy of these results is 
somewhat questionable in view of their retrospective nature. Overall permanent 
toxicity rates of 0-18% and 2.5-23% have been reported with modern EBRT and 
RS techniques [161]. However, the lack of prospective data necessitates 
caution in interpretation of these figures.  For EBRT, optic neuropathy and 
retinopathy are rare with doses ≤54Gy and 45Gy respectively (<2Gy per 
fraction) [254-256, 172] and rates of severe dry-eye syndrome, retinopathy, and 
optic neuropathy increase steeply after doses of 40, 50, and 60Gy to related 
organs respectively [254, 255, 257]. Pituitary hormone insufficiency, seizures, 
hearing and other cranial nerve deficits and necrosis are occasionally reported 
[171, 191, 180, 183].  
 
RS series rarely report doses to critical structures, although most centres 
largely follow the constraints suggested by Timmerman [258]. Bloch et al, cite 
increasing tumour size and supratentorial location to be associated with toxicity 
rather than prescribed dose. Likewise, Pollock et al reported increased tumour 
volume and a parasagittal/falx/convexity location as risk factors for permanent 
RS complications [259].  
Formal evaluation of cognitive toxicity in meningioma is limited. Steinvorth et al 
reported a transient memory decline following the first fraction of FSRT. [260] 
However this subsequently improved, in association with improved mood, and 
no changes were later noted (only 14 patients had 1 year follow-up). Another 
group found that although meningioma patients exhibited long-term deficits in 
neurocognition, these seemed due to antiepileptic drugs and tumour location as 
there was no difference between the surgery only or surgery plus radiotherapy 
groups [261, 262]. 
 
There are no meningioma-specific second malignancy data. The relative risk of 
second malignancy following EBRT for pituitary adenoma compared to the 
normal population was reported as 10.5, with 10 and 20 year absolute risks of 
2.0% and 2.4% [263]. Long-term follow-up of IMRT patients is required to 
assess whether this historic data remains comparable in view of the larger 
volumes of normal tissue receiving low-dose radiation with IMRT. There are 
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only a few reported cases of second malignancy following RS [264] and the 
largest study of almost 5000 patients showed no increase in second tumours 
compared to the general population, but no patient had ≥20 years follow-up 
(364 patients had >15 years follow-up) [265].  
 
The lack of prospectively collected toxicity data, particularly with newer 
radiotherapy techniques, makes it difficult to counsel patients on the realistic 
likelihood of developing long-term toxicity following radiotherapy. 
 
1.15 Challenges in radiotherapy for meningioma 
 
1.15.1 What is the Target Volume? 
The definition of target volumes correspond to ICRU 50/62 recommendations: 
gross tumour volume (GTV) outlines macroscopic tumour, clinical target volume 
(CTV) accounts for microscopic tumour spread and planning target volume 
(PTV) accounts for set-up errors [266]. However, optimal meningioma target 
definition has not been prospectively addressed and there is a lack of evidence 
to make recommendations. In EBRT reported PTVs include GTV plus 2cm [7], 
GTV plus 1cm [172], down to GTV plus 2mm (FSRT) [180]. In this latter report 
no margin failures were reported but median follow-up was too short to draw 
conclusions (35 months). As non-benign meningiomas are more likely to be 
infiltrative, many authors support an increased CTV margin for non-benign 
tumours. Adeberg et al recommend a CTV of GTV+1-2cm for grade 2 
meningiomas and GTV+2-3cm for grade 3 [193]. The same group report using 
CTV margins of 1-3mm for benign skull base meningiomas [167].   The current 
RTOG and EORTC study specifications are detailed in table 1.8 (intermediate 
or high risk tumours). Most RS series do not specify target definition, but the 
general RS principle is to target enhancing disease alone (no CTV).  
 
Information about where recurrences occur in relation to target volume is scarce 
for meningioma. Askoxylakis et al, reported location of progression post-EBRT 
in 22 meningiomas [267]: marginal in 50% (most commonly in benign tumours) 
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and central in 50% (more common in non-benign tumours). This suggests 
improvement in target delineation and dose escalation may be more important 
for benign and non-benign meningiomas respectively.   
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Study Groups Margins Dose 
RTOG 0539 
Low risk group: 
observational study 
 
Non-low risk groups: 
phase 2 study 
 
G1 post surgery (GTR or STR) 
 
 
Intermediate Risk: 
G1 recurrent disease and G2 post 
GTR 
 
High Risk: 
G2 recurrent disease, G2 post STR 
and G3 any 
 
No RT 
 
 
GTV = tumour bed, nodular dural enhancement, 
hyperostotic/ directly invaded bone. Dural tail/ oedema NOT 
included 
CTV54= GTV + 1cm  (reduce to 0.5cm at natural barriers) 
 
GTV as for intermediate risk 
CTV54= GTV +2cm (reduce to 1cm at natural barriers) 
CTV60= GTV + 1cm 
 
No RT 
 
 
54Gy in 30# 
IMRT or protons 
 
 
 
60Gy in 30# 
IMRT only 
EORTC  22042-26042 
Group 1: observational study 
 
 
 
 
 
Group 2: phase 2 study 
 
G2 and G3 post GTR 
 
 
 
 
 
G2 and G3 post STR 
 
GTV = post-op residual 
CTV60= GTV + “subclinical microscopic tumour” (may 
include pre-operative tumour bed, peritumoral oedema, 
hyperostotic changes, pre-op dural enhancement/ 
thickening) + 1cm 
 
GTV as Group 1 
CTV60 as above 
CTV70 = GTV + 0.5cm 
 
60Gy in 30# 
 
 
 
 
 
70Gy in 35# 
Table 1-8 Current RTOG and EORTC Study Target Volume Specifications
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1.15.2 Hyperostosis 
Hyperostosis (figure 1.7a) is reported in association with meningioma in 25-75% 
of cases, most commonly in the convexities and sphenoid wing [268, 269, 95, 
94]. Direct bony invasion from meningioma is well documented[95], but 
“reactive” bone expansion has also been demonstrated. The few pathological 
correlation studies available frequently demonstrate meningioma cells in bone 
when hyperostosis is present on imaging, but not all cases of bone invasion are 
identified on imaging. Goyal et al identified hyperostosis on pre-operative 
imaging in 75% of meningioma patients [269]. Tumour cells were present in 
bone in 23.3% of all patients, of whom 88% had hyperostosis on pre-operative 
imaging. Pieper et al, reported that of the 51 patients with CT hyperostosis, 26 
had biopsy-proven bone invasion, but 10 more had bone invasion without CT 
hyperostosis [95]. The same group recently reported similar results: 13 of 14 
patients with imaging-identified hyperostosis had meningioma in bone [270]. 
The majority of these tumours were grade1 with Ki67 <4%, indicating bone 
invasion does not itself indicate aggressive histology. Nakasu et al found that 
the association between bone invasion and recurrence disappeared when 
incomplete excision was considered[271].  However, one group reported an 
association between poorer prognosis and bone invasion in atypical 
meningiomas [272]. 
 
1.15.3 Dural Tail 
Figure 1.7b depicts a “dural tail”, commonly seen in meningioma. The clinical 
significance of the dural tail remains unclear. The largest study of 179 patients 
with resected dural tails from convexity meningiomas found 88.3% contained 
tumour cells, of which 95% lay within 2.5cm of the tumour base [273] (no 
difference between benign/ non-benign tumours). This raises the question of 
whether margins required to pathologically clear disease differ from those 
required for radiotherapy as this extent of dural tail is often not included in 
radiotherapy target volumes and local control rates are excellent. In other 
series, approximately half of meningioma dural tails contained tumour and half 
were attributed to dural inflammation and vascular congestion (around 80 
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patients total) [274-280]. The RTOG and EORTC studies specify GTV-inclusion 
of only “nodular” dural tails, although “smooth” dural tails appear as likely to 
contain meningioma cells (but are associated with benign disease) [273]. 
DiBiase et al reported PFS rates of 96% versus 77.9% at 5 years for patients 
who did or did not have the dural tail included in the RS prescription isodose 
respectively [281]. However, this association did not remain statistically 
significant on multivariate analysis and some argue that recurrences are no 
more likely in the dural tail than any other portion of dura next to the main 
tumour mass and that improved control with dural tail inclusion simply reflects 
larger target volumes[282 ]. Practice varies between centres and there is a 
need for prospective evaluation with quality assurance for contouring and 
dosimetry. 
 
 
 
Figure 1-7 a) Abnormal bone associated with meningioma; b) Dural Tail 
 
1.15.4 Peri-tumoural oedema 
Peritumoural oedema has been found to be an indicator of the likelihood of 
brain invasion (for each centimetre of oedema, the probability of brain invasion 
increased by 20%) [159] and has been shown to relate to tumour 
aggressiveness, correlating with a high meningioma MIB-1 index[9, 160]. Most 
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authors do not specifically include oedema within the target volume, although 
the current EORTC study states that it may be included in CTV (non-benign 
disease).  
 
1.15.5 Post-operative Changes 
In general outlining the tumour volume on the pre-operative MRI assists in 
distinguishing between tumour and post-operative changes. However, many 
patients have had several operations by the time they come to radiotherapy 
planning or there may have been further growth since their operation. 
Conversely, there may be no visible tumour on imaging where higher grade 
tumours are treated with adjuvant radiotherapy. As such, defining target 
volumes in the post-operative setting often remains a challenge. 
 
1.15.6 What Imaging Best Defines theTarget? 
1.15.6.1 Standard Imaging 
The success of radiotherapy depends on the accurate determination of target 
volumes and OAR. Target volume delineation can be challenging in many 
meningiomas and targeting certainty is increasingly important with growing 
utilisation of highly conformal treatment techniques such as IMRT/ RS, where 
dose fall-off is very sharp out-with the defined target. 
 
Contrast-enhanced MRI co-registered to planning CT is the current standard 
imaging: meningioma out-with bone is clearest on post-contrast T1-weighted 
MRI [283] and bone is clearest on CT. Better soft tissue definition also permits 
more accurate delineation of many OAR on MRI. Only one study has 
specifically evaluated the need for coregistered MRI and CT in meningiomas. 
Khoo et al described a successful method of MRI-CT co-registration and 
reported that, in 7 patients with meningiomas, target volumes defined on MRI 
were typically larger than those defined on CT, but that the MRI-defined region 
did not necessarily include all of the CT-defined region and both volumes could 
be markedly different[284]. Many other studies evaluating the combination of 
both imaging modalities for radiotherapy planning of other CNS tumours have 
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shown that MRI information considerably alters target volume definition.[285-
287] [288].  
 
1.15.6.2 PET 
To try and better delineate target volumes in challenging regions, several 
groups have evaluated whether PET/CT is useful in addition to standard MRI 
and planning CT [289-294].  68Gallium DOTATOC which binds to somatostatin 
receptors and the amino acid tracer 11C Methionine have been evaluated. In 
general, PET information results in alterations in the target volume in the 
majority of patients. In all studies the PET information resulted in bi-directional 
changes in target volumes as the PET positive regions were both smaller and 
larger than the CT/MRI volume in different patients. Most differences were 
apparent in the bone.  
 
1.15.7 What is the Optimal Radiotherapy Prescription Dose? 
Standard treatment doses for EBRT are 50-60Gy in ≤2Gy per fraction. Data 
regarding whether a dose-response relationship exists is scarce and study 
quality poor (retrospective case series, small numbers of heterogeneous 
patients, varying treatment schedules and combined results for tumour grades). 
Katz et al found no apparent improvement in local control for non-benign 
meningiomas following hyperfractionated treatment plus RS boost (approx 
60Gy in twice daily fractions plus 10-17.5Gy boost) [295]. Others report 
improved local control with doses >52-53Gy in both benign and higher grade 
tumours [172], lower recurrence rates in patients who received >50Gy 
(combined tumour grades) [176] and improved PFS and OS with ≥60Gy in non-
benign meningiomas [223].The EORTC and RTOG are currently running non-
randomised studies investigating dose escalation in non-benign meningioma 
(table 1.8).  
 
Optimal RS dose is also debated. The median marginal dose in studies 
published since 2000 has been 11-18Gy. Several groups propose a minimal 
marginal dose of 12-16Gy [296, 239, 297], but others prefer 14-15Gy [241]. 
Pollock et al [241] highlighted that a 12Gy single fraction only equates to 42Gy 
of EBRT in 2Gy fractions (alpha/beta ratio 2). However, they found no 
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improvement in local control with increasing dose. The few reports of RS for 
non-benign meningiomas generally used higher median marginal doses 
(approximately 18Gy) [242]. Attia et al reported improved PFS for atypical 
meningiomas treated with >14Gy [251] and some recommend doses >20Gy in 
this setting [298]. 
 
Interestingly, non-benign meningiomas are more commonly reported in the 
convexity or parasagittal regions where there may be more scope to increase 
dose compared to other regions. 
 
1.16 Protons  
 
1.16.1 Basics of Proton Therapy 
All photon radiotherapy techniques are limited by the physical properties of 
photon travel and energy deposition characteristics. After a short build-up 
region, photon dose decreases relatively slowly with increasing tissue depth. 
Treatment plans generally aim to encompass the target within the 95% isodose. 
This means that the surrounding tissues inevitably receive a percentage of the 
overall dose. The ideal therapeutic radiation would deliver a defined dose 
distribution within the target volume and none outside it. Charged particles have 
been considered for this purpose since the 1940s based on their theoretically 
favourable dose deposition characteristics compared to photons, although the 
vast cost and complexity involved in developing specialist facilities has limited 
their widespread use.   
 
Protons are the most commonly used charged particle in the therapeutic setting. 
The typical dose deposition curve differences between photons and protons are 
shown in figure 1.8. When a charged particle enters tissue the energy it 
deposits is approximately inversely proportional to the square of its velocity: as 
the particle slows, ionisation events increase [299]. Decreasing velocity at the 
end of the particle’s path results in a rapid accumulation of ionisation events 
and causes a dose deposition peak - the ‘Bragg’ peak. The particles have very 
little energy beyond their Bragg peak and deposit minimal energy past that 
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point. This physical characteristic of protons gives them a theoretical advantage 
over photons because the region of maximum energy deposition can be 
positioned within the target for each beam. However, to cover a tumour 
adequately Bragg peaks have to be “spread out” (SOBP).  
 
 
 
Figure 1-8 Depth dose curves of photons and protons highlighting the rapid dose 
fall-off with protons compared to photons. Note that the entrance dose with both is 
similar for clinical use as protons require a SOBP 
 
The original and still widely used method to create a SOBP involves the use of 
sequentially penetrating absorbers of variable thickness, known as “passive 
scattering”. This requires a different compensator and collimator for each field 
for each patient, making it logistically difficult and it cannot account for the 
proximal contour of the target. Furthermore, neutrons are produced from proton 
interactions with the scattering foil which can be damaging to surrounding 
normal tissue. Newer facilities tend to exploit the fact that protons can be 
deflected magnetically with “scanning” techniques. There are a variety of subtly 
different scanning approaches, but the core principle is that narrow mono-
energetic "pencil" beams of different energies are sequentially scanned 
magnetically across the target volume layer by layer to cover the full depth of 
tumour (the highest energy beam treats the deepest layer and the lowest 
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energy treats the most superficial), as shown in figure 1.9. No compensators 
are required and neutrons are not produced.  
 
 
Figure 1-9 Representation of the location of pencil beam scanning proton spots 
in tumour 
 
 
The biggest potential advantage of scanning proton techniques may be that it is 
possible to “intensity-modulate” the beam and provide intensity-modulated 
proton therapy (IMPT) in a manner akin to IMRT. As with IMRT, IMPT 
theoretically produces better dose distributions than standard therapy, but there 
is an even higher risk that IMPT could be “too accurate” and risk geographical 
target misses or high dose deposition in critical structures adjacent to target due 
to the very small region of dose deposition in proton therapy. 
 
There are many other unresolved questions around proton therapy. From a 
physics standpoint there are numerous uncertainties meaning that in proton 
plans “what you see is not what you get”. Fundamentally, although we know 
protons deposit their energy at the Bragg peak, we do not know exactly where 
the Bragg peak is for each beam. Furthermore, lateral penumbras are uncertain 
(probably no better than photon penumbras), CT Hounsfield units cannot be 
used directly to calculate absorbed dose as in photon therapy, the 
consequences of nuclear interactions are unclear (neutrons) and the effect of 
organ motion and immobilisation devices may have significant impact on where 
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the dose is delivered. From a biological point of view, whether the target 
prescription and OAR tolerance doses from photon therapy can be directly 
transferred to proton therapy is unknown as is the true relative biological 
effectiveness (RBE) of protons compared to photons. Proton RBE is widely 
simplified to a generic value of 1.1, but there is clear experimental evidence in 
vitro and in vivo that the proton RBE does not have a single value, with 
variations in the clinically relevant dose range of 10%-15%.  
 
1.16.2 Protons in Meningioma 
Several meningioma planning studies suggest that protons may provide better 
dose distributions than photon plans, mainly in terms of reduced integral dose 
which may result in fewer long term toxicities. A small planning study indicated 
that proton therapy may half the risk of second malignancy and reduce doses to 
neurocognitive and visual/ auditory structures [300]. However, there are few 
clinical study reports. As we have seen for other data regarding outcomes 
following treatment for meningioma, most reports are retrospective and 
relatively small. Protons have been used as a monotherapy fractionated course, 
as single fraction RS or combined with photon therapy as a boost. Published 
clinical outcomes are summarised in table 1.9. Overall the results appear 
comparable to modern photon therapy, although in some circumstances toxicity 
appears greater with protons. That said, as with the transition from 2D to 
3DCRT to IMRT in photon therapy, there have been continuing advancements 
in proton therapy that are not necessarily reflected in these reports.  
An increase in understanding of the biology and physics of proton therapy is 
required to fully exploit their theoretical benefits. Whether there is a clinical 
benefit with protons over photon therapy in meningioma remains to be 
established, particularly as toxicity rates with IMRT are expected to be low, 
meaning that any absolute benefits of protons may be very small. 
 
78 
 
Table 1-9 Clinical Series of Proton Therapy for Meningioma 
Series 
Institute 
Year 
Pts Grade F/up months 
(mean or 
median) 
Treatment OS PFS Late Toxicity  
(% ≥ G3) 
Wenkel  
MGH 
2000*[301] 
46 1 53 Photons plus protons 
53.1-74.1CGE (protons: 8-34 #; 
photons: 0-23#)  
93% 5yr 
77% 10yr 
100% 5yr 
88% 10yr 
20% 
Vernimmen 
Tygerberg 
2001[302] 
23 NS 40 Protons only 
Group 1:18 pts 20.3CGE in 3# 
Group 2: 5 pts 54-61.6CGE in 
16-27 # 
NS 88% 5yr (group 
1) 
100% 5yr (group 
2) 
13% 
Noel 
Orsay 
2005[303] 
51 1** 25.4 Photons plus protons 
Photons: median 30.6Gy  
Protons: 30CGE 
(1.8-2CGE per #) 
100% 4yr 98% 4yr 4% 
Boskos 
Orsay 
2009[304] 
24 II, III 32.2 Photons plus protons 
Photons: median 30.96CGE 
Protons: median 34.05CGE 
(1.8-2CGE per #) 
42.6% 8yr 46.7% 8yr 4% 
Halasz 
MGH* 
2011[305] 
50 1** 32 Protons only 
13CGE single # 90% isodose 
(range 10-15.5CGE) 
NS 94% 3yr 5.9% 
Weber 
PSI 
2011[306] 
39 All 62 Protons only 
Grade 1: 52.2-56CGE 
Grade II/III: 60.8 +/-5.3CGE 
(1.8-2CGE per #) 
81.8% 5yr All Grades: 
84.8% 5yr 
Benign: 100% 
5yr 
13% 
Slater 
Loma Linda 
2012[307] 
72 1(47) 
UK (21) 
II (4) 
74 Protons only 
G1: 50.4-66.6CGE 
G2: 54-70.2CGE 
(1.8CGE per #) 
NS 96% 5yr 5.5% (but 
tumours 
encasing optics) 
Combs 
Heidelberg 
2013†[308] 
71 1 NS Protons only 
57.6CGE 
NS 100% 0% 
MGH: Massachusetts General Hospital; PSI: Paul Scherrer Institute; NS: not stated; UK: unknown; *Wenkel patients from 1981-1996; Halasz patients 
from 1996-2007); **where pathology available; †paper details a wide variety of tumours, f/up for benign meningiomas unclear (high grade meningiomas 
treated with photons and carbon ions) 
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1.16.3 Carbon Ion Therapy 
Carbon ions confer favourable dose deposition characteristics in a similar 
manner to protons and also have increased relative biological effectiveness. A 
phase II single-centre study is currently evaluating progression-free survival, 
overall survival, safety and toxicity of a carbon ion boost applied to the 
macroscopic tumour in conjunction with photon radiotherapy in patients with 
atypical meningiomas after incomplete resection or biopsy [309]. The same 
group have reported that re-irradiation with carbon therapy following 
progression after previous photon radiotherapy can be safely achieved for 
meningiomas and may offer palliation (3 patients) [310]. 
 
1.16.4 Systemic Therapy  
There is very little role for systemic therapies in routine management of 
meningiomas. Benign meningiomas have excellent local control and survival 
rates and as such, even the most potentially effective adjuvant therapies would 
offer little absolute benefit. Systemic agents have been evaluated in the 
palliative setting as a treatment for the small numbers of refractory or 
inoperable high grade meningiomas. Studies have been small and non-
randomised. To date chemotherapy and hormonal therapies have shown little 
benefit. Hydroxyurea has been most studied [311-316]  as it has been shown to 
be a potent inhibitor of cultured meningioma cells in vitro [317]. However, in 
humans, although well tolerated and convenient, it has shown little efficacy – 
the largest reports showed a median PFS of 2 months and 4 months for high 
grade and recurrent grade 1 disease respectively [316, 318].  Temozolomide 
and irinotecan have also appeared inactive in this disease in small studies 
[319, 320].   
 
1.16.5 Targeted therapy 
Approximately 60% of meningiomas have prolactin receptors and 30% 
oestrogen receptors. Consequently, a variety of hormonal therapies have been 
evaluated in the treatment of recurrent meningiomas. Results for megace, 
mifepristone and tamoxifen have all been disappointing and these agents have 
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not warranted further study [321, 322]. Like hydroxyurea, the 
immunomodulatory agent interferon alpha is reported to have some cytostatic 
activity in meningiomas in vitro, but results of study in humans have been 
underwhelming [323]. 
Molecular-based targeted therapies may hold more promise than conventional 
chemotherapy, but a greater understanding of the molecular genetics of 
meningioma is required. Meningiomas are vascular tumours and VEGF 
expression is increased in atypical and anaplastic histologies, compared with 
benign meningiomas [324]. Two retrospective case series have reported 
outcomes following the use of bevacizumab (an anti-VEGF monoclonal 
antibody) for heavily pre-treated progressive meningiomas (15 and 14 patients 
each, across different institutions). Six month PFS rates of 43-86% are 
reported and further prospective study may be warranted [325, 326].  
The majority of reports of other targeted molecular therapies have produced 
results probably not dissimilar to what would be expected without treatment. 
Preliminary evaluation of imatinib as a PDGF inhibitor has not been promising 
– 6 month PFS was 29% [327]. Likewise erlotinib/ gefitinib, sunitinib and 
vatalanib all report 6 month PFS of 25-40% [328-330]. 
 
1.16.6 Somatostatin Receptor Targeted Therapy 
 
As discussed in section 1.10.6.1, somatostatin receptors, especially the sstr2A 
subtype, are present on most meningiomas [111, 115]. In vitro, the addition of 
somatostatin usually inhibits meningioma growth, but there are some studies 
where growth is stimulated.  Three small phase 2 studies/ case series have 
reported the use of long acting somatostatin analogues in patients with 
meningiomas with very varied results. One study reported a median time to 
progression (MTP) of 17 weeks (11 patients) [331] in patients with recurrent 
progressive disease whilst another found the MTP to be 115 months (13 
patients) [332]. It should be noted that this later report was a retrospective case 
series in patients with benign residual disease post-operatively who had not 
undergone radiotherapy so it represents a very different population from 
patients with advanced meningioma usually treated with systemic therapy 
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(indeed, the outcomes may have simply reflected the natural history of the 
disease rather than any treatment effect). The largest formal phase 2 study of 
patients with progressive disease (16 patients) reported a partial radiographic 
response in 31% and a 44% PFS at 6 months [333]. The other reports did not 
find any radiographic response. A newer somatostatin analogue with higher 
affinity and a wider sstr spectrum (including subtypes 1, 2, 3 and 5) than the 
sustained release somatostatin described above is being examined in a phase 
II trial for patients with recurrent or progressive meningiomas [334]. 
 
1.16.6.1 Radioisotopes 
The fact that meningiomas possess a high density of sstr could potentially be 
exploited for therapeutic gain with peptide receptor radionuclide therapy (PPRT) 
in a manner similar to sstr-positive neuroendocrine tumours. PPRT involves 
systemic administration of synthetic somatostatin analogues, radiolabelled with 
a suitable beta-emitting radionuclide. The radiopeptides generally used for 
PRRT for neuroendocrine tumours are 90Y-DOTATOC ([90Y-DOTA0,Tyr3]-
octreotide) or more recently 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3]-
octreotate). 
 
For meningiomas, PRRT remains experimental and experience is limited mainly 
to the palliative setting. The largest case series reported results following 90Y 
DOTATOC therapy for 29 patients with meningiomas that had progressed 
following standard therapy [335]. All tumours were scintigraphically positive for 
sstr2. Patients received intravenous 90Y-DOTATOC for 2–6 cycles for a 
cumulative dose in the range of 5–15 GBq. The treatment was well tolerated in 
all patients.  66% had stable disease on MRI three months after treatment 
completion and 34% PD. Better results were obtained in patients with grade I 
meningioma than in those with grade II–III, with median time to progression 
(from beginning PRRT) of 61 months in the low-grade group and 13 months in 
the high-grade group.  
 
Sabet et al reported a case of progressive metastatic meningioma with severe 
associated symptoms where stable disease was achieved with significant 
symptomatic improvement following therapy with 177Lu-DOTATATE [336]. Van 
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Essen et al included 5 meningiomas in their case series reporting the use of 
177Lu [337]. Patients received 2-4 cycles at an interval of 6-10 weeks. At the end 
of treatment 2/5 patients had SD (one patient had SD prior to treatment). 
Patients with high grade bulky disease did not appear to respond to therapy.  
 
Kreissl et al targeted patients earlier in the disease process in a pilot study 
assessing the feasibility and tolerability of a combination of standard EBRT 
(median dose 53Gy) with a 7.2Gy PRRT boost (177Lu) [338]. They found that 
this treatment regime was tolerated well and there was a minor reduction in 
tumour size overall, but longer follow up is required to comment on outcomes. 
 
The biological rationale for PRRT in meningiomas is compelling and further 
study is warranted. 
 
1.17 Summary 
 
Meningiomas are common, although many remain clinically silent and do not 
require treatment. When intervention is required, surgical excision is usually the 
treatment of choice, but tumour location may prevent complete resection. 
Radiotherapy is often used for the more challenging cases where the 
meningioma cannot be excised because of its close proximity to critical 
structures, when it has recurred after previous resection or in non-benign 
disease. Overall control rates following radiotherapy appear impressive for 
benign tumours, but the evidence base regarding outcomes and toxicity is poor 
with a lack of prospective studies. As patients treated with radiotherapy for 
meningioma can generally be expected to live for many years, minimising long-
term toxicity is of paramount importance. Newer techniques of planning and 
delivering radiation such as IMRT have the potential to spare normal tissue and 
reduce side-effects. However, tumour control with these techniques is heavily 
reliant on precise target volume definition which can be challenging and there 
has been little work into methods for improving target contouring in 
meningiomas. Proton radiation therapy has been reported to reduce integral 
dose to normal tissue, an attractive prospect in the brain, but reports of proton 
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therapy are prone to hyperbole and further study is required before this 
becomes a standard treatment for meningiomas. Finally, there is no effective 
treatment option for meningiomas that have progressed following radiotherapy 
and the increased understanding of tumour surface receptor expression opens 
the door for exploration of receptor-targeted therapies. 
 
1.18 Aims of this Thesis 
 
The remainder of this thesis is structured into four parts each of which explores 
a particular aspect of advanced radiation therapies for meningiomas. The first 
section describes outcomes in a prospective observational study in patients with 
meningioma treated at University College London Hospital with IMRT.  
 
In the second section I report my findings regarding the development and 
evaluation of the use of simultaneous PET/MRI using 68Gallium DOTATATE in 
meningioma radiotherapy planning. The technical hurdles that had to be 
overcome to allow PET/MRI to be integrated into meningioma target volume 
definition are described and the effect of PET/MRI use on interobserver 
variability analysed. 
 
Part three is a planning study analysing dosimetry to tumour and normal tissue 
using protons versus optimal intensity modulated radiotherapy. My institution is 
currently commissioning one of two UK proton centres. Although meningiomas 
are not currently one of the indications for proton therapy for UK patients being 
sent abroad for treatment, the list of indications for proton therapy is likely to 
increase when there are two UK facilities. In view of the possible long-term 
neurocognitive effects from the exposure of normal brain to radiation and the 
associated potential for inducing second malignancies and the fact that several 
proton centres treat meningiomas, I evaluated whether the proton planning 
techniques we plan to use improve treatment plans versus our current VMAT 
IMRT plans.  
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The final section details my preliminary evaluation of the use of the radionuclide 
177Lutetium DOTATATE to treat patients with advanced meningioma whose 
disease had progressed following radiotherapy. This was carried out to 
establish whether a larger formalised study was warranted and to explore 
methods of evaluating response to therapy in meningioma studies.   
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2 Chapter 2: Outcomes and toxicity 
associated with Intensity Modulated 
Radiotherapy in the treatment of 
meningioma: a prospective observational 
study 
_______________________________________________________________ 
 
2.1 Introduction 
 
2.1.1 Background 
As discussed in Chapter 1, the dose of therapeutic radiation that can be 
delivered to intracranial tumours is often limited by the proximity of tumour to 
radiosensitive critical structures. Furthermore, our understanding of tolerance 
levels of many regions of the brain important for higher mental functions is still 
in its infancy. Intensity modulated radiotherapy (IMRT) has dosimetric 
advantages over 3D conformal radiotherapy (3DCRT) as described in section 
1.13.3. IMRT provides better conformity of high dose around target, improved 
target coverage and better sparing of critical structures. This is particularly 
relevant in meningiomas where patients usually have long life expectancies. 
Similar advantages can be provided with single fraction radiosurgery, but IMRT 
is applicable to a wider group of patients as it is not subject to the contra-
indications of radiosurgery [239].  
 
Although the theoretical benefits of IMRT are clear in terms of plan parameters, 
there are drawbacks associated with IMRT compared to 3DCRT. From an 
economic standpoint, the creation, quality assurance and delivery of IMRT 
plans is significantly more time consuming than 3D CRT, experienced planners 
are required to produce optimal plans and expensive hardware/ software is 
necessary (although usually already available due to IMRT use in other tumour 
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sites). Due to the steep dose gradients associated with IMRT there is potentially 
more risk of overdose to critical structures, concomitant radiation dose is higher 
due to the required daily image-guided set-up and concerns remain regarding 
the low-dose bath region. 
 
2.1.2 IMRT Study 
The potential clinical advantages of IMRT are clear, but there remains a paucity 
of patient data evaluating the use of IMRT in the brain. There has been concern 
regarding the effects of a possible increase in integral dose to the normal brain 
with IMRT, although emerging evidence indicates that this is not necessarily the 
case with careful IMRT planning [339]. Virtually all published series regarding 
outcomes following radiotherapy for meningioma are retrospective, lack 
objective measures and combine outcomes for many radiation techniques.  
 
Therefore, it was deemed important to introduce IMRT for meningiomas to my 
institution within a prospective observational study. This was designed to 
evaluate the potential of IMRT to reduce the dose to neurological dose limiting 
structures and to collect dosimetric, toxicity and outcome data. A single arm 
observational design was followed rather than a randomised approach 
(between 3DCRT and IMRT) for several reasons. Firstly, documenting IMRT 
outcome data as a single arm approach would provide greatest patient numbers 
and the most robust data. Despite the paucity of published data, it is intuitive 
that toxicity from meningioma radiotherapy is largely dependent on tumour 
location and a vast number of patients over many centres would be required to 
show any difference between two randomised treatment arms which would not 
have been feasible. Furthermore, it was anticipated that IMRT would become 
standard therapy within a few years of commencing the study and so continued 
randomisation to an inferior 3DCRT would have been unethical. Indeed, one of 
the benefits of introducing IMRT to a department within a study is the clear 
protocol and review process, which is enhanced by having larger patient 
numbers.  
 
The specified primary study outcome measure was the proportion of patients 
suffering ≥ grade 2 late neurotoxicity at ≥ 1 year, assessed in the standard 
manner by the National Cancer Institute Common Toxicity Criteria for Adverse 
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Events (NCI CTCAE) scale v.3.0. Secondary outcome measures were to 
determine the feasibility of delivering IMRT to patients with meningiomas, to 
assess progression free and overall survival and other acute and late toxicity. 
Important and appropriate aspects of toxicity with objective measures were 
included: ophthalmology, quality of life and neuropsychology.  
At the inception of the study the plan had been to include a comprehensive 
battery of formal neuropsychology testing administered by our neuropsychology 
department. However, there was no funding available to support this. Therefore, 
for practical purposes the Folstein mini mental state examination (MMSE) was 
used as the only objective measure of higher mental functioning for the majority 
of patients in this study. In the intervening years it has become clearer that this 
is not a sensitive tool to identify changes in neurocognition for patients with 
CNS tumours in clinical trials [343]. In 2011, expansion of my institution’s 
neuropsychology department permitted more advanced neuropsychology 
testing within the study and, following a substantial amendment the tests listed 
in table 2.1 are now carried out in patients who chose to participate in this 
aspect of the study. However, these data are not presented here as further 
patient recruitment and follow-up is required to draw conclusions.  
 
The study began recruitment in 2006. I was not involved in the original study 
design, but collected patient follow-up data and recruited new patients from 
2010-2013. I was solely responsible for data analysis and carried this out when 
50 patients had been recruited with a minimum follow-up of 1 year.  
 
I made several substantial amendments to the protocol in 2011 to allow:  
 inclusion of patients with a firm radiological diagnosis of meningioma. 
Initially a histological diagnosis of meningioma (any grade) was required, 
but many meningioma patients are diagnosed on radiological grounds 
without histology due to the risks of biopsy.  
 a volumetric arc technique (VMAT) to deliver IMRT. The original protocol 
specified a static gantry dynamic MLC radiotherapy technique (SG 
DMLC) with 4-9 non-opposing coplanar fields. However, as discussed in 
section 1.13.3, volumetric arc techniques (VMAT) have since been 
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proven to produce equivalent plans that can be delivered in a shorter 
time with less monitor units. 
 the use of PET information to assist in target volume definition (chapter 
3) 
 more extensive formal neuropsychology testing (table 2.2) with 
evaluations at baseline, 3 months, 1 year and 3 years.   
 the inclusion of an EEG substudy (appendix 2).  
 
Table 2-1 Neuropsychology tests added to protocol 
Test Name What Test Measures 
Weschler Adult Intelligence Scale/ 
National Adult Reading Test 
Intelligence estimate 
Recognition Memory Test for Words and 
for Faces  
Visual and verbal memory, distinguishes 
between right (visual) and left (verbal) 
hemisphere damage 
Adult Memory and Information Processing 
Battery: Story and Figure recall/ List and 
design learning  
Speed and accuracy of information 
processing 
 
Graded Difficulty Naming Test  Word-finding difficulties 
Incomplete Letters (vosp) Visual object and space perception 
Stroop Colour Word Test  Selective attention and executive function 
Trail Making Test (parts A and B) Visual motor speed and executive function  
Controlled Oral Word Association Test Verbal fluency 
Symbol Digit Modalities Test  General cerebral dysfunction 
Hospital Anxiety and Depression Scale Mental states that may interfere with other 
test results 
 
 
2.2 Aims 
To prospectively assess the following: 
 The feasibility of using IMRT to treat meningiomas 
 Symptom response and toxicity following IMRT for meningioma  
 The rate of local control of meningiomas following IMRT 50.4Gy in 28 
fractions 
 Patient reported quality of life following IMRT for meningioma 
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2.3 Methods 
 
2.3.1 Patients 
Patients due to receive radiotherapy for meningioma were recruited between 
November 2006 and November 2012. All patients would receive IMRT. Ethical 
approval for the conduct of this study was obtained by the Regional Ethics 
Committee (reference 06/Q0502/81). Inclusion criteria were: age over 18 and 
ECOG performance status 0-2. Patients were excluded if they had previous 
radiotherapy to the region or other illness that interfered with the protocol 
treatment plan. Patients could undergo IMRT as a primary treatment or 
following previous surgery.  
Fifty patients were evaluated. Patients were largely recruited from the local 
neurooncology practice, although some patients were referred from centres 
where IMRT was not available. For the purposes of data collection, these 
patients continued their follow-up at my institution. All patients were deemed 
appropriate for IMRT following discussion in the neurooncology multidisciplinary 
meeting where their clinical scenario, radiology and pathology were reviewed. 
Patients provided written informed consent to undergo IMRT. Median follow-up 
was 36 months (range 12-76 months). Table 2.2 details baseline patient 
demographics. The patients with visual symptoms are detailed in a separate 
column to assist in interpretation of the visual outcome data which was the most 
robust measure. 
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Table 2-2 Patient Characteristics 
Characteristic Total Patients n (%) Patients with visual 
symptoms n (%) 
Total 50 39 (78% of total) 
Sex 
Male 
Female 
 
20 (40) 
30 (60) 
 
 
14(36) 
25 (64) 
 
Age (years) 
Median 
Range 
 
50.5 
19-75 
 
 
50 
19-75 
Location 
Sphenoid Wing 
Parasagittal 
Cavernous Sinus 
Suprasellar 
Optic Nerve/ Apex 
Frontal 
Cerebellopontine Angle 
Occiput 
Middle Ear 
 
14 (28) 
  7 (14) 
11 (22) 
  5 (10) 
  4 (  8) 
  3 (  8) 
  3 (  6) 
  2 (  4) 
  1 (  2) 
 
 
14 (36) 
  2  ( 5) 
11 (28) 
  5 (13) 
  4 (10) 
  1 (  3) 
  0 
  2 (  5) 
  0 
Number of Previous 
Operations* 
None 
Biopsy only 
1 
2 
3 
 
 
  5 (10)  
  5 (10) 
28 (56) 
  9 (18) 
  3 (  6) 
 
 
  5 (13) 
  4 (10) 
20 (51) 
  7 (18) 
  3 (  8) 
 
Timing of Radiotherapy 
Primary 
Immediate post STR  
Immediate post GTR  
Progression post surgery  >1 
year previously 
 
 
  7 (14) 
20 (40) 
  6 (12) 
17 (34) 
 
  6 (15) 
18 (46) 
  0 
15 (39) 
Time to PD between last 
operations (months) 
Median 
Range 
 
 
31 
6-108 
 
 
60 
6-192 
Grade 
Not possible 
1 
2 
3 
 
  7 (14) 
27 (54) 
15 (30) 
  1 (  2) 
 
  7 (18) 
24 (62) 
  8 (21) 
  0 
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2.3.2 Radiotherapy Procedure 
Patients were immobilised with a thermoplastic shell and CT scanned in 
treatment position (2.5mm slices). Planning CT scans were fused with T1 plus 
gadolinium MRI sequences (pre and post-operative, slice thickness varied 3-
6mm). From July 2012, select patients also had 68Gallium PET imaging co-
registered (chapter 3). Target volumes were delineated using Oncentra 
Masterplan. GTV encompassed the visible tumour. A 1cm margin was applied 
in the plane of dural enhancement, bone or brain invasion to form the CTV. A 
5mm margin was applied to create PTV. PTV margin was reduced to 3mm from 
2012 as per institution guidelines. A 3mm margin was added to organs at risk 
(OAR) to create a planning organ at risk volume (PRV).  
Treatments were planned on Eclipse version 8.9, Varian Medical Systems, Palo 
Alto, using the Anisotropic Analytical Algorithm (AAA) and a 2.5mm calculation 
grid. Each plan was optimised for a 6MV beam on a Varian 2100 Series Clinac 
or Truebeam STx and normalised to the mean target dose prescribed.  The 
IMRT method initially used was a 5-9 field SG DMLC technique; this was 
replaced by VMAT (Varian RapidArc® ) in March 2012. The VMAT technique 
consisted of either a single arc or two arcs of 270-360⁰ (coplanar or non 
coplanar) to meet plan constraints. Prescribed dose was 50.4Gy to mean target 
dose in 28 daily fractions. Plan optimisation was performed to reflect the 
following PTV and PRV constraints: 99% PTV receives >90% dose; 95% PTV 
receives > 95% dose; 50% PTV receives 100% dose; a maximum of 5% PTV 
receives >105% dose; a maximum of 2% PTV receives >107% dose; brainstem 
receives < 55Gy (not an issue for prescribed dose of 50.4Gy); each lens receive 
<6Gy; each optic nerve receives < 50Gy; optic chiasm receives < 50Gy.  
Patients were moved on-set to correct for systematic errors with daily online Kv 
imaging and weekly cone beam CT (frequency of CT increased if difficulties 
with set-up).  
2.3.3 Radiotherapy Plan Evaluation 
Radiation plans were accepted if they met the above constraints. However, to 
provide more detail in accordance with the International Commission of 
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Radiation Units Report 83, I evaluated further data that was not part of the initial 
plan analysis: 
 
 the D98% and D2% to the PTV. These represent the near minimum and 
near maximum doses respectively. The mean values plus standard 
deviations (SD) are presented when data distribution was Gaussian and 
median plus interquartile range (IQR) when data was skewed.  
 
 PTV homogeneity index = (D2%-D98%) 
                                                           D50% 
 
 Conformity index (CI) = VPTV95%  
                                                   V95%  
 
This CI, described by Wagner et al [231], reflects the fact that 100% of the 
target is not necessarily covered by the 95% isodose and thus can be 
interpreted in a meaningful way (e.g. a CI of 0.8 means that 80% of the 95% 
isodose lies within the PTV and 20% outwith).  
 
2.3.4 Patient Evaluation 
 
2.3.4.1 General 
Formal evaluation was scheduled pre-IMRT, at one month, 3-6 months and 12 
months post-IMRT and annually thereafter. I carried out these evaluation as the 
clinical research fellow from 2011-2013. Prior to this, evaluations were 
performed by the previous research fellow or the consultant in charge of the 
patient’s care. Evaluations were recorded and stored in hard copy (no 
database). Toxicities were recorded fortnightly during treatment. ECOG 
Performance Status (PS), medications, medical problems and clinical 
examination features were recorded each visit. Symptoms and early and late 
treatment toxicity was recorded using the CTCAE version 3. Alopecia was 
assessed in relation to hair loss within the radiotherapy fields. Neurocognition 
was assessed by the MMSE at each visit. I considered a changes in an 
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individual’s score ≥4 points significant as per other published literature and the 
EORTC 22042-26042 meningioma study [342]. 
 
2.3.4.2 Quality of life 
It was chosen to assess quality of life with the validated and widely used 
EORTC questionnaires QLQ-C30 and QLQ-BN20 (Appendix 1). Patients were 
asked to complete EORTC questionnaires QLQ-C30 and QLQ-BN20 at each 
visit. QLQ-C30 evaluates global health status, functional status (physical, role, 
emotional, cognitive, social) and symptoms (fatigue, nausea/vomiting, pain, 
dyspnoea, insomnia, appetite, bowel upset, financial difficulties). EORTC QLQ-
BN20 is a brain specific module evaluating future uncertainty, visual loss, motor 
dysfunction, communication deficit, headaches, seizures, drowsiness, itchy 
skin, alopecia, weak legs and bladder dysfunction. The standard EORTC 
scoring procedure requires a “raw score” for each scale (15 scales for QLQ-C30 
and 11 scales for QLQ-BN20). This is the mean value of all responses for each 
scale. Raw scores are linearly transformed to a 0-100 scale as shown in Box 
2.1. 
 
Box 2.1 Linear transformation of QLQ scores 
 
                               Functional Scales: Score =     1 - (RS-1)      x 100  
                                                                                     Range  
 
 
                               Symptom Scales: Score =     (RS-1)}     x 100 
                                                                               Range 
 
 
                               Global Quality of Life: Score =      (RS-1)}      x 100 
                                                                                      Range 
                                          
 
RS: raw score; Range: difference between maximum and minimum possible 
raw scores (i.e. for a scale of 1-4 the range is 3). 
 
Interpreting the clinical relevance of changes from baseline to 3 years for each 
scale in EORTC QLQ-C30 varies between papers. I chose the method 
proposed by Cocks et al [340] as these specify clinically relevant small and 
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medium sized changes for each subscale (different for improvement and 
deterioration). Table 2.3 summarises the criteria. Such detailed guidelines are 
not available for interpretation of QLQ-BN20 and I therefore set a “minimal 
clinically important difference” as a standard change of ≥10 points for both 
improvement and deterioration in each subscale as this has been used in other 
brain tumour studies [341]. 
 
Table 2-3 Clinical relevance of changes in scores as proposed by Cocks et al 
[340] 
Subscale              Improvement 
Small          Medium       Large 
              Deterioration 
Small          Medium      Large 
 
 
 
 
Function 
 
 
 
Physical 
 
Role 
 
Cognitive 
 
Emotional 
 
Social 
 
↑2-7 
 
↑6-12 
 
↑3-7 
 
↑6-9 
 
↑3-8 
 
↑>7 
 
↑>12 
 
↑>7 
 
↑>9 
 
↑>8 
NE 
 
NE 
 
NE 
 
NE 
 
NE 
↓5 -10 
 
↓7-14 
 
↓2-10 
 
↓3-12 
 
↓3-12 
↓10 -17 
 
↓14-22 
 
↓>10 
 
↓>12 
 
↓>12 
↓>17 
 
↓>22 
 
NE 
 
NE 
 
NE 
 
Global Health Status 
 
 
↑5-8 
 
↑>8 
 
NE 
 
↓5-10 
 
↓10-16 
 
↓>16 
Symptom Fatigue 
 
Nausea 
 
Finance 
 
Pain 
 
Constipation 
 
Diarrhoea 
 
Dyspnoea 
 
Insomnia 
 
Appetite 
↓>9 
 
↓3-9 
 
↑>3 
 
↓5-9 
 
↓4-10 
 
↓3-11 
 
↓2-9 
 
↓5-9 
 
↓7-13 
 
↓4-9 
 
↓>9 
 
NE 
 
↓9-14 
 
↓>10 
 
↓>11 
 
↓>9 
 
↓>9 
 
↓>13 
NE 
 
NE 
 
NE 
 
↑>14 
 
NE 
 
NE 
 
NE 
 
NE 
 
NE 
↑2-9 
 
↑5-11 
 
↑2-10 
 
↑3-11 
 
↑5-15 
 
↑5-15 
 
↑5-11 
 
↑2-9 
 
↑2-14 
↑9-17 
 
↑11-16 
 
↑>10 
 
↑11-20 
 
↑>15 
 
↑>15 
 
↑>11 
 
↑9-17 
 
↑14-26 
↑>17 
 
↑>16 
 
NE 
 
↑>20 
 
NE 
 
NE 
 
NE 
 
↑>17 
 
↑>26 
 
Individual patient scores for global health status were also analysed. There is 
no guidance as to what would be deemed a significant change for individual 
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patients but changes of ≥3 points were recorded. A pituitary blood screen 
(random time) was performed pre-IMRT and at follow-up: FSH, LH, 
testosterone/ oestradiol, GH, IGF-1, TFTs, cortisol, and prolactin. Routine 
stimulation tests were not performed.  
 
2.3.4.3 Ophthalmic Evaluation 
Patients with baseline visual symptoms had ophthalmic evaluation performed by 
a neuro-ophthalmologist. Both eyes were evaluated. Visual acuity was 
assessed with a Snellen chart (+/- pinhole) and scored as per table 2.4.  A 
defect was defined as 6/12 vision or worse; an increase of ≥2 points was an 
improvement. A defect in colour vision, as assessed by Ishihara plates, was 
defined as ≥3/17 plates not read; an increase in ≥3 plates read constituted an 
improvement. The test plate had to be read correctly to indicate sufficient acuity. 
Visual fields were assessed by Humphrey automated perimetry when vision 
allowed (expressed as the mean deviation (MD) in decibels (dB)) or Goldmann 
kinetic perimetry (expressed as mean radial degrees (MRD) on the 14e isopter). 
In Humphrey perimetry an improvement was a decrease of ≥3dB; in Goldman 
perimetry improvement was an increase of ≥10 MRD. Improvements had to be 
sustained during subsequent testing. Deterioration criteria were the converse of 
improvement criteria. Pupil examination, fundoscopy, ocular motility, ocular 
pressures, retinopathy, cataract, keratitis, ptosis, proptosis and dry/ watery eye 
were documented according to the CTCAE version 3.0. Toxicities were deemed 
short-term or persistent depending on whether they lasted for less or more than 
6 months following IMRT. 
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Table 2-4 Scale for Scoring Visual Acuity 
Snellen Chart Reading Score 
6/5 12 
6/6 11 
6/9 10 
6/12 9 
6/18 8 
6/24 7 
6/36 6 
6/60 5 
Finger Counting 4 
Hand movements 3 
Light Perception 2 
No light perception 1 
 
 
2.3.5 Radiology 
Patients underwent MRI plus gadolinium pre-IMRT (≤8 weeks prior), at 3 
months, 1 year then annually. Tumour status was assessed according to the 
modified RECIST criteria detailed in the RTOG study (Box 2.2). Standard 
multiplanar sequences performed were T1, T1 plus gadolinium, T2, FLAIR.  
 
2.3.6 Statistical analyses 
Influence of prognostic factors on outcome was assessed using logistic 
regression in a univariate model and the association between dose to lacrimal 
gland and the development of a dry eye was assessed by logistic regression 
with dose as a continuous variable. SPSS version 21 was used for all statistical 
analysis with a value of p<0.05 deemed statistically significant.  
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Box 2.2 Modified RECIST Criteria Used 
 Continued No Evidence of Disease (CNED): no measurable residual 
meningioma pre or post IMRT  
 
 Complete Response (CR): disappearance of any residual, measurable 
meningioma. 
 
 Partial Response (PR): measurable meningioma decreases by ≥20% in 
any diameter, but does not meet the criteria for CR. 
 
 Minor Response (MR): measurable meningioma decreases in any 
diameter  
by <20%. 
 
 Stable Disease (SD): measurable meningioma remains unchanged, or 
increases in any diameter by <20%. 
 
 Progressive Disease (PD): measurable meningioma increases in any 
diameter by >20%, or new nodular enhancement occurs in patients with 
no measurable meningioma pre-IMRT 
 
 Neurologic Progression (NP): new or progressive neurologic deficit 
attributed to meningioma, with or without measurable meningioma 
growth. 
 
2.4 Results 
 
2.4.1 Radiotherapy Plan Evaluation 
39 patients had SG DMLC plans with 4-9 fields (mean 5) and 11 had VMAT 
plans (1-2 arcs). Mean monitor units to deliver the plan was 618 for IMRT (SD 
166.8) and 368 for VMAT (SD 55.6). The median PTV for all cases was 
89.5cm3 (IQR 62-144cm3) with a median 95% isodose coverage of 96% of PTV 
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(IQR 95.5-96.6%). Mean PTV D98% was 94.4% prescribed dose (SD 1.7%) 
and mean PTV D2% was 104% (SD 1.4%). Mean homogeneity index was 0.1 
(SD 0.03): there was an average 10% difference of dose across the PTV. Mean 
conformity index was 0.83 (SD 0.08): an average of 83% of the 95% isodose lay 
within the PTV.  
Mean brain-PTV dose was 10.4Gy (SD 3.9Gy). Doses to PRVs are recorded in 
table 2.5. In select cases doses to PRV above those specified were accepted, 
e.g. higher ipsilateral eye PRV doses were accepted in the case of an ipsilateral 
blind eye when the aim of treatment was to spare contralateral vision. In 
general, PTV coverage was not compromised to reduce dose to lenses. All 
patients completed the prescribed treatment course.  
 
2.4.2 Tumour control  
88% of patients had measurable meningioma on imaging prior to IMRT. Four 
patients had a minor radiological response and 42 patients SD. No patients had 
a CR or PR. Of those with a minor response, the tumour reduction had occurred 
on the one year scan in two and the two year scan in two. Four patients 
exhibited radiological PD (3 were G2, 1 was G1). One progression occurred at 
24 months, two at 30 months (new symptoms prompted imaging) and one at 64 
months (G1). Radiological local control rates at a median follow-up of 36 
months were 96.3% for known G1 tumours, 81.3% for known higher grade 
tumours and 100% for tumours diagnosed radiologically (most likely G1). 
Of the four patients with PD, one had further surgery plus experimental 
radioisotope therapy (chapter 5), one had experimental radioisotope therapy 
alone and two have had no further treatment (one asymptomatic and one unfit 
for surgery). One further patient with a cavernous sinus tumour developed 
increased ptosis presumably related to tumour progression but without clear 
change on MRI (neurological progression). Two patients in the cohort died, one 
due to progressive meningioma and one of unrelated causes.  
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Table 2-5 PRV: Dose Objectives Set and Actual Doses Accepted  
OAR dose Maximum 
Dose 
Objective Set 
(Gy)* 
Accepted 
Dose 
Range (Gy) 
 
Accepted Dose Median (Gy) 
  
Number of Patients with accepted 
dose > objective dose ** 
 
All Pts (n=50)          Pts with visual 
symptoms  
(n=39)                 
All Pts (n=50) Pts with visual 
symptoms 
(n=39) 
Right lens  6 0.2-14.2 5.4 6.0 12 12 
Left lens  6 0.2-38.0 5.2 5.5 9 9 
Right ON PRV  50 0.7-54.6 36 47.9 6 5 
Left ON PRV 50 0.4-52.3 47.6 47.6 6 5 
Chiasm PRV 50 0.5-51.9 49.5 50.0 7 7 
Right globe PRV 45 0.3-52.3 24.2 28.5 3 3 
Left globe PRV 45 0.2-49.8 26.1 27.1 4 4 
Brainstem PRV 55 0.9-54.2 51.4 49 0 0 
Right lacrimal gland  None 0.1-31.2 
(mean) 
n/a 12 n/a n/a 
Left lacrimal gland  None 0.1-38.5 
(mean) 
n/a 8  n/a n/a 
*Dose objective data refers to 2Gy per fraction, in our patients 1.8Gy per fraction was being delivered. Dose equivalents were not calculated due to 
associated uncertainties. **Doses to PRV > objective were accepted for example if risk of damage from meningioma > than risk of damage from 
radiation or in already blind eyes. 
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2.4.3 Symptoms  
95% of patients had meningioma-related symptoms pre-IMRT. All 
symptoms had been present for 6 months or more (median 24 months, IQR 
12-46 months).   
 
2.4.3.1 Visual Symptoms  
Baseline 
Visual symptoms were the most common, present in 39/50 (78%) patients. 
35/39 (89.7%) had tumours affecting the anterior visual pathways including 
three patients with ONSM. At baseline 25/39 patients had a defect in visual 
acuity and/or colour vision, six of whom were blind in the ipsilateral eye (no 
light perception). 18 had a defect in visual field and 16 a defect in extra-
ocular movements. Thirty-two had more than one ophthalmological 
symptom/ sign, often related to the same nerve/ pathway. Eight had ptosis 
and eight had proptosis. 
 
Improvements 
The original visual deficits improved in 15/39 patients (38.5%) and were 
stable in 24 (61.5%). In patients with more than one visual deficit, 
improvements were often congruous across symptoms/ signs related to the 
same nerve. Outcome data are stated in relation to the number of patients 
that had each defect at baseline. There were improvements in visual acuity 
in 1/20 patients, colour vision in 4/10 and visual field in 5/18. Rarely both 
eyes were affected: one patient had colour vision abnormalities in both eyes 
that improved in both eyes and three patients had field defects in both eyes 
that improved in both eyes in one patient. The majority of patients had some 
changes noted in measurable variables too small to meet the pre-defined 
criteria that indicated test/ re-test reliability. Indeed, even “clinically relevant” 
test improvements were not necessarily such that the patient noted an 
improvement. Figure 2.1 displays changes noted in patients with defects in 
acuity, colour vision and field. Table 2.6 details overall baseline symptoms 
and outcomes.  
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Extra-ocular movements improved in 5/16 patients. 3/8 patients with ptosis 
noted significant improvement and proptosis improved in 2/8 patients. 
Improvement in extra-ocular movement or proptosis corresponded with 
reduced patient-reported diplopia. Three patients had convergence defects 
prior to IMRT that remained stable and were treated with prismatic 
correction. Median time to improvement following completion of IMRT was 6 
months (range 1 month- 30 months). One patient with ptosis had a 
significant improvement at 3 months that returned to baseline by 1 year 
then remained stable.  
On univariate analysis, none of the following were found to be predictive of 
a clinical response in vision following IMRT: age, sex, grade, type of 
baseline clinical abnormality, blind eye, previous surgery, time since 
surgery, location of tumour, time since symptom onset or PTV size (table 
2.7). There was a trend towards a baseline deficit in visual acuity being a 
negative predictive factor for any form of visual clinical response (OR=0.27, 
CI=0.07-1.09, p=0.066). One of the six patients with a blind eye had an 
improvement, but this was in the contralateral visual field. Three patients 
with baseline optic disc pallor had clinical visual improvements associated 
with improved optic nerve function without change in disc appearance. 
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Table 2-6 Ophthalmology deficits at baseline and last follow-up in patients with baseline deficit 
Deficit Number of patients with 
baseline defect (eye 
number if different) 
Outcome at last follow-up 
Number of patients (eye number if different) 
 
Improvement Stable  Deterioration  
Acuity 20 1 (1) 38 0 
Colour Vision 10 (11)* 4 (5) 35 0 
Visual Fields † 18 (22) 5 (7) 31 1 
Pupil Defect 25 4 35 0 
Disc Swelling 2 1 38 0 
Ophthalmoplegia 16 5 34 0 
Ptosis 8 3 36 0 
Proptosis 8 2 37 0 
Retinopathy 0 0 38 1 (unrelated) 
 *10 further patients could not see the test plate due to poor acuity; † 2 patients not included in outcome analysis had field changes unrelated to IMRT 
(glaucoma surgery and retinal detachment) 
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Figure 2-1 Outcomes for patients with baseline visual acuity, colour or field 
deficits 
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Table 2-7 Univariate Analysis of Baseline Predictors of Any Response  
Baseline Characteristic Odds 
Ratio 
95% CI P value 
Age (continuous) 1.0 0.95-1.06 0.798 
Female 1.41 0.37-5.45 0.614 
Impaired Acuity 0.27 0.67-1.09 0.066 
Impaired Colour Vision 0.92 0.25-3.42 0.923 
Disc Abnormality 0.59 0.16-2.21 0.589 
Pupil Abnormality 0.85 0.21-3.36 0.847 
Visual Field Restriction 1.41 0.37-5.45 0.614 
Proptosis 0.45 0.08-2.42 0.338 
Ptosis 0.86 0.18-4.16 0.864 
Ophthalmoplegia 0.42 0.08-2.07 0.285 
Blind 0.31 0.03-2.94 0.306 
Prior Surgery 1.43 0.16-3.74 0.745 
Size of PTV (continuous) 1 0.99-1.01 0.583 
Region of Tumour*   0.976 
Time Since Symptom Onset†   0.959 
*data categorised into ONSM, cavernous sinus, sphenoid wing, parasellar, posterior pathway; 
all categories were non-significant so detail not displayed  
†data categorised into < 12 months, 1-2 years, 2-5 years and >5 years; all categories were non-
significant so detail not displayed 
 
2.4.3.2 Other Symptoms  
Forty patients completed evaluation of non-visual symptoms and ECOG 
performance status. Headache was the most common with ten patients 
reporting moderate or severe headache prior to treatment. The severity of 
headache had reduced to at most mild (not requiring regular analgesia) in 7/10 
patients by one year post-IMRT, although four remained on the neuropathic 
agent they had been taking prior to IMRT. Two patients had an increase in 
headaches following radiotherapy: scar pain increased from moderate to severe 
at three months following radiotherapy in one patient but returned to moderate 
following lidocaine injection at one year and the other patient with baseline mild 
headache developed severe headache one year following radiotherapy which 
returned to mild headache following treatment for anxiety and depression.  
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Five patients experienced seizures before IMRT (four had simple partial 
seizures, one had grand mal seizures). The frequency of seizures reduced in 
two patients in the two years following IMRT, but they also had alterations in 
anti-epileptic medications around the time of IMRT. One patient had resolution 
of seizures and stopped anti-epileptic medication. One patient developed new 
seizures as a late toxicity.  
Other symptoms were very varied and largely dependent upon tumour location. 
Figure 2.2 details the grade of non-visual symptoms at baseline and most 
recent review. Overall, 20 patients reported ≥G2 (moderate) non-visual 
symptoms at baseline (34 moderate symptoms in total as some patients had 
more than one moderate symptom). On their most recent visit ten patients 
reported moderate non-visual symptoms (15 moderate symptoms in total) 
equating to a 50% decline in patients reporting moderate symptoms. 
 
2.4.4 Toxicity  
2.4.4.1 Acute 
Fatigue, alopecia, dermatitis, nausea, ocular surface irritation (watery or 
inflamed eye) and a sensation of ear “fullness” causing some irritation and 
conductive hearing reduction were reported (figure 2.3).  Acute side-effects 
peaked at around ten weeks from commencing treatment (1 month post-
treatment) and were almost at baseline by 6 months post treatment. 87.5% 
experienced at least moderate fatigue, but >30% of patients had reported this 
level of fatigue at baseline, many of these patients had recent surgery, were 
taking strong analgesia/ anti-epileptic medication or had other health problems 
that could have accounted for the fatigue. Fatigue levels were at baseline by 
one year. 77.5% reported moderate alopecia at ten weeks following treatment 
although 15% had baseline alopecia due to recent surgery (unrelated alopecia 
not included). Ocular surface irritation refers to erythema and watering of the 
eye. Two patients reported new G1 diplopia during treatment that had resolved 
by week 18. 
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Figure 2-2 Non visual symptoms pre and post IMRT 
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Figure 2-3 Acute Toxicities 
 
 
2.4.4.2 Performance Status 
A temporary deterioration in ECOG performance status, largely related to 
fatigue, was documented in 16 patients (figure 2.4):  12 patients increased from 
PS0 to PS1, three patients from PS1 to PS2 and one patient from PS2 to PS3.  
These all returned to baseline by 6 months. PS improved between baseline and 
six months in three patients: one improved from PS2 to PS0 and two from PS1 
to PS0, although the baseline poor PS in two of these patients could be 
attributed to recent surgery rather than tumour. 
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Figure 2-4 ECOG Performance Status pre and post IMRT 
 
 
2.4.4.3 Persistent Toxicity  
One patient developed grade 2 keratitis and dry eye at week ten which 
remained at 28 months and was managed with lubricants and anti-inflammatory 
eye drops. Doses to globe PRV in this case were: mean 25Gy, maximum 41Gy, 
D2% 40.7Gy, lacrimal gland mean 30Gy. The same patient developed grand 
mal seizures two years after treatment with an apparent new region of 
meningioma beside the original tumour that was found to be necrotic tissue 
without tumour at surgery. The patient has had no further seizures. One patient 
with a suprasellar meningioma developed asymptomatic persistent patchy 
contralateral temporal hemi-field loss first detected at 6 months (pre-IMRT MD -
1.1dB; 6 months MD -4.1). There was no radiological progression which 
suggests the cause was chiasm-related radiotherapy toxicity (chiasm PRV max 
49.5Gy, D2% 49.12Gy). Three patients developed ipsilateral G1 cataract not 
requiring intervention at 10, 15 and 18 months - lens doses (organ, not PRV): 
5Gy, 12Gy and 16Gy. One patient developed posterior vitreous detachment in 
week 6 and contralateral retinal detachment 18 months later (globe doses 39 
and 41.5Gy). These were thought to be probably unrelated to treatment. No 
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patient with baseline uniocular symptoms developed toxicity in the contralateral 
eye. 
Five patients reported mild dry eye (requiring intermittent use of over the 
counter drops) and two patients had persistent mild watery eye after 1 year. 
Lacrimal gland doses in the patients who developed G1 dry eye were 23-
31.2Gy (median 29Gy). Eight other patients with lacrimal gland doses >23Gy 
did not report dry eye. Increasing dose (in Gy) to the lacrimal gland was 
associated with the development of dry eye (OR=1.18 for each 1Gy increase in 
dose to the lacrimal gland, CI= 1.06-1.3, p=0.003). The doses quoted to the 
lacrimal gland were delivered to the organ itself; no PRV was created as dose 
constraints were not specified. 
One patient with a meningioma in the region of the auditory canal reported 
increased tinnitus three months following radiotherapy that was still present at 
18 months. One patient developed in-field ophthalmic herpes zoster (HZ) at 10 
months. The skin rash resolved following standard HZ therapy, but neuropathic 
pain persisted at 30 months.  
 
2.4.5 Quality of Life 
Baseline QLQs were available for 40 patients. Time points were analysed when 
>50% of patients initially surveyed completed follow-up QLQs: baseline, 3-6 
months, 12 months and 2-3 years post-IMRT (table 2.8).  
 
Table 2-8 Quality of Life Questionnaire returns 
Time point Expected Received % Return % of Initial 
Baseline 40 40 100 100 
1 month post RT 40 4 10 10 
3-6 months post 
RT 
40 36 90 90 
12 months post 
RT 
33 23 69.7 57.5 
24-36 months 
post RT 
24 23 95.8 57.5 
≥48 months post 
RT 
9 7 77.8 17.5 
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Table 2.9 compares the baseline and 1 year QoL scores for this cohort of 
patients with EORTC scores from the general population and “all cancer” 
patients [344].  Despite the fact that most meningioma patients had 
histologically benign disease, their baseline mean global health status was 
almost identical to the “all cancer” patients. Functional scores in our patients 
were lower than “all cancer patients” particularly fatigue, insomnia and financial 
difficulties.   At one year post-IMRT mean global health status in our patients 
had risen to almost equate the general population mean, although functional 
and symptom scores generally remained similar to those reported by “all cancer 
patients”. 
Using the criteria by Cocks et al [340] there was a medium improvement in 
mean global QoL by 1 year (increase of 8.4 points over baseline) that persisted 
but was classified as small at 2-3 years (increase of 5.9 points over baseline). 
Small improvements were also documented in pain by 3 months (reduction in 
5.5 points from baseline), appetite by 1 year (reduction in “loss of appetite” of 
8.1 points) and finances by 2-3 years (reduction in financial symptoms of 7.3 
points). A medium reduction in cognitive functioning was identified at 3 months 
(reduction in cognitive function of 17.2 points), but this returned to baseline level 
by 1 year and remained the same at 2-3 years.  
For QLQ-BN20 the only change classified as significant (≥10 point change) was 
an increase in daytime drowsiness at 2-3 years (11.2 point change). This had 
been stable at one year.  
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Table 2-9 Quality of life scores for study population compared to general 
population and “all cancers” population 
Scale General 
Population 
(Mean) 
All Cancers 
(Mean) 
Meningioma 
Patients Pre-
IMRT (Mean) 
Meningioma 
Patients 1 
year post- 
IMRT (Mean) 
Global Health 
Status 
71.2 61.3 61.5 69.9 
Physical 
Functioning 
89.8 76.7 76.2 76.8 
Role 
Functioning 
84.7 70.5 65 67.4 
Emotional 
Functioning 
76.3 71.4 66.3 69.3 
Cognitive 
Functioning 
86.1 82.6 75.8 76.1 
Social 
Functioning 
87.5 75.0 70.0 71.7 
Fatigue 24.1 34.6 38.1 34.8 
Nausea 3.7 9.1 4.2 1.5 
Pain 20.9 27.0 27.5 23.9 
Dyspnoea 11.8 21.0 13.3 10.1 
Insomnia 21.8 28.9 35 27.5 
Appetite Loss 6.7 21.1 21.7 7.3 
Constipation 6.7 17.5 19.1 11.6 
Diarrhoea 7.0 9.0 7.5 10.2 
Financial 
Difficulties 
9.5 16.3 30 30.4 
n.b. For Global Health Status and Functional subscales the closer the score is to 100 the better; 
for Symptoms subscales the closer the score is to 0 the better 
 
As only 57% of those with baseline scores had 2-3 year scores, I re-analysed 
changes from baseline to 2-3 years in only those with 2-3 year scores. The 
improvements detailed above were maintained, but small improvements were 
also noted at 2-3 years in role functioning and insomnia, and the improvement 
in appetite was medium rather than small. Furthermore, the significant increase 
in daytime drowsiness no longer remained significant (6.2 point increase as 
opposed to 11.2). 
For individual patients, eight patients had significant improvements in global 
health status (≥3 points) between baseline and their most recent visit. In all 
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cases these improvements had occurred by 1 year (three patients had an initial 
decline at 3 months). Three patients had a decline in global health status 
between baseline and their most recent visit. Unrelated issues accounted for 
this decline in two of these three patients. Figures 2.5 and 2.6 depict trends in 
quality of life measures in relation to IMRT. 
 
 
 
Figure 2-5 Global quality of life for all patients  
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Figure 2-6 Quality of life results for specific domains  
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2.4.6 MMSE 
Forty patients had baseline and subsequent MMSE scores. Three patients had 
baseline MMSE ≤25/30 (classified abnormal). The median baseline MMSE was 
30/30. One patient’s score declined by 4 points at 2 years (from 29 to 25), but 
this was attributable to disease progression rather than radiotherapy. All other 
patients remained within 3 points of their baseline score at their last follow-up, 
i.e. no significant change. 
 
2.4.7 Pituitary 
Thirty-one patients had full pituitary blood screens done at every visit (median 
32 months follow-up), 2 others had thyroid function only checked.  
Three patients had baseline panhypopituitarism (two long-standing diagnosis, 
one new diagnosis following the study bloods). Two other patients had baseline 
high prolactin levels (>2x ULN). Three other patients developed prolactin levels 
up to 3 x upper limit of normal one year following radiotherapy. All patients with 
high prolactin levels were female and all had disease in the pituitary/ 
hypothalamus region, except one whose hyperprolactinaemia was felt to be 
medication-related. Prolactin levels remained elevated in the patients with high 
baseline values, but reduced to <1 x ULN by two years in the patients who 
developed raised levels after radiotherapy. 
 
2.5    Discussion 
 
2.5.1 Treatment Plans 
IMRT provided excellent target coverage and organ at risk avoidance. However, 
the prescribed dose of 50.4Gy was within tolerance of most OARs except the 
retina.  IMRT would be preferable to 3DCRT if higher doses were prescribed 
particularly around visual pathways. The overall impression was that dosimetry 
for patients treated with SG-DMLC IMRT or VMAT was comparable, although 
duel planning would be required to confirm this. As previously discussed, VMAT 
115 
 
became the preferred mode of IMRT delivery due to the reduced treatment time 
and monitor units. Conformity and homogeneity indices are not routinely 
evaluated in plan approval and it may be useful to include such indices when 
standard dose constraints are fairly easily met. 
   
The significance of a mean brain-PTV dose of 10.4Gy is unclear. In recent 
years, the OAR sparing capabilities of IMRT has naturally stimulated research 
into whether constraints should be set for other regions of the brain related to 
higher mental function. The hippocampus is one region which has an important 
role in memory function and appears to be extremely radiosensitive. Gondi et al, 
found that equivalent dose in 2Gy per fraction of >7.3Gy to ≥40% of the bilateral 
hippocampi was associated with some degree of memory impairment at 18 
months [345]. These results should be considered preliminary due to the very 
small sample size, but they provide a rationale for minimising dose to the 
region. To ensure that VMAT techniques would not be inferior to SG-DMLC for 
hippocampal sparing I carried out a small planning study detailed in Appendix 3 
to establish whether the hippocampal dose constraint suggested by Gondi’s 
work could be achieved for meningiomas using both techniques. In summary, 
dose to the hippocampi could be markedly reduced by specifically setting 
hippocampal constraints in the optimiser, but it was difficult to meet the D40% 
≤7.3Gy (in 2 Gy per fraction) constraint for tumours close to the hippocampi. 
VMAT was generally superior to SG-DMLC. 
 
2.5.2 Tumour Control 
Tumour control rates in this study compare well to published series where the 
majority of patients were treated with 3DCRT (stereotactic or standard): 92% 
overall radiological stable disease (96% for G1 and 81% for G2). However, 
larger patient numbers and longer follow-up is required as late PD can occur. 
Progression-free survival curves have not been presented here as they are 
misleading in view of the recurrence at 64 months in the benign group in 
relation to the small number of patients followed up to that point.  
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2.5.3 Symptom Control 
2.5.3.1 Vision 
In the patients with baseline visual symptoms and detailed neuro-
ophthalmological assessment, 38.5% had objective sustained improvement 
following IMRT. Symptoms remained stable in the others. Symptoms associated 
with optic nerve impairment appeared as likely to respond as those related to 
cavernous sinus cranial nerves, whilst improvements in proptosis or ptosis were 
also recorded. The likelihood of overall clinical response was assessed but no 
clear predictors were found although, there was a trend towards a deficit in 
acuity being a negative predictor (p=0.06). Rush et al reported that visual 
improvement occurred predominantly in patients with limited baseline visual 
deficits who were treated with primary radiotherapy for pituitary 
macroadenomas [346]. Adeberg et al reviewed outcomes in 40 patients with 
ONSM treated with FSRT (mostly 3DCRT) of whom 29 had baseline visual 
impairment. Long-term visual outcomes were better in patients without previous 
surgery and larger tumour volumes [165]. None of the three ONSM patients in 
our study had a response, but two patients were blind prior to treatment. Patient 
numbers in both these studies and our own are too small to draw firm 
conclusions regarding predictors of response. 
 
2.5.3.2 Other symptoms 
 
50% of patients with ≥G2 (moderate/ severe) non-visual symptoms reported a 
reduction in the symptom to ≤G1 (nil/mild). Improvements were often noted in 
more than one symptom. However, symptomatic improvements are likely to be 
multi-factorial and the role of IMRT is hard to define. Headache was the most 
common non-visual symptom and 7/10 patients no longer required regular 
analgesics one year post-IMRT, but the addition of regular neuropathic agents 
in some patients confound the issue. Similarly, the reduction in seizure 
frequency documented may also be largely related to medication changes. 
Measurement of non-visual symptoms is relatively subjective, particularly when 
patients were assessed by different clinicians. Notwithstanding, the symptom 
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scales used are frequently applied in EORTC-badged studies and are the best 
available tools.  
 
2.5.4 Comparison to other studies 
Several retrospective studies have reported outcomes following radiotherapy (a 
variety of techniques and dose schedules) in larger groups of patients. Combs 
et al, published a retrospective evaluation of outcomes in 508 meningioma 
patients following radiotherapy [167]. They report visual improvements in 29% 
and patient reported other symptom improvements in 26%, but criteria for 
improvement are undefined. Milker-Zabel et al, reported improvements in pre-
existing neurological deficits in 47.9% following all types of radiotherapy in all 
meningioma locations (317 patients)[186], an improvement in 39.8% of patients 
receiving IMRT for base of skull meningiomas (94 patients)[162] and a clinical 
response in 19% of patients with cavernous sinus meningioma (57 patients) 
[347]. Most improvements concerned diplopia, exophthalamus and trigeminal 
hypo/ dysesthaesia, but there is no detail regarding response criteria. Stiebel-
Kalish et al found that 38% and 50% of patients with anterior visual pathway 
meningiomas treated with FSRT had an improvement or stabilisation in vision 
respectively (16 patients) [348] . 
There are many retrospective surgical series categorised by tumour location 
and surgical technique. Jacob et al, found an improvement in vision in the 
ipsilateral eye in 23%, stable vision in 27% and deterioration in 50% of patients 
who underwent surgery for cavernous sinus meningioma[349]. Improvements in 
visual symptoms following surgery for suprasellar meningioma are reported in 
42-78% with deterioration in 13-28%[350]. Post-operative improvements in 
vision has been reported in 30% of cases of spheno-orbital ridge meningiomas, 
with a reduction in proptosis in 85%, but new cranial nerve deficits in 21%[351].  
There are no direct randomised trials comparing surgery with radiation, 
although a few studies have compared outcomes in patients treated with 
radiotherapy against a historical surgical cohort. Andrew’s et al, reported 150% 
higher probability of visual improvement in the radiotherapy group [195] and 
Turbin et al, found that patients who received radiation alone showed the 
118 
 
highest rate of vision preservation [352]. Whether radiotherapy was the primary 
treatment or followed previous surgery did not predict clinical response in our 
cohort, but patient numbers were too low and confounding factors too high to 
make any recommendations regarding the merits of either approach. No 
patients in our study had rapid visual deterioration so it is not possible to advise 
upon whether radiotherapy would be an alternative to surgery in this situation.  
An improvement in symptoms was reported in 40% of patients with 
meningioma-related visual field disturbances following radiosurgery with no 
deteriorations [353]. In view of the higher theoretical potential for toxicity with 
large single fractions, radiosurgery dose reductions to areas of meningioma 
adjacent to visual pathways are often necessary. Longer term results and 
further study is required. It must be noted that single fraction radiosurgery would 
not have been suitable for the majority of patients in this study in view of relative 
contraindications. However, short course fractionated radiosurgery, e.g. with 
Cyberknife, may be a suitable and convenient alternative to IMRT. 
 
2.5.5 Radiology  
Despite the number of patients with a notable improvement in symptoms, few 
had radiological improvement and no patient had a response sufficient to be 
regarded as a PR by RECIST criteria. Improvement in symptoms without 
radiological tumour shrinkage has been reported previously [208, 353, 162]. 
This may be due to very minor changes in normal tissue and tumour geometry, 
a reduction in peritumoural oedema or be related to changes in tumour 
vasculature. MRI based measures such as apparent diffusion co-efficient or 
perfusion values may give additional information about response to therapy. 
Although our radiology protocol included such MRI sequences, unfortunately 
issues in radiology protocoling resulted in inadequate numbers undergoing 
baseline diffusion/ perfusion sequences prior to 2011 and there are currently 
insufficient patient data to evaluate.  Clearly, the current linear-based criteria 
used for response evaluation in meningiomas (RECIST or WHO) are insufficient 
to predict clinical response and even the modified criteria used here appear 
insensitive. Volumetric analysis may be a more sensitive alternative (discussed 
further in section 5.5).  
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2.5.6 Toxicities 
Acute toxicities peaked one month post-IMRT and generally resolved by six 
months. Fatigue and alopecia were experienced by the majority, although 
alopecia was confined to small areas and appeared to be less frequent in those 
treated with VMAT rather than SG-DMLC IMRT. I have previously found that 
scalp surface radiation dose was approximately 10Gy less for VMAT plans 
compared to the same brain tumour volumes planned with SG-DMLC IMRT 
[354]. No unexpected acute toxicities occurred. 
Persistent toxicity was low, the main symptom being low grade dry eye. An 
increase in dose to the lacrimal gland was associated with an increase in 
reported dry eye, although, the odds ratio of 1.18 per 1Gy increase in dose to 
the lacrimal gland may represent a mean as there is likely to be a threshold 
dose where risk increases exponentially. Lacrimal gland tolerance levels are not 
well defined and larger numbers would be required to perform modelling. There 
are no specified lacrimal gland dose constraints in meningioma study protocols 
or the QUANTEC initiative. Bhandare et al developed a normal tissue 
complication probability model predicting a total dose of 34Gy and 38Gy to the 
major lacrimal gland would correspond to a 5% and 10% incidence of severe 
dry eye syndrome (DES) following radiotherapy for head and neck cancer [355]. 
They reported a decrease in latency of DES onset with an increase in total dose 
and dose per fraction to the lacrimal gland. It is unclear whether total dose 
corresponded to mean or maximum dose (plans from 1965 onwards).  Mean 
dose may be more relevant for lacrimal gland function (similar to parotid). 
However, the sensation of dry eye is likely to be influenced by dose to other 
ocular glandular structures and interventions such as previous surgery. 
Moreover, dry eye is a relatively common complaint in the general population 
with a reported prevalence of 14.4% [356].  
Of note, the patient in our study with persistent grade 2 dry eye had 
experienced acute keratitis. She also went on to develop a small region of 
radiation necrosis with associated oedema that presented as a grand mal 
seizure. These symptoms developed despite all structures being within 
standard tolerance levels, suggesting a degree of individual radiation sensitivity. 
Another patient developed visual field deterioration consistent with chiasm 
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damage. Chiasm PRV was within tolerance levels and she was not diabetic.  
These cases highlight the fact that there is still some risk to normal structures at 
doses considered acceptable and fraction sizes of <2Gy.  
It has been reported that a dose per fraction <1.9Gy minimises the risk of 
radiation-related optic neuropathy or retinopathy[255, 254] and that long term 
morbidity increases with a total dose >54Gy[172]. Within my study, dose 
constraints to ocular PRV were conservative and readily achievable in view of 
the 50.4Gy prescription. Nevertheless, little is known about dose constraints for 
structures such as the extraocular muscles/ nerves and posterior visual 
pathways and it is reassuring that I documented no toxicity associated with 
these regions.  
 
2.5.7 Quality of Life 
Quality of life assessments are most commonly associated with studies in the 
palliative setting and QoL evaluation is lacking for meningiomas. However, it is 
very important for meningioma patients as survival is generally not the issue 
and there are various treatment options to consider that may have varying 
impact on QoL. It is interesting to note that although only one meningioma was 
malignant, the overall QoL scores closely resembled the scores for patients with 
“all cancers” rather than the general population. This highlights the considerable 
impact of meningiomas upon QoL.  
Clinically significant improvements were documented in global health status, 
pain, appetite and finances following IMRT (most improvements by 1 year). The 
decline in self-reported cognitive function at 3-6 months post-IMRT is likely 
related to fatigue as both returned to near baseline at 1 year. Daytime 
drowsiness appeared to increase at 2-3 years following IMRT, but this finding 
disappears when the baseline results of those who had not completed 2-3 year 
questionnaires are excluded.  The drop-out rate of patients completing QoL 
forms over time (due to death, lack of follow-up or non-compliance) is a major 
problem with interpretation of QoL data. This study followed standard reporting 
for QoL in brain tumours by presenting findings when ≥50% of those completing 
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baseline forms had completed forms at a certain time-point, but with a small 
cohort this will cause interpretation difficulties. 
In recent years, several groups have attempted to define what constitutes a 
meaningful clinical difference in mean QoL values. However, it remains difficult 
to interpret what a mean change of 10 points represents in real-terms. It can be 
more intuitive to report changes in the percentage of patients experiencing a 
symptom “not at all” or “very much” but this is not possible with many aspects of 
the EORTC questionnaires where the score averages responses to several 
questions. Furthermore, with personal involvement in assessing the patients in 
this study it was clear to me that the QoL responses were often largely 
influenced by other health/ personal problems unrelated to the meningioma or 
radiotherapy. For example, one patient correctly reported pain “very much” but 
this related to a recent skiing accident and another patient reported insomnia 
and worrying “very much” but this related to marital difficulties. Furthermore, an 
individual’s personality appears to have a large impact on responses - several 
of the most symptomatic patients actually reported the best global health status 
and vice versa. The reporting of mean scores should balance out such 
discrepancies when patient numbers are large.  
Two accounts of QoL following radiotherapy for meningioma are published. 
Henzel et al, reported a prospective study of 44 patients with two years follow-
up after 3DCRT [357] using a well-validated but generic QoL assessment tool 
not specifically designed for cancers (SF36). They found that patients with 
meningiomas had impaired QoL compared to the German national population 
and reported an initial decline in QoL following radiotherapy that recovered 
towards pre-treatment values by two years without significant improvements. 
They used a higher dose (59.4Gy for non-benign tumours) and had generally 
smaller target volumes than this study. Combs et al, included a retrospective 
estimation of QoL in their study of 507 patients[167]. They had a 56% response 
rate to a bespoke questionnaire (283 patients) sent out 1-270 months after 
treatment (no baseline comparator). Assessment appears to have been based 
on the question “how do you feel after radiotherapy?” They reported QoL to be 
unchanged, improved or worse following radiotherapy in 47.7%, 37.5% and 
11% respectively. Whilst this is a pragmatic attempt to generate some 
estimation of QoL following radiotherapy, a more formal prospective evaluation 
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is required. Unfortunately no QoL assessment is included in the protocols for 
the current RTOG or EORTC meningioma dose escalation studies. 
 
Jakola et al, recently published QoL data prospectively collected on 54 patients 
following surgery for meningioma using the EQ-5D questionnaire (complete 
data on 46 patients). Like the SF36, this is a generic questionnaire which does 
not evaluate aspects such as cognitive function. However, the group had 
previously demonstrated a good correlation between the EQ-5D and 
performance status in patients with gliomas and shown it to be responsive to 
new neurological deficits [358]. They reported clinically significant 
improvements in 25 patients (49 %) following surgery and significant 
deteriorations in 10 patients (20 %). Improvements were mostly related to 
reduced pain/discomfort or anxiety/depression and improved capability of 
performing usual activities.  
 
2.5.8 Neuropsychology Evaluation 
No patient had a significant reduction in MMSE score attributable to 
radiotherapy (decline of ≥4 points), although one patient did in relation to 
progressive disease. As only three patients had baseline scores ≤26/30, the 
sensitivity of the MMSE to detect any improvements was limited. The MMSE 
has been widely used to assess neurocognition in brain radiotherapy studies 
[342], [359] and it is the sole method of cognitive assessment in the current 
EORTC meningioma study. However, cognitive functions affected by radiation 
are likely to include impairments of learning and memory, processing speed, 
executive function, and fine motor control related to frontal-subcortical white 
matter dysfunction. Such aspects of cognition are not assessed by the MMSE 
which instead concentrates assessments on markers of dementia including 
aphasia, apraxia, orientation, and attention, unlikely to be significantly 
influenced by radiation (although brain tumours themselves could obviously 
affect such functions). As detailed in section 2.12, a more comprehensive 
battery of neuropsychology assessments is now carried out, but it will be 
several more years before this can be analysed. The new neuropsychology 
protocol was developed specifically to assess many different aspects of 
cognitive function as effects may differ depending on the location of the 
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meningioma. It is carried out by a trained neuropsychologist and takes around 1 
hour. For larger multicentre studies this may be impractical and Meyers et al 
have suggested an abbreviated battery to be carried out by oncologists/ cancer 
nurses (after a short period of training) that take approximately 20 minutes 
[343].  
Whilst radiation-related cognitive decline is a concern in treating patients with 
meningiomas, little formal study data has been published. Steinvorth et al [260] 
reported a transient decline in memory following the first fraction of FSRT. 
However memory and attention subsequently improved, associated with 
improved mood, and no later changes were noted (only 14 patients had 1 year 
follow-up). Another group found that long term neurocognitive deficits in 
meningioma patients were largely due to antiepileptic drugs and tumour location 
and there was no difference between the surgery only or surgery plus 
radiotherapy groups [261, 262].  
 
A greater understanding of the effect of radiation on neurocognition and better 
assessment of changes in higher mental function following radiotherapy is of 
increasing relevance now that IMRT techniques would permit sparing of 
important neurocognitive structures. Whilst clinical neuropsychology evaluation 
is a relevant method to evaluate effect of radiation on a patient’s functioning it 
only shows the outcome rather than offering detail on the cause of any 
changes.  
 
2.5.9 Endocrine Evaluation 
IMRT has so far not had significant effects on pituitary function in our patients. 
Two patients had baseline tumour-related panhypopituitarism. 16% of patients 
(5/31) with full endocrine evaluation had high prolactin levels, 3 of which 
developed after IMRT (one probably unrelated). In all patients the pituitary 
received >40Gy. A recent review reports mild to modest elevation in prolactin 
level in 20–50% of adult females with pituitary doses >40Gy although it can be 
impossible to separate tumour and radiation effects when the tumour is in the 
pituitary region [360]. Tumour-related hyperprolactinaemia is thought to relate to 
compression of the pituitary stalk reducing the delivery of the inhibitory 
neurotransmitter dopamine to the anterior pituitary where it reduces prolactin 
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secretion. Radiation-induced hyperprolactinemia is also thought to be largely 
due to reduced dopamine and is usually subclinical. Prolactin levels can 
gradually decline to normal, possibly reflecting late radiation-induced damage to 
the pituitary lactotroph.  
 
Some degree of growth hormone deficiency (GHD) following radiotherapy is 
reported in 30-100% of patients at pituitary doses of 30-50Gy for non-pituitary 
adenomas [360]. However this mostly relates to childhood irradiation and other 
factors influenced diagnosis of GH dysfunction: radiation schedule (larger 
fraction size causing more problems) length of post-irradiation follow up and the 
diagnostic thresholds for deficiency. Bloods taken in our study were at random 
times and GH itself is a poor measure of true GH function due to its diurnal 
variation. IGF-1 was also measured as it is a more stable GH-dependent 
marker, but a stimulatory insulin tolerance test (ITT) is gold standard. However, 
this is clearly not a practical screening tool and testing in adults is only indicated 
in patients who manifest signs and symptoms suggestive of severe GH 
deficiency. Compensated deficiency is described (impaired GH response to 
stimulation but normal spontaneous GH function), but no treatment is required.  
Following 30-50Gy to the pituitary, gonadotrophin deficiency is reported in 20–
50% (usually related to younger age at irradiation), TSH deficiency in 3–9% 
long-term and ACTH deficiency in 3% long-term [360], but this rarely required 
hydrocortisone replacement. As such routine testing in the absence of clinical 
symptoms is probably not indicated, but the potential for pituitary dysfunction 
should be borne in mind: in this study panhypopituitarism was discovered on 
study bloods in one patient, but they were symptomatic. 
 
2.6 Conclusion 
IMRT undoubtedly produces more conformal treatment plans than 3D CRT. 
However, prospective evidence is required to show that this translates into 
better patient outcomes in terms of toxicity and perhaps tumour control for 
meningioma. This study reports encouraging tumour control rates with low 
toxicity rates, but longer follow-up and a larger patient cohort is required to 
confirm these findings. Objective improvements in visual symptoms were 
documented in a significant proportion of patients. A substantial number of 
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patients also reported improvements in non-visual symptoms, but these are 
harder to quantify and medication changes can confound interpretation of 
results. Clinical and QoL improvements can occur without significant MRI 
change. QoL is an important aspect of treatment outcomes largely neglected in 
meningioma studies. It was clear from this cohort that, whilst meningiomas are 
largely pathologically benign and often do not impact upon life expectancy, 
baseline QoL scores were similar to patients with malignancies indicating that 
there is significant morbidity associated with meningiomas. However, this study 
also highlights the considerable challenges to interpreting QoL information. 
Further work is required to investigate QoL outcomes particularly as there are 
often several treatment options available (surgery, fractionated EBRT or 
radiosurgery). Likewise, evaluation of the impact of treatment on higher mental 
function requires more sophisticated prospective study particularly as IMRT 
techniques would permit sparing of regions of the brain associated with 
cognition.   
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3 Chapter 3: Simultaneous 
68
Gallium 
DOTATATE PET/MRI in meningioma 
radiotherapy target volume delineation: a 
feasibility study with evaluation of the 
impact upon inter-observer variability in 
target volume delineation 
_______________________________________________ 
 
3.1  Introduction 
 
3.1.1 Challenges in Meningioma Target Volume Definition 
Target volume definition for meningiomas treated with radiotherapy can be 
challenging. As discussed in section 1.15, target definition protocols are often 
vaguely reported in case series and differ widely between centres and even 
within the same centre over time. Although some groups have attempted to 
recommend appropriate margins, there is a lack of prospective evaluation. 
Furthermore, even for a specified protocol, the exact tumour borders of 
meningiomas treated with radiotherapy can be hard to define due to bone 
thickening, enhancing dural tails and post-operative changes. 
Uncertainty in target volume definition has two potential consequences: the 
target is larger than required and excess normal tissue falls within the high dose 
region increasing the risk of treatment-related toxicity, or the target is too small 
and regions of meningioma are undertreated which in turn increases the 
likelihood of disease progression.  
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Knowledge about where post-radiotherapy failures occur in relation to the 
defined target is required to evaluate optimal target delineation. Progression 
within the high dose region implies inherent tumour radioresistance; progression 
at the margins points to a geographical miss of tumour cells. There is a paucity 
of information regarding the location of progressions following radiotherapy in 
meningiomas, presumably reflecting the fact that there are few multi-centre 
studies and, as control rates following radiotherapy are high, the number of 
cases of post-radiotherapy progression recorded in a single institution is low. 
Furthermore, the range of planning techniques and dose scheduling practices, 
even within the same institution, make it difficult to draw conclusions. One group 
reported a 50:50 ratio for central versus marginal progressions following EBRT 
(n= 22) with non-benign tumours more likely to progress centrally [267].  
 
3.1.2 IMRT Confers a Greater Need for Precision in Target Volume 
Definition 
Although local control rates following radiotherapy for meningioma are very 
good, this does not negate the need for accurate target definition. Furthermore, 
older radiotherapy techniques may have compensated for undercontouring as 
extra normal tissue was inevitably covered by the 95% isodose (figure 3.1).  
 
 
Figure 3-1 Comparison of Distribution of prescribed dose: IMRT (left) versus 3D 
CRT (right) showing that extra normal tissue was included in the high dose region with 
3D CRT (only the 95% isodose and above is shown in colour wash) 
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IMRT techniques produce steep dose gradients permitting sculpting of the high 
dose region closely around the target. Increasing use of IMRT therefore confers 
a greater need for accurate target definition to ensure tumour coverage. 
Conversely, target volumes in EBRT may have traditionally been too generous, 
particularly in view of the comparable outcomes following radiosurgery where 
no margin for subclinical disease is usually added. Therefore improved target 
contouring would better exploit the normal tissue sparing capabilities of IMRT.  
 
3.1.3 PET in Meningioma Target Volume Definition 
The current gold standard imaging for meningioma target volume definition is 
contrast-enhanced MRI co-registered to planning CT. Meningioma out-with 
bone is best visualised on post-contrast T1-weighted MRI [283], but bone itself 
is better visualised on CT [361]. Several groups, detailed in table 3.1, have 
published data regarding the integration of functional information from PET/CT. 
PET tracers used are either somatostatin analogues or are amino-acid based. 
PET positive regions can be smaller or larger than the CT/MRI volume in 
different patients. Whether the addition of PET information improves the 
accuracy of target volume definition is not clear. 
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Table 3-1 Previous studies of PET for meningioma radiotherapy planning 
Tracer Study Design Findings 
68
Ga 
DOTATOC 
Milker-Zabel 
2005 [289] 
 
 
 
Gehler 
2009[290] 
 
 
 
Nyuki 
2009[291] 
 
 
 
 
 
Graf 
2012[363] 
26 patients  
All regions 
FSRT 
 
 
26 patients 
All regions 
IMRT 
 
 
42 patients  
All regions 
SRT (no detail) 
2 pts -ve PET   
 
 
 
16 patients 
Infracranial extension 
 
PTV alterations in 73% 
PTV ↓35% ; ↑38% 
Main benefit base of skull 
Pituitary/ tumour border unclear 
 
CTV alterations in 65% 
GTV ↑38%; ↓ 50% 
Most changes in base of skull or 
after surgery 
  
GTV alteration in 72% 
GTV↑23%, GTV↓49% 
All bidirectional changes 
Mean GTV↑9cm
3 
Additional lesions seen on PET 
Main changes in bone 
 
Infracranial extension detected by 
PET > MRI/ CT 
11C-
Methionine 
Astner 
2008[293] 
 
 
Grosu 
2006 (same 
study as 
Astner)[294] 
32 patients  
Skull-base 
FSRT 
 
10 patients 
FSRT 
Evaluation of IOV with 
and without PET 
GTV alterations 91% 
PTV ↓16% , ↑75% 
Mean GTV increase 9.4% 
 
↓IOV with addition of PET 
IOV: intraobserver variability 
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3.1.4 Interobserver Variability In Meningioma Target Definition 
Analysis of interobserver variability (IOV) in target definition between 
appropriately trained observers is commonly used to assess optimal imaging 
modalities or protocols for radiotherapy planning [364]. A reduction in IOV acts 
as a surrogate for improved delineation. There has been little formal evaluation 
of IOV in meningioma target definition. Khoo et al, reported a reduction in IOV 
when combined MRI and CT was used to define target volumes compared to 
CT alone in 7 patients, with 70-75% overlap between two observers in small 
volume tumours <20cc [284]. Grosu et al evaluated target volumes drawn by 
two observers with and without 11C-methionine PET in ten meningiomas 
treated with primary radiotherapy [294]. They reported a considerable baseline 
IOV in GTV definition with a mean agreement of 69% using CT/MRI and 
agreement of ≥80% between contoured volumes in only 1/10 patients. The 
addition of PET information resulted in a 10% increase in the median volume of 
intersection between observers. From the limited information available, it 
appears there is substantial IOV in target volume definition in meningiomas, 
even when using the same protocol. This indicates differences in image 
interpretation. However, data are limited and it is possible that the addition of a 
further imaging modality may actually compound differences in interpretation 
and not necessarily reduce IOV in target definition [286]. Further work is 
therefore required to evaluate methods of standardising meningioma target 
volume definition. 
 
3.1.5 Preliminary Work 
I carried out preliminary work at my institution to evaluate the location of 
meningioma disease progression in relation to the radiotherapy fields, the 
extent of baseline IOV in target definition and whether the use of 68Ga-DOTA 
PET changed target definition for patients treated with radiotherapy for 
meningioma. This work is detailed in Appendix 4. In summary, of the 90 patients 
with meningioma who underwent radiotherapy when combined CT/MRI was 
used to define target volumes, there were 11 progressions (8/11in non-benign 
disease). Five progressions were clearly central, three clearly marginal and it 
was unclear in the other three. The mean level of agreement in defined GTV 
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and CTV was 67% between two observers in ten meningiomas, similar to that 
reported by the groups detailed above. The addition of 68Ga-DOTATATE 
PET/CT information substantially altered target definition by a single observer in 
two of the three cases assessed. These findings supported the need for further 
evaluation into the use of PET in target volume definition at my institution. 
 
3.1.6 Simultaneous PET/ MRI 
PET is generally obtained on a combined PET/CT scanner, in which each 
imaging modality is sequential to the other. However, there are limitations with 
PET information derived from PET/CT: spatial resolution is relatively poor at 5-
7mm, there can be considerable partial volume effects and noisy reconstruction 
algorithms and patient motion between the PET and CT acquisitions can cause 
poor image co-registration.  
 
Recently combined PET/MRI imaging has become commercially available in 
which imaging modalities are obtained simultaneously, but clinical applications 
of this technology in oncology are yet to be defined. Theoretically PET/MRI has 
better spatial resolution and it appears that PET/MR can identify separate small 
meningiomas not seen on PET/CT [365].  
 
The first case report of PET/MR for radiotherapy treatment planning showed 
that PET/MR identified meningioma infiltration along the falx that had not been 
included in the treatment plan created for the PET/CT plus co-registered MRI 
volume [366]. The same group also reported identification of additional small 
regions of meningioma with PET/MRI, although the clinical relevance of 
identifying such disease is questionable [367]. It should be noted that these 
reports used sequential rather than simultaneous imaging. The rigid anatomy of 
the intracranial tumours makes them an ideal region to initially explore the use 
of PET/MRI although it is likely that there may be more advantage of the 
simultaneous nature of PET/MRI outside the brain where organ movement 
during imaging may be a significant issue (e.g. in the neck or pelvis). 
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3.2 Study Aims 
 
1. To assess the feasibility of using simultaneous 68Gallium-DOTATATE 
PET/MRI for target volume definition in meningiomas 
2. To evaluate whether PET information changed individual target volume 
definition and altered interobserver variability in meningioma contouring  
3. To establish whether there were differences in target volumes defined 
using PET/CT or PET/MRI.  
 
3.3 Materials and Methods 
 
3.3.1 Imaging Specifications 
ARSAC and regional ethical approval was obtained to study 68Ga DOTATATE 
PET/MRI in radiotherapy planning. A Siemens Biograph Molecular 3 Tesla MRI 
scanner (PET/MR) was used for radiotherapy planning at my institution. The 
PET detector assembly has 8 rings of 56 detector blocks with 8 x 8 lutetium 
oxyorthosilicate crystals (4x4x20mm) per block, coupled to an array of 3x3 
water-cooled avalanche photodiodes installed between the gradient and 
radiofrequency coils to prevent interference and inhomogeneities between PET 
and MRI modalities. PET/MR pixel size was 1.4 x 1.4mm with a 2-dimensional 
2mm slice thickness (0.1-200mm possible). The full width half maximum 
(FWHM) axial resolution was 4.21mm at the centre of the field of view (FOV) 
(6.62mm 10cm from the centre). PET reconstruction was performed using the 
Poisson ordered subset expectation maximisation (OSEM) resolution modelling 
algorithm with 6 iterations, 16 subsets and 3D scatter correction. Attenuation 
correction was performed according to a 2-point Dixon MR sequence, which 
segments the Dixon images into 4 compartments: air, lung, fat, and soft tissue. 
PET/CT imaging (sequential) was performed using a Siemens Biograph HiRez 
16 unit scanner, equipped with 4 x 4 x16 mm3 lutetium oxyorthosilicate (LSO) 
scintillation crystals in combination with a 16-slice CT. Pixel size was 1.95 x 
1.95mm with a slice thickness of 3.27mm and FWHM axial resolution of 5.1mm 
at the centre FOV. 
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3.3.2 Volunteer and Phantom work 
The feasibility of imaging patients in the radiotherapy treatment position with 
thermoplastic (TP) shell was assessed. An MRI-compatible acrylic flat couchtop 
designed and manufactured in-house was used and the MRI body coils placed 
upon a TP bridge over the shell (figure 3.2). A healthy volunteer was scanned to 
assess the tolerability of scanning with the shell in the 60cm bore scanner.  
 
 
  
Figure 3-2 Radiotherapy Immobilisation and Imaging Equipment: (a) acrylic 
baseboard, (b) body coil, (c) thermoplastic bridge over shell, (d) shell, bridge and coil 
 
To evaluate the extent of PET attenuation by the radiotherapy equipment (i.e. 
couch and shell), a striatal phantom (seven regions of interest filled with FDG) 
was imaged with and without the radiotherapy equipment. The percentage 
attenuation of PET SUV from a prototype couchtop designed by Medibord® 
specifically to reduce PET attenuation was assessed by means of a germanium 
phantom. Imaging was performed on PET/CT as a surrogate for PET/MR as 
standard PET/MR attenuation correction (AC) sequences do not depict the 
radiotherapy equipment and hence will not account for any attenuation. As there 
may have been potential for the PET detectors to interfere with the MRI images, 
we assessed MRI image distortion using a bespoke water-based phantom and 
co-registration of PET/MR to CT using a Lucy® phantom.  
a b 
c d 
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3.3.3 Patient Imaging Protocol 
A departmental work instruction was written to ensure consistency of imaging 
and contouring (Appendix 5). Ten patients with meningioma underwent PET/MR 
imaging followed immediately by PET/CT. Table 3.2 details their clinical 
features. Patients were selected for PET imaging when it was felt that their 
meningiomas were likely to be difficult to define using standard imaging. The 
imaging protocols used are detailed in figure 3.3.  A separate planning CT was 
not required as the PET/CT was performed in the radiotherapy treatment 
position.  
 
Table 3-2 Patient Characteristics 
Case Tumour Location  Grade Clinical Situation 
1 Parasellar/ 
Sphenoid 
2 Resection 18 months previously with small 
residual 
Post-operative RT delayed due to co-morbidity 
Recent growth of residual on MRI  
 
2 Occiput  1 Surgery 20 years previously 
Significant growth on MRI without symptoms  
Surgery not repeated as CR impossible due 
to sagittal sinus invasion and previous  
post-operative complications 
3 Frontal/ Falx 2 Continued MRI progression after multiple  
Previous operations and radiosurgery 
4 Foramen Magnum  1 Previous debulking surgery with residual disease 
5 Cerebellopontine 
Angle 
1 Surgery 5 years previously with major  
post-operative complications, residual disease  
in critical location 
6 Sphenoid UK Primary Treatment (CR not possible due to  
proximity to visual apparatus) 
7 Occipital UK Primary Treatment (CR not possible due to  
proximity to sagittal sinus) 
8 Frontal 2 Multiple previous operations, residual disease 
9 Occipital 2 En-plaque disease, multiple previous operations 
10 Sphenoid 1 Debulking surgery (for severe proptosis) six  
months previously with gross residual disease 
UK: unknown (no histology)
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Figure 3-3 Imaging Protocol 
Time (mins) 
 
0  
 
 
 
 
 
5-30 
 
 
 
 
40-45 
 
 
 
 
 
 
 
 
 
75 - 90 
 
 
 
 
 
PET/MRI (no head shell) 
T2 and DW sequences 
PET/MRI (head shell)T1 (-/+ 
gadolinium) 
Simultaneous PET  
Attenuation Correction 
PET/CT (head shell) 
No iodine contrast 
Laser alignment 
Static emission scans in 2 overlapping bed 
positions in tumour region. 
 
 
100MBq iv 
68Gallium 
DOTATATE 
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3.3.4 Image registration 
The PET/CT and MRI data were co-registered with Eclipse version 10 or 11 
radiotherapy planning software for contouring using a standard rigid 
coregistration technique (automated with manual adjustment as required). 
Evaluation of an appropriate method of registering the PET/MR data to 
radiotherapy planning software was carried out.  
 
The degree of rotation (x, y, z) required for co-registration to the planning CT of 
the T2 (without shell) and the T1 (with shell) sequences was evaluated to 
establish the accuracy of the immobilisation equipment used in the MRI. It was 
not anticipated that the use of the shell would significantly improve co-
registration accuracy in the brain but an overall manual check was made. The 
intention had been to formally assess the differences in co-registration at certain 
landmarks in the planning CT to the two MRIs, especially where the tumour 
extended below the base of skull, but this proved impossible to perform 
accurately in view of differences in appearance in the two MRI sequences and 
the lack of CT contrast. In regions of rigid anatomy, such as the brain, other 
groups have used the distance between the skin on each side of the head to 
assess alignment, but as the shell compresses the skin this was not a reliable 
method of registration comparison between imaging with the shell on or off. 
 
3.3.5 Contouring Protocol 
Three radiation oncologists with experience in neuro-oncology provided the 
contours. Observers 1 and 2 were those whose contours were evaluated in 
appendix 4.  All observers were affiliated with the same institution and used the 
same contouring protocol in their standard practice. Margins were the same for 
grade 1 and 2 disease: 
 
GTV1 = visible tumour on MRI and CT 
GTV2 = visible tumour on MRI, CT and PET(from PET/CT) 
GTV3 = visible tumour on MRI, CT and PET(from PET/MR 
CTV1 = GTV1 + 1cm in the plane of dural enhancement, bone or brain invasion 
CTV2 = GTV2 + 1cm in the plane of dural enhancement, bone or brain invasion 
CTV3 = GTV3 + 1cm in the plane of dural enhancement, bone or brain invasion  
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For reference, a guide PET positive region for PET(CT) and PET(MRI) (the 
biological target volume – BTV) was defined by a nuclear medicine consultant 
without an SUV threshold limit, but the inclusion of this in the GTV was at the 
discretion of the individual observer.  To reduce intra-observer variability in 
CT/MRI interpretation, each observer copied the GTV1 and CTV1 using the 
automatic software function and altered as they wished in view of the PET 
information. 
 
3.3.6 Differences in Target Volume Contours With and Without PET 
Absolute target volumes defined with MRI/CT alone and MRI/CT plus either 
PET modality were compared and a qualitative evaluation made of regions of 
difference. Qualitative differences in PET images produced by either modality 
were also noted. The Jaccard coefficient (figure 3.4) is widely used in the 
radiotherapy literature to reflect IOV between two observers. It represents the 
ratio of the intersection volume divided by the composite volume, but cannot be 
used to directly compare more than two observers. Therefore, the 
Kouwenhoven conformity level (KCL) was calculated [368]. The KCL is a 
mathematically based generalisation of the Jaccard coefficient unbiased to the 
number of delineations and specifically designed for evaluation of IOV in 
radiotherapy studies. It takes an average value from a conformity histogram 
formed by distributing the total of delineated volumes according to the number 
of times the particular volume appears. 100% is full concordance and 0% is no 
concordance. 
 
KCL was evaluated using Surrey Heuristic Engine for Radiotherapy, 
Radiobiology and Imaging (Sherri) software version 1.32. This software is 
endorsed by the National Cancer Research Institute (NCRI) Radiotherapy Trials 
Quality Assurance Group. Statistical evaluation of differences in KCL was 
performed on SPSS version 21 by one way repeated measures analysis of 
variance (ANOVA) for the overall group and Tukey’s multiple comparison test to 
compare between all pairs of results. A statistical significance level of ≤0.05 was 
set. 
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Jaccard Coefficient =       ___b___ 
                                          a+b+c 
 
Figure 3-4 The Jaccard Coefficient represents the similarity of two volumes: the 
intersection volume divided by the total volume 
 
 
3.4 Results 
 
3.4.1 PET/MRI Technical Aspects 
Mean MRI distortion was less than 1mm at the isocentre (table 3.3).  Co-
registration of the MRI to planning CT as measured on the Lucy® phantom 
resulted in <1mm uncertainties throughout. Attenuation of PET SUV by the 
radiotherapy equipment (shell, headrest and couchtop) and from the Medibord® 
is detailed in figures 3.5 and 3.6. Although an underestimation of SUV of 1.8-5% 
was still noted with the Medibord®, this is within the pre-determined test-retest 
probability and is substantially less than the other couchtop. 
 
Table 3-3 Mean MRI distortion  
Position Mean Distortion 
X axis (mm) 
Mean Distortion 
Y axis (mm) 
Axial isocentre 0.5 0.6 
Saggital isocentre 0.3 0.3 
Coronal isocentre 0.4 0.2 
Axial Top slice 0.9 1.0 
Axial Bottom slice 1.0 1.0 
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Direct registration of the PET/MR data to Eclipse version 10 was not possible as 
the systems did not recognise the PET data despite it being in DICOM format. 
Therefore a two-step process was required for the first five patients: rigid co-
registration of PET/MR (T1 plus gadolinium sequences) to planning CT (plus 
PET) based on a co-ordinates system was carried out on bespoke software 
provided by the Netherlands Cancer Institute and subsequently this “pre-
coregistered” data could be transferred to Eclipse version 10 for contouring. An 
upgrade to Eclipse version 11 allowed direct co-registration of all modalities 
from patient six onwards. The PET images could be viewed and windowed in 
greyscale only (for contouring), but this was satisfactory as the European 
Association of Nuclear Medicine recommends the use of grey-scale rather than 
colour for outlining PET target volumes [369]. 
 
All patients completed the planned imaging protocols and reported that imaging 
with the shell on was tolerable but they universally preferred the PET/CT to the 
PET/MR. Four patients reported mild to moderate anxiety in the PET/MR with 
the shell, of whom two reported similar anxiety in the CT scanner with the shell 
and in the MRI scanner without the shell.  
 
The bespoke couchtop and shell fixation system provided effective 
immobilisation as mean rotations required to co-register images without the 
shell were: x 5.33⁰, y 3.21⁰ and z 6.12⁰ and with the shell were: x 0.56⁰, y 0.41⁰ 
and z 0.46⁰. However, the shell was not necessarily required for meningiomas 
as manual inspection of the coregistered images showed no clear differences 
with or without shell. 
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Figure 3-5: Attenuation of PET signal using standard radiotherapy equipment  
 
 
Figure 3-6: Attenuation of PET uptake using Medibord prototype 
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3.4.2 Differences in Overall Volume 
Absolute volumes contoured are detailed in figures 3.7a and 3.7b. Using 
standard CT/MRI only Observer 1 consistently contoured the largest volumes 
and Observer 3 the smallest (up to 91% smaller). With the addition of PET 
information, Observer 1 still tended to contour the largest volumes. There was a 
reduction in the difference between the largest and smallest GTV of >10% when 
PET was added in six cases and an increase in three cases (for both PET 
modalities). There was less alteration in CTV differences with a >10% decrease 
in the difference between the largest and smallest CTV in two cases (for both 
PET modalities).  
 
The observers approach to altering volumes based on PET images varied 
greatly. Observer 1 rarely changed GTV in relation to PET information: no 
changes or very minor change in 8/10 cases, with a change of >10% in only 
one case. Conversely Observers 2 and 3 made changes of >10% in GTV in 
relation to PET information (either modality) in eight and ten cases respectively, 
corresponding to a respective CTV change of >10% in five and nine cases. 
Observer 2 increased GTV in relation to PET in six cases with a decrease in 
two, and increased CTV in four cases with a decrease in one. Observer 3 only 
increased volumes in relation to PET information. There were several cases 
where change in absolute volume with PET information differed >10% between 
PET/MR and PET/CT. On occasion observers included equivocal PET positive 
regions in CTV rather than GTV. 
 
The largest change in volume with the addition of PET imaging was seen for 
case 4 by Observers 2 and 3. This was a very unusual case where the 
meningioma had tracked down through the skull base into the soft tissue of the 
facial muscles. The small tumour above the skull base was clearly seen on MRI, 
but the inferior portion of tumour was less clear. It was obvious that the tumour 
extended into the soft tissue on both PET modalities (figure 3.8).  
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Figure 3-7a GTVs per Observer for each case 
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Figure 3-7b CTVs per Observer per case 
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Figure 3-8: Example case where PET highlighted tumour not identified on MRI, 
but in retrospect visible on MRI. All observers outlined the upper part of the tumour 
on MRI (a). This region was confirmed as PET positive on b. Only Observer 1 included 
the lower tumour using MRI/ CT (c and d). Observer 2 and 3 included the lower region 
when it was highlighted with PET imaging (e and f) 
 
 
3.4.3 Kouwenhoven Conformity Level 
The KCL between contours with each group of imaging modalities were 
generally low reflecting significant IOV in target volume delineation (table 3.4 
and figure 3.9). Overall, the addition of PET information resulted in only a very 
small improvement in mean KCL. GTV1 mean CL was 0.34 (range 0.1-0.48), 
versus 0.38 (range 0.1-0.52) for GTV2 versus 0.39 (range 0.1-0.54) for GTV 3 
(p=0.06 for difference between all three groups, p>0.05 for difference between 
individual pairs).  CTV1 mean CL was 0.31 (range 0.1-0.52) versus 0.35 (range 
0.1-0.55) for CTV2 versus 0.35 (range 0.11-0.53) for CTV3 (p=0.04 for 
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difference between all three groups, p>0.05 for difference between individual 
pairs). The small overall improvement with PET (both PET/CT and PET/MRI) 
was largely influence by case 4 (figure 3.8). This was the only case where there 
was an improvement in KCL of ≥10% in both GTV and CTV (for both PET 
modalities). Therefore, although the absolute volumes often became more 
consistent with the addition of PET information, this did not necessarily translate 
into the volumes being more similar overall.  
 
Table 3-4 KCLs for each case 
GTV/CTV1 (CT/MRI only); GTV/CTV2 (CT/MRI plus PET(CT); GTV/CTV3 (CT/MRI plus 
PET(MRI) 
Case Conformity Level 
 
GTV1         GTV2         GTV3         CTV1          CTV2         CTV3  
1 0.1 0.1 0.1 0.1 0.11 0.11 
2 0.37 0.4 0.4 0.36 0.36 0.36 
3 0.48 0.52 0.54 0.52 0.55 0.53 
4 0.2 0.44 0.46 0.23 0.42 0.42 
5 0.39 0.35 0.35 0.32 0.35 0.35 
6 0.27 0.27 0.33 0.27 0.29 0.32 
7 0.36 0.46 0.46 0.19 0.18 0.18 
8 0.34 0.34 0.36 0.3 0.32 0.32 
9 0.43 0.42 0.42 0.43 0.42 0.42 
10 0.42 0.46 0.46 0.4 0.5 0.5 
Mean 
SD 
0.34 
0.12 
0.38 
0.12 
0.39 
0.12 
0.31 
0.12 
0.35 
0.14 
0.35 
0.13 
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Figure 3.9 GTV and CTV KCL per case 
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3.4.4 Regions of difference 
The most common region for differences in contours between observers was 
bone (five cases), followed by dural tail (three cases) and post-operative 
changes (three cases). There were also two occipital tumours where there were 
clear differences in inclusion or exclusion of the confluence of the sinuses and 
the transverse sinuses. There were only minor differences between observers 
in the inclusion of the contents of the pituitary fossa. Most differentiation 
between “hot” or “cold” regions on PET was in bone (figure 3.10). However 
although observers consistently increased their volumes to include “hot” bone if 
they had not already done so, they were not always willing to reduce volumes in 
relation to PET information. On occasion, differences in the superior or inferior 
extent of GTV were irrelevant to the treated volume because all the bone in the 
region was included in CTV. For the majority of cases, a “correct” volume could 
not be defined. However, Observers 2 and 3 clearly missed soft tissue 
extension of tumour without the PET information in case 4 (figure 3.8). Figure 
3.11 depicts the regions of difference for each case. 
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Figure 3-70 Examples of cases where PET could potentially decrease or increase 
target volume. (A1 and A2) bone suspicious on CT; the same region is ill-defined on 
MRI (B1 and B2), but appears negative on PET (C1 and C2). 
 
 
 
  
A1 B1 C1 
A2 B2 C2 
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Figure 3-8 Regions of IOV per case (table continues to page 147) 
Case Regions of IOV Example of GTV1 contours in regions of IOV 
1 Sphenoid bone 
inclusion 
(the two smaller 
contours almost overlap 
on this slice, the other is 
very different) 
 
2 Sinus inclusion  
Extent of dural tail  
 
3 Sphenoid bone 
inclusion 
(as for Case 1 two 
contours are very 
similar and one very 
different ) 
 
4 Soft tissue extension 
Bone inclusion 
See figure 3.8 
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Case Regions of IOV Example of GTV1 contours in regions of IOV 
5 Extent of tumour bulk/ 
dural tail 
 
6 Bone inclusion 
 
7 Sinus inclusion 
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3.4.5 Comparison of Different PET modalities 
In general there was a reduced “halo” effect around the positive region with 
PET(MR) images compared to PET(CT) giving a more defined edge to the PET 
positive region (figure 3.12). As a result, the PET (MRI) guide BTV was smaller 
than the PET (CT) guide BTV in 9/10 cases but this rarely impacted upon the 
Case Regions of IOV Example of GTV1 contours in regions of IOV 
8 Secondary region of 
tumour: on the left slice 
only 2/3 Observers 
contoured tumour at 
that point 
Differentiation of 
tumour from post-op 
changes 
Extent of dural tail 
 
9 Extent of tumour bed 
Extent of dural tail 
(on the left slice there is 
considerable IOV but 
volumes are very 
consistent on the right) 
 
10 Bone 
Differentiation of 
tumour from post-op 
changes 
Dural Tail  
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GTV and CTV delineated by the radiation oncologists (figure 3.13). The PET 
positive region appeared clearer when using an SUV colour-scale (figure 3.14), 
but as there is no defined SUV threshold for meningiomas, this may be 
misleading. Greyscale was used in the study and indeed the colour scale could 
not be used for contouring on ARIA version 11.  
 
 
Figure 3-12 Four cases with tumours in different regions: corresponding MRI, 
PET(CT) and PET(MRI) showing the sharper image with PET(MRI). This led to smaller 
guide BTVs with PET(MRI) 
 
  
153 
 
 
Figure 3-13 Three nuclear medicine physicians defined BTV on PET(CT) (left) and 
PET(MRI) (right). PET(MRI) BTV was smaller than PET (CT), but this did not impact 
upon volumes defined by radiation oncologists using co-registered MRI, CT and PET 
information. 
 
 
Figure 3-14 SUV colour scale clearly demarcates regions of different SUV, but 
currently no SUV threshold for meningioma is known so this could not be used to 
define tumour. 
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3.5 Discussion 
 
3.5.1 Challenges with Target Volume Definition in Meningioma 
There is no consensus regarding the protocol for defining radiotherapy target 
volumes in meningiomas. Paradoxically, prospective evaluation of margins is 
hampered by the excellent radiotherapy control rates for benign tumours and 
the fact that disease progression can occur many years after treatment. Multi-
centre studies would be required to generate enough patients with progressive 
disease to permit assessment of regions of recurrence as a surrogate for 
margin suitability in meningioma and there are considerable differences in 
radiotherapy treatment techniques and approaches to contouring between 
centres and even within the same centre over time. Theoretically, defining the 
GTV should be less contentious than CTV. However, defining the extent of 
bone, dural tail and even enhancing residual tumour after multiple operations is 
subject to interpretation of complex imaging data. 
In view of the excellent long-term control rates in benign disease, one could 
question the need to improve consistency in meningioma contouring. However, 
these control rates are based on 2D or 3D treatment planning methods where 
some normal tissue outside of the target inevitably received high radiation 
doses. Furthermore, the default position in contouring is often to include 
equivocal regions in the target and if dose escalation proves effective in the 
ongoing multi-centre studies in non-benign meningiomas, tighter target volumes 
would be preferable. A raft of procedures aiming to reduce uncertainties and 
errors has accompanied the introduction of IMRT, e.g. daily image guidance 
and improvements in co-registration software including deformable packages. 
However, as this study highlights, the target volume contours drawn by the 
radiation oncologist are the biggest source of uncertainty. Fundamentally, to 
derive maximum benefit from IMRT it is therefore important to understand 
where the differences lie between contours drawn by different observers and to 
study measures that may improve contouring.  
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3.5.2 Baseline IOV 
This study confirms anecdotal evidence and the findings of Khoo and Grosu et 
al, [284, 294] that target volume definition varies greatly in meningiomas. It also 
refutes the suggestion that such variation is merely attributable to the use of 
different protocols between centres. The mean conformity levels are very low 
for both GTV and CTV. Even the removal of case 4, where two observers 
certainly missed disease, only slightly improved mean KCL. However, the very 
high level of IOV in this study may be an overestimate because patients in this 
study were specifically selected to undergo PET because it was anticipated that 
defining target volume may be challenging.  
Interestingly, Mukesh et al [370], used the KCL to evaluate IOV in CTV for 
parotid tumours and organs at risk (spinal cord, brainstem, contralateral parotid 
gland). They reported an overall mean KCL of 30% for CTV, 23% for brainstem 
and 25% for the spinal cord (axial conformity for brainstem and spinal cord 
44.8% and 60.3% respectively). Theoretically, contouring organs at risk should 
be less contentious than meningiomas. This suggests that our low KCL results 
are not exceptional.  
The involvement of more observers would increase confidence that our results 
are a true reflection of IOV in meningioma contouring, although an outlier will 
always skew results. However, the fact that this was a single institution study 
limited the number of appropriately trained observers. There were several 
reasons to keep the study in-house. Firstly as observers were used to following 
the protocol this increased the likelihood that IOV was due to interpretation of 
the imaging rather than interpretation of the protocol. Furthermore, the software 
requirements involved restricted contouring to the study institution. Other 
studies comparing IOV have included staff of less experience or radiologists, 
however, this would have introduced further variables to cause IOV. A separate 
study to analyse GTVs delineated by radiologists compared to radiation 
oncologists would be interesting and could help to define the gold standard that 
is missing from meningioma literature.  
There seemed to be two factors driving the high baseline IOV in this study: 
image interpretation and clinical judgement. The biggest differences in image 
interpretation occurred in regions of bone. Specifying the window level for 
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evaluating bone may have reduced interpretation issues and window levels 
should ideally be pre-specified in the protocol of IOV studies. It also seemed 
clear that observers tended to go “off-protocol” and include equivocal bone in 
the CTV rather than the GTV. As the observers themselves had written the 
protocol this underlines the challenges in achieving protocol compliance in 
radiotherapy studies. However, the fact that some observers included bone in 
GTV and others CTV cannot explain the high IOV as conformity levels were 
very similar for both. As expected, other common regions of discrepancy were 
the dural tail and post-operative bed. There was also considerable variation in 
relation to inclusion of the dural sinuses. Meningiomas are known to invade the 
venous sinuses and sinus invasion is often a reason preventing complete 
surgical excision. Clearly if there is documentation of sinus invasion at surgery 
then the region should be included in the target volume, but invasion is often not 
clear cut on imaging and what extent of sinus to include is not known. 
Differentiation between tumour and pituitary is ill-defined with 68Ga DOTA as 
there is high uptake in the normal pituitary, but there was only minor baseline 
variation within this region, probably as a result of deliberate case selection. 
 
In the parotid contouring study by Mukesh et al, discussed above, the CTV KCL 
improved to 54% with the use of a standardised COSTAR study segmentation 
protocol. Unfortunately, a segmentation protocol would not be possible for 
meningiomas as there is such variability in tumour location and appearance. 
However, publication of MRI/ CT references by an expert body regarding what 
constitutes involved and uninvolved bone, dural tail and sinuses may be a 
useful reference tool. On a local level it may also be possible to reduce IOV due 
to image interpretation by involving neuroradiologists in planning sessions and 
by discussing operative findings with the treating surgeon in patients treated 
post-operatively.  
 
Clinical judgement as a cause of IOV is perhaps harder to define and is far 
harder to influence than image interpretation. However, it was clear that the 
observers followed a general pattern in their approach to contouring: Observer 
1 nearly always contoured the largest volumes, followed by Observer 2 then 
Observer 3. This reflects each individual’s approach to risk benefit analysis of 
undertreating tumour versus overtreating normal tissue. Likewise, Observer 1 
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minimally altered contours in relation to the PET information, whereas 
Observers 2 and 3 were more willing to make changes (particularly in terms of 
reducing volumes). 
 
Many centres use universal 3D margins to grow GTV to CTV, which should 
reduce CTV IOV. The more complicated CTV margin in this protocol added 
further scope for clinical judgement, highlighted by the fact that there was 
slightly greater IOV in CTV definition. 
 
3.5.3 Impact of PET on IOV  
The 4-5% improvement in KCL with the addition of PET data was disappointing 
and is probably not of major clinical significance as the baseline level was so 
low. Although observers did alter contours with PET information, this did not 
necessarily improve consistency. From these results I could not recommend 
inclusion of PET into standard imaging protocols to improve target volume 
contouring in meningiomas, but PET is likely to add useful information in 
particularly challenging cases. Notwithstanding, one of the main reasons that 
IOV did not improve substantially was that there were differences between 
observers in their willingness to allow PET information to influence the target 
contoured, particularly with regard to reducing GTV in relation to PET. Again, 
this reflects differences in clinical judgement between observers and confidence 
regarding the ill-defined sensitivity of PET. This was particularly noted for 
Observer 1 who consistently contoured the largest volumes and did not reduce 
volumes. However, the approach of this observer was no doubt influenced by 
their status as the treating physician. This is likely to have introduced some bias 
to the results.  Ideally contouring studies should involve “test cases” where no 
physicians are the treating physician and all have exactly the same information 
regarding the patient, but this would be challenging in a single institution study. 
The impact of this bias was particularly apparent in case 4 where Observer 2 
and 3 clearly missed disease on standard imaging. Although the disease was 
much clearer on PET, it was apparent on the standard MRI with careful 
analysis. This highlights the importance of full evaluation of the standard 
imaging available, rather than the need to necessarily add in another imaging 
modality. 
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The target volumes in this study were generally larger than in other meningioma 
case series and as observers rarely reduced volumes with regard to PET 
information, the potential for PET to improve conformity may have been limited. 
With the exception of case 4, PET rarely highlighted disease that had not been 
included on the CT/MRI contours. As the sensitivity of PET for small volume 
disease is not known, it seems reasonable that the observers exercised caution 
in reducing volumes. Further work, is necessary to clarify PET sensitivity and 
confirm that the PET “halo” is simply an artefact rather than subclinical disease. 
This could be approached in several ways. The gold standard would be 
histological evaluation. Ethically and practically it is unlikely that such a study 
could be carried out in patients undergoing primary radiotherapy, but pre-
operative PET could potentially be performed in patients undergoing primary 
surgery with sampling from equivocal regions of the bone/ dural tail. 
Alternatively discordant regions could be further evaluated with more complex 
MRI sequences, such as diffusion weighted sequences, or more than one PET 
tracer could be analysed. More simply, it is possible that using 1mm MRI and 
CT slices for contouring, as is often the case for radiosurgery, would clarify the 
target to some extent by reducing the partial voluming effect of 3mm cuts. 
 
Controversially, counter to the general first principles of radiotherapy, it may be 
that not all peripheral meningioma cells need necessarily be included in the 
target volume to achieve disease control in benign disease. In the largest 
pathological study of meningioma dural tails, 95% lay within 2.5cm of the 
tumour base [273], but this extent of dural tail is rarely included in radiotherapy 
target volumes and local control rates remain excellent and margins are 
generally not added in radiosurgery. Margins required to obtain pathological 
clearance may differ from those required to achieve control with radiotherapy. 
 
3.5.4 PET/MRI versus PET/CT 
The reduced ionising radiation exposure incurred with PET/MR compared to 
PET/CT and the potential to reduce the number of scans required in situations 
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where MRI and PET negate the need for CT are clear practical advantages of 
PET/MR in the diagnostic setting. However, the CT scan remains the primary 
data set for radiotherapy planning and the decision to treat a patient is usually 
based on a recent standard MRI meaning that a further MRI is not required. 
Therefore, the number of scans and radiation exposure for radiotherapy 
patients may not be reduced with PET/MRI if the PET/CT can be carried out in 
the planning position.  
 
Although PET/MRI images are acquired simultaneously, these still require co-
registration and simultaneous image acquisition may not substantially improve 
anatomical contouring, particularly within the brain where coregistration is 
usually straightforward. Study of PET/ MRI contouring in other regions that rely 
on MRI soft tissue definition but are subject to more movement, such as the 
pelvis or the neck would be warranted. Whilst the planning CT remains the 
primary data set, the argument could be made that it would be better to have 
simultaneous PET/CT than PET/MRI.  However, simultaneous PET/CT would 
require the development of new detectors that can simultaneously detect and 
discriminate gamma rays and CT x-rays. Of note, iodine-based CT contrast 
probably attenuates PET SUVs more than gadolinium-based MRI contrast [371] 
which may have to be factored in if a threshold SUV was set to define tumour. 
 
There was no significant difference between the small improvements in IOV 
with PET whether the PET images were generated on the PET/CT or PET/MRI. 
Theoretically the PET(MRI) images may have technical advantages over 
PET(CT) in terms of better spatial resolution and smaller voxel size. Indeed, the 
PET (MR) images did have a reduced “halo” around the tumour compared to 
PET(CT) images. However, the smaller slice thickness will also have reduced 
the partial voluming effect. Nonetheless, in practice, the apparent improvement 
in sharpness of PET images did not appreciably alter the contours drawn when 
CT/MRI and either PET were co-registered. The reduced “halo” with PET MRI 
does however weaken the argument that this equivocal region around the clear 
PET positive area is subclinical disease and make it more likely to be imaging 
artefact. 
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It should be noted that to minimise systemic radiation exposure and streamline 
the process, only one radioisotope injection was given. As such, there will have 
been a small amount of isotope decay between PET(MR) and PET(CT), but this 
was kept to a minimum and did not appear to have had any impact on the 
results. 
 
3.5.5 Technical implementation of PET/MRI planning 
Several technical questions regarding attenuation and co-registration were 
addressed as they arose which limits the strength of the data. Overall, it was 
feasible for patients to undergo PET/MRI in the radiotherapy planning position 
with the shell on, but a pre-defined patient questionnaire may have been helpful 
to better assess patient comfort. At the analysis stage I found that it was not 
possible to effectively compare co-registration with and without shell due to the 
differences between T1 and T2 weighted images and the fact that we had not 
used CT contrast. Qualitatively the shell appeared to make little difference to 
co-registration of cranial tumours and therefore would not necessarily be 
required for future brain cases. However, it did prove that it will be possible to 
undertake studies of regions where reproducible immobilisation is required for 
coregistration purposes. 
Likewise, the phantom work carried out in this study was not formally pre-
planned. Accordingly, due to phantom and isotope availability, different 
phantoms were used to compare the standard radiotherapy equipment 
attenuation and the different couchtops. Although, this does not invalidate the 
overall conclusion that the Medibord® was substantially less attenuating than 
standard equipment, it does preclude a robust comparison. In the diagnostic 
PET/MRI setting, Mantlik et al observed an underestimation of PET activity of 
up to 22% without accounting for the vacuum mattress (also sometimes used 
for radiotherapy positioning), but relatively insignificant attenuation by the foam 
pads used in the lower limbs [372]. An attenuation factor could be calculated on 
separate CT images for a dedicated set of positioning devices and matched to 
the estimated extent of these devices on MR images but, this would be time-
consuming and error-prone. A more attractive proposition is likely to be 
ultrashort echo (UTE) MRI sequences that are currently under evaluation. 
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These may allow delineation of positioning aids as well as bone on MRI. This is 
a particularly attractive concept for intracranial tumours where bone is 
important.  
PET attenuation by the positioning aids was probably not of significance in this 
study, but if an SUV threshold was used to determine PET-positivity or if 
treatment response were to be monitored according to SUV values, attenuation 
by positioning aids would become more important. There is no data regarding 
whether a change in 68Ga DOTATATE PET SUVs for meningiomas occurs 
following radiotherapy and whether such a response would be prognostic. 
Although this is an interesting potential research question, the clinical relevance 
is not clear as it would be unlikely to alter management and would expose 
patients to more ionising radiation during follow-up (although PET/MRI would be 
preferable to PET/CT).  
 
A major challenge that became apparent after the first study patient had been 
scanned was that the planning software available did not have the capacity to 
display the PET images from the PET/MRI. To prevent treatment delays, 
patients were treated using volumes delineated using the PET/CT plus co-
registered MRI until bespoke software became available that allowed a work-
around, although this was extremely time-consuming and impractical for 
standard practice. Fortunately an upgrade of the planning software solved the 
problem. This underlines the fact that advances in diagnostic imaging often 
require corresponding software advances in the therapeutic setting. 
3.5.6 Methods of determining  IOV 
Despite analysis of IOV being a common research topic, there is no widely 
accepted method of contour comparison. The majority of studies report absolute 
volumes, but as demonstrated in this study, volume alone is misleading. In 
several cases the absolute volumes in this study were very similar, but overall 
conformity levels were rarely above 50%. Many studies therefore assess 
deviation in contours from a gold standard. However, a gold standard volume 
could not be defined in this study in view of the controversy around meningioma 
target volume contouring.  
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In this situation, the conformity level (or index) is used to describe how similar 
volumes are. The Jaccard coefficient (figure 3.4) cannot be directly applied to 
more than two observers - the result would be dependent on the number of 
delineated volumes which would prevent comparison between studies with 
different numbers of observers (i.e. the more observers, the smaller the 
coefficient of intersection to composite volume). The two acceptable methods of 
determining conformity level are either to determine an average of the Jaccard 
coefficient for all possible sets of pairs or to use the KCL which was specifically 
devised for radiotherapy. Both methods give very similar results, but the KCL 
was chosen for this study  as it is more sensitive in situations when one volume 
is quite different from the other two. The mathematics of this is explained in 
detail by Kouwenhoven [368], but the basic principle is that if two volumes are 
identical the average of the Jaccard coefficient for pairs can never fall below 
0.33 regardless of the size of the third contour. The KCL may therefore be more 
sensitive at lower conformities. For studies using greater numbers of observers 
the KCL is more practical. IOV is increasingly studied in the radiotherapy 
literature and standardisation of the mode of reporting IOV would allow easier 
inter-study comparisons. 
 
3.5.7 PET as a means of reducing IOV in radiotherapy planning for 
other tumour types 
The previous studies evaluating the use of PET for meningioma radiotherapy 
planning have shown that the addition of PET alters target volumes, but 
whether this reduces IOV is not well studied. Grosu et al, reported a 10% 
median increase in the region of agreement in meningioma GTV defined by two 
observers with the addition of 11C methionine PET/CT. The same group 
reported similar results for glomus tumours [373].  
 
There has been more work regarding the effect of the addition of PET 
information on IOV in target volume delineation in other tumour types, mainly 
using 18F FDG. This tracer is not of use in meningiomas due to the very high 
background uptake of FDG in the normal brain and meningiomas are usually 
hypointense for FDG.  In most studies target volumes are generally altered in 
relation to PET information, but there are varied results regarding whether this 
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reduces IOV. Several studies show that PET does improve IOV in defining 
rectal GTV, although this may not necessarily impact on CTV which includes 
prophylactic treatment of the pelvic nodes (although some centres boost the 
rectal GTV) [374, 375]. The results in lung cancer largely indicate that the use of 
PET reduces IOV and phase two studies regarding boosting the PET-positive 
region are ongoing [376, 377]. However, one study showed that PET did not 
improve concordance between trained radiation oncologists, although it did 
result in trainees’ contours being more similar to a reference contour [378]. 
Head and neck studies are less consistent [379] and an initial study in cervix 
cancer did not show an improvement in IOV with PET [380], whereas a study 
evaluating the use of pre-chemotherapy PET in lymphoma target volume 
delineation did show reduced IOV. It is important to note that several of the 
studies that showed a reduction in IOV with PET involved auto-contouring of the 
PET volume based on a set SUV level which is intuitively likely to increase 
consistency amongst observers. SUV thresholding is not currently possible for 
meningiomas.  
 
3.6 Conclusion 
This study showed very high baseline levels of IOV in meningioma target 
volume definition using standard coregistered CT/MRI. It is feasible to use 68Ga 
DOTATATE PET/MRI, but this only slightly improved consistency in contours. 
Some observers did increase target volumes on occasion to include regions of 
tumour identified on PET that they had missed on standard imaging, but these 
were usually identifiable on CT/ MRI following re-evaluation of the standard 
imaging. If PET is used, its coregistration to MRI and CT appears more 
important than whether the PET is acquired on PET(CT) or PET(MRI), although, 
in isolation, the PET/MRI images do appear slightly sharper. Overall there 
remained considerable variation in contouring between observers even with the 
addition of PET and further work is required to clarify whether volumes can be 
safely reduced in PET negative regions.  
In theory, IOV in the target defined should be accounted for in the CTV to PTV 
margin. However, typical PTV margins in the brain of 3mm will not achieve this 
and contouring variability is likely to remain the biggest uncertainty in radiation 
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planning and delivery for meningiomas. With the increasing use of highly 
conformal radiotherapy techniques, further work to reduce IOV is required. 
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4 Chapter 4: Do protons improve plan 
parameters compared to photons for 
radiotherapy in meningioma? 
_______________________________________________________________ 
 
4.1 Introduction 
In section 1.12.5, I detailed the excellent control rates following EBRT for 
benign meningiomas (approximately 90% local control at 10 years) and 
described the improved target coverage and reduced critical structure dose 
associated with IMRT compared to older photon delivery techniques. In Chapter 
2 the clinical outcomes of patients undergoing IMRT for meningioma in a 
prospective study were evaluated. Documented toxicity rates were low, 
although longer follow-up is required.  
 
The OAR sparing capabilities of IMRT has stimulated research into whether 
dose escalation can improve control rates for non-benign meningiomas and 
whether constraints should be set for other regions of the brain related to higher 
mental function. The hippocampus is one region which has an important role in 
memory function and appears to be extremely radiosensitive. Gondi et al, found 
that equivalent dose in 2Gy per fraction of >7.3Gy to ≥40% of the bilateral 
hippocampi was associated with some degree of memory impairment at 18 
months [345]. These results should be considered preliminary due to the very 
small sample size, but they provide a rationale for minimising dose to the 
region. As detailed in appendix 3, advances in photon technology allow for 
marked dose reduction to the hippocampus when specific dose constraints are 
set for this region, but it remains difficult to meet the D40% ≤7.3Gy (in 2 Gy per 
fraction) constraint for tumours close to the hippocampi.  
 
However, many regions other than the hippocampus are involved in higher 
mental functions. Several groups have reported that moderate dose to the 
temporal lobes is associated with impairments in memory, IQ and other 
166 
 
cognitive functions [381, 382] and working memory is independent of temporal 
lobe structures and can be impaired following cranial irradiation [345, 383, 384]. 
Therefore, any radiation delivery method that can minimise dose outside of the 
target is of significant interest. Furthermore, all IMRT techniques are associated 
with an increased “low dose bath” to normal tissue. What effect, if any, this will 
have in the long term is unknown as more twenty years follow-up in a large 
number of patients would be required to evaluate second cancer risk. 
Treatment-related second malignancies are of particular concern for patients 
with meningiomas because these are usually benign tumours that often do not 
reduce life expectancy.   
 
As discussed in section 1.16, all photon radiotherapy techniques, regardless of 
their complexities, are limited by the physical principles of photon travel and 
energy deposition characteristics. Compared to photons, proton therapy offers 
the theoretical advantage of more localized deposition of energy due to the 
dose deposition characteristics of the Bragg peak (figure 1.8). Several planning 
studies have indicated that there may be a role for protons in treating 
meningiomas. Most contained a variety of tumour types. Baumert et al, initially 
compared photon 3DCRT to proton beams (spot scanned) in a brain tumour 
planning study (including one meningioma) and reported that, although protons 
offered no advantage for simple geometries or superficial lesions, the 
conformity index with protons was better than for photons for complex or 
concave lesions or when the PTV was adjacent to critical structures [385]. The 
same group later compared treatment plans using various radiotherapy 
modalities for six patients with base of skull tumours (including four 
meningiomas): static gantry IMRT (photons), spot-scanned protons and 
intensity modulated protons (IMPT). They concluded that dose conformity was 
generally equivalent and that OAR sparing was best for IMRT and IMPT (better 
than standard protons). They noted a reduced integral dose with protons, 
particularly a reduced volume of normal brain receiving <30% of the prescribed 
dose [386].  Bolsi et al compared three photon techniques (3DCRT, VMAT and 
IMRT) with spot scanned protons and passive scattered proton plans for benign 
brain tumours including five meningiomas. They reported that proton techniques 
were superior to all photon approaches in terms of target homogeneity, 
conformity and OAR sparing [387]. The same group later concluded that spot-
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scanning was the best proton method as it produced the lowest maximum 
significant dose to healthy brain and the best conformity index [388].  
 
In the UK, there are currently no high energy proton centres and a very limited 
list of indications for the funding of proton therapy abroad for adults: base of 
skull and spinal chordoma, base of skull chondrosarcoma and spinal/ paraspinal 
sarcomas (non Ewings). More paediatric tumours types are funded but these 
are rare. Two UK proton centres are now being developed (including my 
institution). Therefore, there may be capacity to expand the list of proton-
approved conditions in the UK.  
 
I therefore performed a planning study comparing dosimetric parameters in 
meningioma cases between optimal IMRT and protons using the non-intensity 
modulated spot-scanning proton technique my institution plans to take forward. 
This was to establish the practical aspects of using proton therapy within the 
brain and to investigate whether there was support for the use of protons over 
optimal photon therapy for meningiomas.  
 
4.2 Aims 
Ten patients had three radiotherapy plans created: two volumetric arc therapy 
(VMAT) IMRT photon plans (Clinac RapidArc and Truebeam RapidArc) and a 
single field uniform dose (SFUD) proton plan to:  
 establish the optimal VMAT radiotherapy plan parameters for each case 
 compare the optimal VMAT plan to the proton plan for each case and 
evaluate whether protons appear advantageous 
 identify practical issues with the SFUD proton planning method and 
photon/ proton planning studies 
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4.3 Materials and Methods 
 
4.3.1 Photon Plans 
As discussed in chapter 2, VMAT (Varian RapidArc) is now the preferred 
method of IMRT delivery in my institution where there are two linear accelerator 
models with RapidArc capability: the Clinac 2100Ex (CRA) and the Truebeam 
Stx (TRA). TRA can deliver radiosurgical treatments and has theoretical 
advantages over CRA for fully fractionated radiotherapy: the multileaf 
collimaters (MLCs) are smaller, the field is almost entirely defined by the MLCs 
rather than the jaws and tight jaw tracking reduces leaf transmission. However, 
it is not clear whether plan parameters are improved with TRA. 
 
Duel VMAT plans (CRA and TRA) were created for ten unselected consecutive 
cases of meningioma to establish our best VMAT plan. The CRA is equipped 
with Millenium multileaf collimator (MLC) (120 leaves with 5mm resolution over 
the central field) and the TRA with HD 120MLC (120 leaves with 2.5mm 
resolution over central field). Patients were immobilised with a thermoplastic 
shell and CT scanned in the treatment position with slice spacing of 2.5mm. 
Scans were fused with the appropriate MRI sequences (section 2.3.2) and 
target volumes were delineated on Oncentra Masterplan. Photon treatments 
were planned on Eclipse version 10, Varian Medical Systems, Palo Alto, using 
the Anisotropic Analytical Algorithm (AAA) and a 2.5mm calculation grid. A 3mm 
margin was added to the CTV to produce a PTV and to OAR to create planning 
organ at risk volume (PRV). One or two arcs were used as required to meet 
constraints. The prescription was 50.4Gy mean target dose in 28 daily fractions 
of 1.8Gy and plans were normalised to the mean target dose. ICRU83 
recommends prescribing to the median target dose. Our institution is moving 
towards this, but we have noted previously that the mean and median are within 
0.2% of each other for brain tumours (RA). Plan optimisation was performed to 
reflect the following PTV and PRV constraints: 99% PTV receives >90% dose; 
95% PTV receives > 95% dose; 50% PTV receives 100% dose; a maximum of 
5% PTV receives >105% dose; a maximum of 2% PTV receives >107% dose; 
brainstem receives < 55Gy (not an issue for prescribed dose of 50.4Gy); each 
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lens receives <6Gy; each optic nerve receives < 50Gy; optic chiasm receives < 
50Gy. Patients were treated using the VMAT plan that provided the best target 
coverage and OAR avoidance. Patients underwent weekly cone beam CT, daily 
Kv imaging and were repositioned as required before treatment to exclude set-
up error. 
 
4.3.2 Proton plans 
Proton plans were created for the same ten cases. Plans were produced under 
direct supervision of personnel experienced in proton planning at the Roberts 
Proton Centre in the University of Pennsylvania (UPenn). The proton beam data 
refers to therapy delivered by pencil beam scanning (PBS) protons with a 
horizontal fixed beam line and 27 clinical energies between 100-226.7 MeV 
using Ion Beam Applications (IBA) Proteus hardware. The PBS technique 
employed was non-intensity modulated single field uniform dose (SFUD). This 
method of PBS delivery was selected as it is the most robust of the “scanning” 
techniques and as such it will be used at our centre initially rather than intensity 
modulated protons (IMPT). Treatment plans were created on Eclipse version 10 
using a 2.5mm grid and a proton convolution superposition dose calculation 
algorithm with a simultaneous spot optimisation algorithm.  
 
Unlike photon therapy, absorbed dose in protons cannot be directly derived 
from CT Hounsfield units (HU). Therefore a HU to stopping power calibration 
curve was determined using stoichiometric calibration. Patient 5 had metal clips 
inside the target and the HU had to be overridden in contouring because of 
artefact. An appropriate stopping power was assigned to the clips at the higher 
extent of the established range taking account of the fact that the clips were in 
the target where the proton energy is lower and the stopping power higher.  
 
GTV and CTV are the same for photon and proton plans as they are 
independent of treatment delivery technique. In photon therapy, treatment plans 
are optimised to the PTV that takes account of set-up error, machine tolerances 
and intra-treatment variations. A 3mm universal margin is added to the CTV to 
create PTV. The concept of PTV is more complicated for proton therapy due to 
additional uncertainties in proton plans, in particular the range uncertainty, i.e. 
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uncertainty where the protons stop. In accordance with the UPenn guidelines, a 
uniform pencil beam scanning target volume (PBSTV) of 5mm was added to the 
CTV to account for the range uncertainty of protons. The photon and proton 
plans produced were therefore optimised to different targets: PTV for photons 
(CTV + 3mm) and PBSTV for protons (CTV + 5mm). This introduces a 
significant issue in comparing the OAR sparing-capabilities of the modalities 
directly, but reflects the reality of proton use in clinical practice. The OAR PRV 
dose constraints were the same for photons and protons. 
 
Proton doses were corrected to a relative biologic effectiveness (RBE) value of 
1.1 and expressed as cobalt gray equivalent (CGE). Due to range uncertainty, 
beam angle was chosen to meet the general rule that no more than 2 out of 3 
beams should be in direct alignment with a critical structure (or 1 of 2 beams). A 
range shifter was applied to each field where the proximal edge of the targets 
was less than the range of the lowest energy (100 MeV, has a range of 7.4 cm). 
To ensure sufficient coverage and to reduce the possibility of high-weighted 
spots close to the edge of the target (which could result in high OAR doses if 
the patient moved), at least one spot was positioned laterally outside the target. 
Prioritising of target coverage or organ sparing was the same for both photon 
and proton plans (dependent on individual circumstances, e.g. if already 
unilaterally blind, the ipsilateral optic nerve would be compromised rather than 
target).  
 
4.3.3 Plan Analysis 
DVHs were compared between photon and proton plans. Target doses for 
PBSTV with protons and PTV for photons are detailed as the respective plans 
were optimised for these volumes. However doses to CTV for both modalities 
are also quoted as this volume was the same for both photon and proton plans.  
As per ICRU 83 recommendations, the D2% (near maximum) and D98% (near 
minimum) doses are quoted. The D95% to target is also quoted as this has 
historically been important and a D95% of 95% remained one of the target 
constraints.  
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Dose conformity around target is represented by the conformity index (CI) 
described by Wagner et al [231]: 
 
For photons:  CI = VPTV 95% 
                                  V95% 
 
For protons: CI = VPBSTV 95%  
                                  V95% 
 
 
As detailed in Chapter 2, this CI reflects the fact that 100% of the target is not 
necessarily covered by the 95% isodose. A CI of 1 is perfect conformity, a CI of 
0.8 means that 20% of the 95% isodose lies outside of the PTV.  
 
Homogeneity of dose across the target is represented by the homogeneity 
index: 
  
HI =     D2% - D98% 
                  D50% 
 
A HI of 0.1 indicates a 10% spread of dose between the near maximum and 
near minimum in the target.          
 
The integral dose to the brain is represented by mean brain dose and the 
V50%, V30% and V10% of “Brain-PTV” with a mean brain-PTV dose volume 
histogram (DVH). For OAR, the D2%, the mean dose and the number of cases 
where the D2% exceeded the dose constraint is quoted to the optic nerves, 
globe, optic chiasm, lens, brainstem PRV.  
 
Standard deviations were obtained using GraphPad Prism v4. Statistical testing 
between plan parameters was not carried out as the role of chance in creating 
different plan parameters is far outweighed by factors such as beam choice and 
treatment planning system used.  
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4.4 Results 
 
4.4.1 Target Volume Characteristics 
Table 4.1 summarises target volume characteristics and treatment plans 
created. The mean PTV was 90.24cc (SD 55.87) and proton PBSTV 118.7 cc 
(SD 65.25). Eight tumours were located in the skull base, one was frontal and 
one parafalcine. 
 
4.4.2 TrueBeam (TRA) versus Clinac RapidArc (CRA) 
All plans met the PTV and PRV constraints (lens dose exceeded for five 
lenses). There was no discernible difference in target coverage or OAR sparing 
between modalities (table 4.2). Likewise the dose conformity was essentially the 
same (TRA mean CI: 0.87, SD 0.05; CRA mean CI: 0.86, SD 0.07) as was dose 
homogeneity across the target (TRA mean HI: 0.07 SD 0.02; CRA mean HI: 
0.08, SD 0.02). The D2% to the majority of OAR PRV was less with TRA than 
CRA, up to 3.5Gy in some instances, but the mean difference on OAR PRV 
D2% was negligible (TRA mean 34Gy, SD 9.1Gy, CRA mean 34.5Gy, SD 
8.9Gy). The most noticeable difference between the two RA modalities was a 
reduced dose 0.5cm superior and inferior to the PTV with TRA than CRA (mean 
dose difference between TRA and CRA superior 16.9%, inferior 14.3%). 
However, the mean brain dose was only a little less with TRA (mean 0.6Gy 
less, SD 0.4Gy). Similarly the volume receiving 50% was a little less in all 
patients with TRA rather than CRA (mean 8.9% less, SD 4.5%). There was no 
clinically relevant difference in number of monitor units used between the two 
modalities (TRA mean 362, SD 32; CRA mean 351, SD 30). On visual 
inspection, the TRA plans were felt on balance to be slightly superior to the 
CRA plans. Therefore all patients were treated on the TRA and the TRA plans 
were compared to the proton plans. 
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Table 4-1 Target features and beams used for each patient 
Patient Tumour 
Location 
     Target Size 
PTV          PBSTV 
Grade Previous Tx    Arcs           Proton Beams Proton Comments 
1 Skull Base 43.8 64.5 N/A Nil 1 R lateral and RSO No issues 
2 Parafalcine 148.5 178.4 2 Surgery 2 Single vertex PBSTV overlaps globe 
To get good coverage had to increase dose 
outside target laterally because of spot size 
3 Frontal 41.6 66.8 2 3 x surgery 2 2 x oblique vertex PBSTV overlaps globe and optic nerve  
Difficult to get full coverage in nasal cavities 
Dose shooting through nasal cavities and 
frontal sinus 
4 Skull Base 129.7 160.4 2 Surgery 2 L lateral and LSO PBSTV overlaps globe  
Dose shooting into nasal cavities 
5 Skull Base 39.6 55.9 2 Surgery 2 L lateral and LSO Some shadowing behind clips  
Dose shooting into nasal cavities 
6 Skull Base 79.1 106 1 Surgery 1 L lateral and LSO PBSTV overlaps globe and chiasm 
Difficult to get coverage anteriorly due to air 
cavities 
7 Skull Base 125.9 164.8 N/A Nil 2 L lateral and LSO  Difficult to get coverage because of 
overlapping OAR and spot size 
Dose shooting through sinus 
8 Skull Base 56.9 84.6 N/A Nil 2 L lateral and LSO PBSTV overlaps globe 
Dose shooting into nasal cavities  
9 Skull Base 195.9 246.9 1 Surgery 2 R lateral and RSO PBSTV and globe overlap 
Spot size increased dose to left globe 
10 Skull Base 41.4 59.1 N/A Nil 2 L lateral and LSO PBSTV overlaps optic PRVs  
Anterior PTV coverage limited by sinuses 
L = left; R = right; SO = superior oblique
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4.4.3 Proton versus RapidArc (Truebeam) 
 
4.4.3.1 Target Coverage 
Due to the increased margin on CTV required for protons (5mm as opposed to 
3mm with photons), the PBSTV was larger than the corresponding photon PTV 
in all cases (mean 37.9% larger, range 24-61%). The proton D98% (near 
minimum dose) to PBSTV was less than the photon D98% (to PTV) in nine of 
ten cases (proton PBSTV mean D98% 5.1% less, SD 4.6%). The 95% isodose 
did not cover 95% of the PBSTV in four cases, but did so in all TRA plans. 
There was no notable difference in the CTV D98% or 95% coverage for either 
modality. The D2% (near maximum) was marginally higher for the proton plans 
(mean D2% for protons 103.9%, SD 1.5; photons mean 102.5%, SD 0.6). 
Accordingly, dose homogeneity was better with photons than protons in nine 
cases (one the same): mean proton HI 0.14 (SD 0.07), mean photon HI 0.07 
(SD 0.02). The HI was ≥0.1, representing a ≥10% range of dose to PBSTV in 
nine cases with protons and one case with photons. 
CI was better with photons in six of ten patients, better with protons in two 
patients and there was no difference in the other two: mean CI95 with protons 
0.8 (SD 0.1) and photons 0.87 (SD 0.1), i.e. an average of 7% more of the 95% 
isodose was outside of the target with protons (PBSTV) versus photons (PTV).  
Figure 4.1 demonstrates the difficulty conforming dose around the air spaces of 
the sinuses with protons and the larger PBSTV often includes more of the 
sinuses. Metal artefacts within the beam path also cause more problems with 
protons (figure 4.2).
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Patient Modality PTV cc 
(PBSTV)* 
d2% PTV 
(PBSTV)* 
d98% 
PTV 
(PBSTV)* 
d95% 
PTV 
(PBSTV)* 
CI 95% HI  CTV 
d98% 
CTV 
d95% 
          
1 Pro 64.5 104.5 91 93 0.82 0.14 95.2 95.8 
1 TRA 43.8 101.8 96.6 97 0.76 0.05 98 98.8 
1 CRA 43.8 101.8 97 97 0.69 0.05 97.8 98 
          
2 Pro 178.4 104 97.8 99 0.82 0.06 100.7 101 
2 TRA 143.5 102 95.7 96.7 0.93 0.06 98 99 
2 CRA 143.5 102.6 95.6 96 0.95 0.07 98 99 
          
3 Pro 66.8 106 91.6 95 0.77 0.14 98.9 99 
3 TRA 41.6 102 95.4 96 0.95 0.07 98.3 99 
3 CRA 41.6 102 95.4 96 0.91 0.07 98 99 
          
4 Pro 160.4 102.7 92.4 95 0.9 0.10 96.5 97.5 
4 TRA 129.7 102 96.7 97.4 0.9 0.05 97.6 98.3 
4 CRA 129.7 102 96.4 97 0.89 0.06 97 98 
          
5 Pro 55.9 102.7 94.4 95.5 0.63 0.08 95.2 96 
5 TRA 39.6 102.5 96.2 97 0.86 0.06 97.3 98 
5 CRA 39.6 103 96 96.8 0.84 0.07 97 98 
          
6 Pro 106 103.4 91.5 95 0.85 0.12 97.3 98 
6 TRA 79.1 103.2 95.5 96.3 0.89 0.08 97.5 98.3 
6 CRA 79.1 103.2 95 96.3 0.86 0.08 97.2 98 
          
7 Pro 164.8 106.8 80 86 0.63 0.27 95 96 
7 TRA 125.9 103 94 96 0.87 0.09 96 98 
7 CRA 125.9 103 94 96 0.84 0.09 96 98 
          
8 Pro 84.6 103.6 88.9 93.6 0.76 0.15 96 96.8 
8 TRA 56.9 102.4 96 97.3 0.82 0.06 97.8 98.6 
8 CRA 56.9 102.4 95 96.7 0.84 0.07 97.8 98.6 
          
9 Pro 246.9 104.3 81.5 90.3 0.99 0.23 92 104.5 
9 TRA 195.9 102.5 92.3 96.7 0.91 0.10 97.3 98 
9 CRA 195.9 102.5 92.3 96.7 0.91 0.10 97.3 95.1 
          
10 Pro 59.1 103 93.3 95 0.86 0.1 96 97 
10 TRA 41.4 103.8 95.2 96.2 0.86 0.09 97 98 
10 CRA 41.4 103.8 95.2 96.2 0.85 0.09 97 98 
Table 4-2 Target Coverage for All Modalities *For proton plans the PBSTV figure is 
quoted rather than PTV, but CTVs are the same 
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Figure 4-1 Inclusion of the sinuses in the target causes problems with protons 
(especially as the PBSTV often includes more of the sinuses than PTV).  
Photon PTV (red line), proton PBSTV (green line). See table 4.1 for proton beam detail. 
 
A) This can result in underdosing of the target (patients 3, 4 and 7) 
VMAT (RapidArc) PHOTONS                       PROTONS 
 
 
Patient 4 
Patient 7 
Patient 3 
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B. Alternatively, this can result in overdosing outside the target (patient 4 and 5) 
Note that patient 4 appears in both underdosing and overdosing circumstances. 
 
VMAT (RapidArc) PHOTONS  PROTONS 
 
 
  
Patient 4 
Patient 5 
178 
 
Figure 4-2 Metal artefacts within the beam path cause more problems with proton 
than photon dosimetry. See table 4.1 for proton beam detail. 
 
PHOTONS                                                      PROTONS
 
 
  
Patient 5 
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4.4.4 Normal tissue sparing 
4.4.4.1 Brain-PTV 
The mean total dose and dose per fraction to brain-PTV was less with protons 
versus photons in 7/10 cases, but the clinical relevance of this is small as the 
mean total dose was only 0.65Gy less with protons (mean total dose 7.69Gy 
with protons, 8.51Gy with photons). The V50% to brain-PTV was higher with 
protons in all cases. However, the V30% and V10% to brain-PTV were 
considerably lower with protons than photons in virtually all cases (table 4.3 and 
figure 4.3).   
Table 4-3 Brain-PTV Doses Per Patient 
Pt Tx Mean Dose 
(Gy) 
V50%            V30%            V10% 
1 Pro 5.8 10 18 27.5 
1 TRA 7.5 8 20 36 
      
2 Pro 9.5 18 24.5 33 
2 TRA 11 17 32 46 
      
3 Pro 4.4 8 11 15 
3 TRA 7.5 4 11 58 
      
4 Pro 9.1 15 25 36 
4 TRA 10.3 12 31 54 
      
5 Pro 6.9 9 21 30 
5 TRA 4.8 5 10 27 
      
6 Pro 8 16 22 31 
6 TRA 8.8 12 23.5 46 
      
7 Pro 9.9 16 28 38 
7 TRA 10.4 12 22.5 46 
      
8 Pro 7.6 12 21.8 30.6 
8 TRA 6.2 6 19 32.5 
      
9 Pro 11.1 21 28.5 39 
9 TRA 14 18 42.5 64 
      
10 Pro 7.3 10 22 32.7 
10 TRA 5.6 8 13 27.5 
      
      
180 
 
 
Figure 4-3 Dose Volume Histogram showing mean brain-PTV dose for protons 
and photons (all patients) 
 
 
Figure 4.4 shows that whilst the RA photon plans appear to spread the low dose 
across a larger volume of normal tissues on the axial slices, the proton plans do 
the same on the sagittal view. This results in the minimal differences in overall 
mean dose to brain-PTV. Again, the brain-PTV doses will be influenced by the 
larger PBSTV for protons. 
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VMAT (RapidArc) PHOTONS   PROTONS 
 
 
Figure 4-4 Dose colour wash screen shots photons versus protons 1. See table 
4.1 for proton beam detail. Axial images show far less dose to normal brain with 
protons, but coronal and sagittal slices show higher entrance dose for protons outside 
the target.  
  
Patient 3 
Patient 8 
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4.4.4.2 Specific OAR PRV Doses 
As detailed in table 4.4, the planning constraints for the OAR PRVs (except the 
lenses) were met in all cases for both photons and protons. The maximum dose 
to lenses was above 6Gy in 9 of 19 lenses assessed for protons and 4 of 19 
lenses for photons. However, a different angle could have been chosen for the 
proton beams to reduce lens dose if sparing lenses was deemed critical. Dose 
to individual OAR PRV obviously fluctuated depending on tumour position and 
the proton beam angle chosen, but the near maximum for OAR PRV was 
generally similar for both modalities: PRV median D2% with photons was 
41.6Gy (IQR 21.4-49.1Gy) versus 43Gy (IQR 18-48.9Gy) with protons. 
Although the larger PBSTV sometimes increased dose to OAR PRV, the beam 
angle chosen for protons could exploit their rapid distal dose fall off to spare 
specific regions of the brain if desired, e.g. temporal lobe (figure 4.5). 
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Table 4-4 OAR PRV Doses 
Pt Tx BS 
D2% 
Gy  
BS 
mean 
Gy 
RG 
D2% 
Gy 
RG 
mean 
Gy 
LG 
D2%  
Gy 
LG 
mean 
Gy 
RON 
D2% 
Gy 
RON 
mean 
Gy 
LON 
D2% 
Gy 
LON 
mean 
Gy 
Chiasm 
D2% 
Gy 
Chiasm 
mean 
Gy 
1 Pro 52 28.5 7.4 1.1 1 0.1 47.9 32.3 19 6.3 48.5 35.8 
1 TRA 51 34.3 16 10 13.7 8 50 33.4 31.4 16.9 49 40 
1 CRA 51 35.7 18.5 9.3 15.1 8.7 48.9 32.3 32 20 49 40.1 
              
2 Pro 0 0 10.7 2.4 17.7 5.4 1.5 0.2 5.5 0.7 0 0 
2 TRA 1.7 0.8 5.5 1.7 8.5 2.3 1.9 1.5 2.1 1.6 2 1.8 
2 CRA 2 0.8 5.8 2 10.5 2.8 2.4 1.9 2.6 1.9 2.8 2 
              
3 Pro 0 0 37.6 13.1 34 10 33 17.2 46 31 35.7 10.3 
3 TRA 10.3 1.9 26 8 27 9.6 21.4 11.3 45.8 20.5 30.3 16.4 
3 CRA 12.2 2.3 24.6 8 26.1 9.5 24.1 14.5 46.5 24 32 19.7 
              
4 Pro 45.8 13.6 12.6 3.3 43 28.4 39.2 19.5 48.8 45.5 48.6 47.8 
4 TRA 42.7 21.8 18.3 9.5 42 21.8 28.1 22 49 44.9 49.3 47.7 
4 CRA 43.4 21.4 20.5 9.8 42.5 21.1 28.4 9.8 49 45.4 49.4 47.9 
              
5 Pro 51.7 18.2 5.3 1 37.6 10.5 32 12.2 48.6 43 48.8 44.7 
5 TRA 48.6 16 16.9 8.9 22.5 11 33 22.2 49.2 37.3 49 37.4 
5 CRA 48.9 16.9 17.6 10 21.5 10 36 22.4 49.4 39.3 49 38.1 
              
6 Pro 51.2 32.1 3.2 0.5 41.4 20.4 18 4.8 50 48.1 49.4 45.2 
6 TRA 48.5 31.5 13.9 7.3 41.6 19.7 25.2 17.5 49.3 48.1 49.6 40.8 
6 CRA 49.1 33.1 15.8 9 41.6 17.4 27.7 20.6 49.3 47.8 49.6 43.6 
              
7 Pro 51.5 24.7 25 4.9 44 25.6 50 33.1 50 46.6 48.9 48.3 
7 TRA 49.9 29 27 15.2 44 23.2 48 35.6 49.1 46.1 49.3 47 
7 CRA 49.9 30.7 28.5 16.3 44 23.7 48.9 37 49.1 45.8 49.3 47 
              
8 Pro 49 15.6 44.4 25.8 40.9 21.5 44.3 25.8 50.2 45.3 48.7 47.1 
8 TRA 46 19.6 23.2 13.7 40.7 17.7 39.6 28 50 43.8 49.6 44.5 
8 CRA 46 20.2 23.2 13 40.7 16.6 39.6 28.7 50 43.2 49.6 44.5 
              
9 Pro 48.8 29.6 40 24.5 30 9.5 n/a n/a 49.1 42.8 49.9 48.6 
9 TRA 50 31.5 44 30.5 29 13.5 n/a n/a 49 40 49.5 45.7 
9 CRA 50 34 44 31 24.9 11 n/a n/a 49 39.1 49.5 45 
              
10 Pro 50 26.6 1.6 0.2 8.2 1.3 20.6 6.7 47.5 25.4 49 48.1 
10 TRA 51.3 24.7 13.4 8.3 16 9.3 23.6 16.1 48.7 23 50 49 
10 CRA 51 24.9 13.7 7.7 16 8.3 27.1 17.3 49 23 49 48.4 
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PHOTONS                                                                  PROTONS
 
Figure 4-5 Dose colour wash screen shots photons versus protons 2. See table 
4.1 for proton beam detail. The PBSTV for protons was larger than the PTV for 
photons. This could increase dose to OAR such as the globe. Conversely, the proton 
field angle and distal dose fall-off can completely spare specific regions of the brain if 
this is desired, e.g. temporal lobes or the globe. However, as shown in figure 4.4, the 
proton dose is largely redistributed elsewhere.  
  
Patient 8 
Patient 10 
Patient 1 
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4.5 Discussion 
 
4.5.1 Plan parameters 
There was little difference in plan parameters between the two different modes 
of delivering VMAT (TRA versus CRA). TRA does have other favourable 
features that would not be identified in a planning study and may result in more 
accurate treatment delivery: tighter mechanical tolerances, a proactive rather 
than reactive control system and a couch with 6 degrees of freedom allowing 
correction of rotational set-up errors. Overall, both TRA and CRA plans were 
very acceptable and met planning constraints (apart from the lens doses in a 
few cases). The TRA plans were chosen as the comparator “optimal” photon 
arm as the penumbra was slightly less. In some cases this did reduce the near 
maximum dose to the PRVs by several Gy, but the average difference was 
<0.5Gy. Improved superior and inferior dose fall off was identified in all TRA 
plans with lower dose at 0.5cm above and below PTV, although the effect of 
this on brain-PTV dose was marginal.   
The theoretical dosimetric advantages of proton therapy were not clearly 
evident in this study mainly due to two factors. Firstly, the photon plans were 
extremely good and met the dose constraints, meaning there was little room for 
improvement with protons. The prescription dose of 50.4Gy used for benign 
meningiomas is within tolerance of most standard OARs in the brain.  Secondly, 
there are more uncertainties associated with proton therapy than photons, in 
particular the range uncertainty. Centres have different approaches to this. We 
chose to follow the UPenn model of adding an additional margin in all 
dimensions. This meant that the proton PBSTV was considerably larger than 
the photon target (PTV), hence the target was often closer to OAR. Although 
the margin added to CTV was only 2mm larger for protons than photons, this 
increased the target volume by a substantial mean of 35.7%. Air spaces are 
difficult to cover in photon therapy and even harder with protons. Often the 
larger PBSTV required for protons included more sinus than the PTV leading to 
poorer PBSTV coverage. Arguably, dose through air spaces may not be of 
clinical significance, but it could result in target underdosing. Of note, the CTV 
coverage was comparable for the photon and proton plans.   
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The main postulated benefit of protons and the study hypothesis was that 
protons can reduce dose to normal brain and OAR. The brain-ptv dose was only 
marginally less with protons and the dose to particular OAR PRV was slightly 
more with protons (although still generally within planning constraints). 
However, again the larger PBSTV will have had a significant influence upon 
this. Most proton literature publishes axial slices showing the distal dose fall-off 
which clearly favours protons, but this study highlights that it is very important to 
display the proton entry dose in the sagittal and coronal images. Although the 
reduction in overall brain-PTV doses were unimpressive with protons, the V30% 
and V10% were generally better. As shown in the mean DVH, the “brain-PTV” 
DVH lines for photons and protons crossed to favour protons at around 15Gy 
(30%). It is low dose of this order (as low as 2.5Gy) to normal brain that has 
been implicated in second cancer risk and impairment of higher mental function. 
Moreover, the reduction in integral dose may be more significant if higher 
prescription doses were applied. Further work is required to identify appropriate 
dose constraints for radiosensitive regions of the brain involved in higher mental 
function, such as the hippocampus, that could be also become OAR avoidance 
structures, as radiation delivery technology has now evolved to potentially spare 
such regions without compromising target dose.  
I compared my institution’s optimal method of IMRT planning (TRA) to SFUD 
proton plans. Arguably, this is not comparing like with like. Intensity modulated 
proton therapy (IMPT) plans are likely to provide better plans than SFUD. 
However, the practical purpose of this study was to explore whether it would be 
beneficial for patients with meningiomas to be considered for proton therapy in 
the UK when this becomes available. I therefore felt it was most useful to 
evaluate the proton technique that will be used initially in the UK. It would have 
been interesting to add an IMPT comparator arm to this study, but the available 
planning expertise and software did not permit this and IMPT is likely to have 
progressed further by the time it becomes available in the UK.  
Clearly bias was introduced in favour of the photon plans by the disparity in 
experience between the photon and proton planners. However, this was 
minimised as much as possible by the fact that the proton planning was heavily 
supervised and reviewed by highly experienced proton planners at UPenn, who 
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deemed all proton plans in this study acceptable, although it is possible that 
they could have been improved further. 
 
4.5.2 Difficulties exploiting the theoretical benefits of proton 
therapy 
In general the lateral penumbra of PBS protons is relatively similar to photons 
as a spot is always positioned outside of the target. This is to prevent spots 
near the edge of the target having a very high weighting which would potentially 
overdose OARs close to target in the event of set-up error. In PBS, the spot 
size is larger than the maximum range of motion, hence for brain cases the 
minimum spot size is 3mm. This can limit dose conformity. Furthermore, as 
shown in this study, the entrance dose of protons is not necessarily better than 
photons. As more than one proton field is usually required, the entrance dose 
can cover a significant volume of normal tissue.  
 
The theoretical benefit of protons lies in the rapid dose fall off distal to the Bragg 
peak. However, the major uncertainties associated with proton biology currently 
prevent full exploitation of the Bragg Peak. Uncertainties in proton therapy 
relate to inaccuracies arising from CT reconstruction, conversion of CT HU to 
proton stopping power and inaccuracies arising from the dose algorithm. HU 
uncertainties contribute approximately +/- 3% uncertainty in range even after 
site-specific CT scanner calibrations have been carried out [389]. As such, the 
exact point of the Bragg Peak for each beam is not known. This range 
uncertainty means that distal fall off cannot be safely relied upon to spare OAR 
adjacent to the target from all beams.  
 
In some cases in this study, slightly better OAR sparing may have been 
achievable with the addition of a third beam angled directly at the OAR, 
however, the trade off would have been more spread of dose to the normal 
brain. This approach was not favoured as the dose constraints were generally 
met by the plans produced. Several centres treat patients with a combination of 
photons and a proton boost, using the Bragg Peak to boost only the GTV 
without a margin (hence reducing the risk of overdosing an adjacent critical 
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structure). Indeed many full proton treatment plans involve boosts to smaller 
targets. Again, this was not required with the relatively modest dose used in this 
study although, if dose escalation for non-benign meningiomas proves to be 
beneficial, such a protocol may have to be revisited. 
 
In brain photon therapy a uniform 3D CTV to PTV margin is standard to account 
for penumbra uncertainties, set up, motion and physician inaccuracies / inter-
observer variability (although this last concept is rarely accounted for in 
practice). Cho et al, found that uniform CTV expansions were adequate for the 
majority of clinical cases [390]. Margins for proton therapy are more 
complicated and are a trade-off between ensuring target coverage, exploiting 
the advantages of protons and minimising risk of errors. Whilst the same “PTV” 
factors have to be considered for protons as photons, range uncertainty is the 
biggest issue and can itself vary when a patient’s anatomy along the beam path 
is changed by variations in set-up. However, if a margin for range uncertainty 
was added to set-up certainty, the resulting margins would be unacceptably 
large. Adding larger margins for protons than photons reduces the plan 
conformity and, as shown in this study, even the addition of an extra 2mm 
seems to have largely negated most of the potential benefits of proton therapy. 
In practice, it is range uncertainty that largely dictates the margin applied to 
CTV for proton therapy.  
 
ICRU 78 discusses the addition of margins to CTV to create a proton planning 
target volume similar in concept to the PTV margin in photons [391].  It 
proposes that the proton PTV be defined relative to the CTV on the basis of 
inaccuracies of the lateral beam alone and that adjustments are made in the 
beam-design algorithm to account for range uncertainties. However, different 
institutions approach range uncertainty and margins in different ways and there 
can be variation between tumour sites. The universal margin approach is 
unsatisfactory when there are significant changes in density in the proximal 
beam path as this affects the range. This is rarely an issue for brain lesions as 
the beams are generally positioned to avoid entry through the sinuses. For the 
purposes of this study, I followed the UPenn approach, where 5mm universal 
margins are added for intracranial tumours. This is largely driven by range 
uncertainty and effectively disregards set-up uncertainties distally as errors are 
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added in quadrature: e.g. if distal range uncertainty was taken as 5mm and 
standard set-up uncertainties as 3mm, combined these uncertainties are 
√(5mm2 + 3mm2) = 5.8mm. Although range uncertainty differs depending on 
depth of each individual’s tumour, an isotropic margin is a pragmatic solution in 
the brain as the ranges to distal beam edge are all quite similar. It also negates 
the need to add a separate margin to each beam as this could lead to 
significant errors in a new centre. Starting with larger margins in a new centre is 
the safest approach and also highlights the importance of choice of beam angle, 
an important factor in planning training.  However, some studies report that 
universal geometric expansion of CTV is inadequate for proton planning [392, 
393]. Park et al, recently published phantom work detailing the use of beam 
specific PTVs in proton therapy to account for range uncertainty and setup 
errors for the specific beam angle (in the prostate) [394]. They found that beam 
specific PTVs ensured better target coverage. The PTV concept may not be the 
best solution to ensure target coverage when dealing with range uncertainty in 
IMPT as this is vastly more complex than SFUD protons [395, 396]. It requires 
more sophisticated solutions than the simple addition of margins and directly 
incorporating uncertainties into the optimisation algorithm is proposed [397]. 
  
4.5.3 Issues with planning studies comparing photons and protons 
The fact that the target volume may be different between photons and protons 
is a major hurdle in planning studies. In fact, the majority of planning studies 
comparing photons and protons optimise to the same PTV with no accounting 
for uncertainty within the optimisation algorithm. A fundamental issue making 
comparisons between proton and photon plans difficult is that “what you see is 
not what you get” with protons. Comparing plans for the two modalities as you 
would with photons is somewhat artificial and may systematically over or 
underestimate the benefits of proton therapy. As per UPenn guidelines, the 
proton plans for the intracranial lesions in this study were optimised to a PBSTV 
larger than the PTV. However, I also evaluated CTV coverage for both. 
Nevertheless, the larger PBSTV undoubtedly increased integral dose and dose 
to adjacent OAR with protons. I did not produce two plans for protons optimising 
for PTV coverage as this is not the approach my institution will take. A reduction 
in the range uncertainty associated with protons would undoubtedly improve 
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photon versus proton plan comparisons. Proton imaging is currently being 
developed that would remove the uncertainty in CT HU to proton stopping 
power conversion, although it is likely to be sometime before this is 
commercially available. 
 
A second considerable uncertainty surrounds the relative biological 
effectiveness (RBE) of protons. Protons have a higher RBE than photons: a 
lower dose of protons than photons is required to achieve an equivalent 
biological effect.  A generalised 10% difference in biological effect is assumed 
when prescribing clinical treatments and proton doses are expressed as their 
photon-equivalent Gy (RBE)/ Cobalt Gy Equivalent (CGE), i.e. the proton dose 
is multiplied by 1.1 [398]. This calculation was already factored into the proton 
planning system used in this study as is the usually the case. Whilst the generic 
value of 1.1 is practical and facilitates comparison between when proton and 
photon studies, it is based on historic in vitro cell survival experiments with 
some in vivo animal experiments [399]. Undoubtedly, it is a gross simplification 
and the true RBE value is likely to fluctuate depending on many factors e.g. 
beam energy, depth of penetration in tissue, specific tissue features, biological 
endpoint, dose per fraction, position in the beam path and initial beam 
properties. It is suggested by animal and cell work that the true proton RBE may 
vary 10%-15% in the clinically relevant dose range [398]. However, this would 
be impossible to reliably incorporate into a treatment planning system and the 
uncertainty is too great to propose RBE values specific to tissue, dose/fraction, 
and proton energy.  Therefore, proton DVHs have to be viewed as an 
approximation, where the same DVH dose for photons and protons may not be 
of exact biological equivalence. This is true for tumour and normal tissues. As 
such, further study is required to establish whether the normal tissue dose 
constraints are the same for photons and protons. 
 
The broader relevance of proton versus photon planning studies is also 
challenging as each proton facility is unique, to a greater extent than photon 
facilities, in terms of hardware characteristics (proton equipment, range shifter 
use etc), how uncertainties are addressed and planning techniques. Experience 
of planners varies considerably. 
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4.5.4 Comparison to Other Planning Studies 
There are a few other planning studies comparing photons to protons in 
meningiomas [385-388, 300]. The majority favour protons mainly due to 
reduced dose outside of the target, although this reduction was not always 
present or significant. There are notable differences between this study and 
previous reports. Meningiomas are a unique tumour type as target volumes are 
often very irregular. Most of the previous planning studies had only a few 
meningioma cases within a mixture of other brain tumours and target volumes 
were generally very small (<30cc versus mean of 90-120cc in this study). Bolsi 
et al, concluded that proton therapy was more effective at reducing integral 
dose in superficial lesions [387]. The majority of tumours in my study were 
deeper base of skull lesions with a resulting substantial proton entry dose.  Of 
significance is the fact that previous studies, with one exception [300], did not 
obviously take account of proton uncertainties. The most fundamental issue is 
that the majority of previous planning studies were published in the early 2000s 
and evaluated less advanced photon techniques – 3DCRT, static gantry IMRT 
or old arc techniques. Modern photon planning techniques, such as those used 
in this study, may leave little room for clinically significant improvement with 
protons.  
In a recent planning study Arvold et al, concluded that protons approximately 
half second tumour risk, but they evaluated static gantry IMRT photon technique 
which is associated with higher integral dose than VMAT [300]. Their study was 
entirely theoretical and the predicted absolute decrease in risk was small (1.3 
per 100000 versus 2.8 per 100000). Furthermore, many assumptions were 
made, including the fact that proton and photons inherently carry the same 
propensity to cause second tumours, and doses to the whole brain were 
significantly higher than in this study for both protons and IMRT (mean 19Gy 
and mean 22.8Gy in Arvold’s study versus mean 7.96Gy and 8.51Gy in this 
study for protons and photons respectively). 
  
4.5.5 Clinical Use of Protons for Meningioma 
There are limited published clinical outcome data following proton treatment for 
meningiomas, despite the fact that many proton centres regularly treat this 
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tumour type. The published case series were detailed in table 1.9 and detail 376 
patient outcomes. A wide variety of protocols were used, with some centres 
combining photon and proton therapy, some using large single fraction proton 
therapy and others using fractionated courses of proton therapy alone. In 
general, the data available suggest that proton therapy is likely to be a 
reasonable treatment option for meningiomas, but so far do not support a 
clinical advantage for proton therapy over modern photon techniques. 
Outcomes appear relatively comparable to photon case series in terms of 
tumour control and documented toxicity can actually be worse, although most 
proton series used higher doses than is standard with photons for benign 
meningiomas and many altered their protocols. The lack of obvious clinical 
advantage calls into question the merits of further investigation into the use of 
protons for meningioma therapy. However, these reports include only a small 
number of patients and have all the methodical problems associated with 
retrospective case series previously discussed in this thesis. Secondly, the 
studies were not performed with modern image guidance and proton delivery 
technology has improved since most patients in the studies were treated. 
Furthermore, aspects associated with subtler toxicity, such as cognitive effects, 
were not evaluated and far longer follow-up is required to evaluate second 
tumour risk.  
4.6 Conclusion 
Despite the theoretical dose distribution advantages of proton therapy over 
photons associated with the Bragg Peak, in this meningioma planning study the 
photon plans were generally favourable to the proton plans. This can likely be 
attributed to several factors. Firstly, the modern photon intensity modulated arc 
technique used as the photon comparator produced excellent plan dosimetry 
with little room for improvement. Indeed, the SFUD proton technique compared 
was arguably more rudimentary and IMPT may have provided better proton 
plans. The prescribed dose of 50.4Gy was also within tolerance of most 
structures. Most fundamentally, the uncertainties associated with protons 
necessitated optimising to a larger proton target volume and this largely 
negated the potential advantages of protons. As a greater understanding of 
protons is developed, it may be possible to better exploit the Bragg Peak. 
However, the practical purpose of this study was to evaluate whether 
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meningiomas would be an appropriate indication for SFUD proton therapy in my 
institution. On the basis of these results, I would not favour the routine use of 
protons over optimal IMRT photons for meningiomas. Additionally, the 
published retrospective case series of clinical outcomes do not indicate a 
significant advantage for protons over photon therapy, although both delivery 
techniques have improved since these analyses and neurocognition was not 
assessed. Nevertheless, I did find that the normal brain received slightly lower 
doses with protons, particularly below V30%. This may be more significant if 
dose escalation proves to be beneficial for higher grade meningiomas. If further 
clinical evaluation of protons for meningioma therapy is carried out this should 
be within carefully planned and executed prospective studies. 
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5 Chapter 5: Preliminary evaluation of 
177
Lutetium DOTATATE as a treatment for 
advanced progressive meningioma 
_______________________________________________________________ 
5.1 Introduction 
 
5.1.1 Background 
The previous chapters have explored techniques of optimising EBRT to 
maximise local control rates and limit toxicity in the treatment of meningioma. 
As demonstrated in Chapter 2, local control rates following IMRT for grade 1 
meningiomas are excellent and modern case series with longer follow-up 
consistently report 10 year local control rates of >90% (table 1.5). However, as 
benign meningiomas are relatively common, disease progression is 
nevertheless encountered in clinical practice. Furthermore, although outcome 
data for higher grade disease treated with radiotherapy is more limited, local 
control rates are undoubtedly poorer: in the order of 50-70% at 10 years for 
grade 2 disease [167, 186] and as low as 13% at 5 years for grade 3 disease 
[193].  
Treatment options for meningiomas that progress following radiotherapy are 
limited. Surgical excision is preferred, but often tumour location limits the extent 
of excision possible. Even with optimal surgery, meningiomas that have 
recurred have a propensity to do so again and some tumours relentlessly 
progress despite multiple operations. As discussed in Chapter 1 studies of 
systemic chemotherapy agents and targeted therapies have been limited to 
case series or small phase 2 designs, but these have proven disappointing and 
none have so far warranted larger study.   
Radiation remains the only non-surgical treatment with proven efficacy in 
meningioma and limited reports of re-irradiation in the setting of progressive 
disease (radiosurgery or EBRT) have been published. Wojcieszynski et al, 
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reported outcomes for the largest series of 19 patients with meningioma 
following re-irradiation [252]. The median time from original radiation was 40 
months and the Kaplan-Meier estimate for PFS at one year following re-
irradiation was 66% (considerably worse for G2/3 than G1 disease). No 
significant toxicities were reported, but dose was prescribed to cover the GTV 
alone to minimise toxicity (no CTV or PTV margin), which may limit the 
effectiveness of re-irradiation in more infiltrative higher grade tumours. 
Targeted radioisotopes have the potential to circumvent many of the problems 
of re-irradiation as radiation dose outside of the tumour should be minimal. 
Somatostatin receptors (sstr) on meningiomas are a key potential target due to 
their abundant expression, although their functional role remains unclear [111, 
115]. Despite the fact that somatostatin analogues have been reported to 
stimulate proliferation of meningioma cells in vitro, the use of long-acting 
somatostatin analogues in patients with progressive meningiomas has been 
associated with progression free survival rates of 44% at 6 months with median 
time to tumour progression of 5 months (n=16) [333] or a median time to 
progression of 17 weeks (n= 11)[331].  
In chapter 3, I showed how sstrs can be manipulated with 68Ga DOTATATE 
PET imaging to aid radiological diagnosis or potentially assist in radiotherapy 
planning.  Somatostatin analogues such as DOTATATE (or other DOTA 
compounds), can also be bound to the radionuclides 90Yttrium (90Y) or 
177Lutetium (177Lu) rather than 68Ga for therapeutic purposes. 177Lu is an ideal 
isotope for peptide receptor radionuclide therapy (PRRT) due to its relatively 
long half life (6.65 days) and therapeutic beta emissions (Emax 0.5 MeV). Unlike 
90Y, it also decays with a low abundance of gamma emissions that can be 
directly measured (113keV; 11% abundance and 208 keV; 13% abundance), 
offering the potential for quantitative evaluation of uptake.  
 
177Lu DOTATATE therapy is well established at my institution (UCLH) for the 
treatment of adult neuroendocrine tumours (NETS) and a phase 2 study to 
assess its therapeutic role in children with relapsed or refractory high-risk 
neuroblastoma is currently underway. This was undertaken after outcome 
analysis of six children with poor prognosis neuroblastoma treated on 
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compassionate grounds indicated that 177Lu DOTATATE appeared to be safe, 
tolerable and potentially beneficial [400]. Evaluation of the therapeutic potential 
of 177Lu DOTATATE in patients with progressive meningioma in a similar 
manner was pursued as the widespread expression of sstr on meningiomas 
provided a rationale for potential benefit in this patient group who have no other 
proven treatment options. Furthermore, a small body of published work has 
described activity of sstr-targeted PRRT against meningiomas [335, 337, 336, 
338]. The largest study by Bartolomei et al, reported outcomes following 90Y 
DOTA therapy (2-4 cycles totalling 5-15GBq) in 29 patients with meningiomas 
that had progressed following standard therapy [335]. 66% had stable disease 
(SD) on MRI 3 months after treatment completion and 34% progressive disease 
(PD). Van Essen et al, included 5 meningiomas in a 177Lu octreotate case series 
[337]. Patients received 2-4 cycles at an interval of 6-10 weeks. At the end of 
treatment 2 patients had SD (one of whom had SD prior to treatment). Sabet et 
al, also reported a case of progressive metastatic anaplastic meningioma with 
severe associated symptoms where SD was achieved with significant 
symptomatic improvement following 177Lu DOTATATE [336]. 
 
Six patients with advanced progressive meningioma were treated with 177Lu 
DOTATATE on compassionate grounds at my institution between September 
2010 and January 2012. I undertook evaluation of outcomes in these patients to 
establish if a formal study was warranted and reviewed various methods of 
categorising disease status in meningiomas to assess the most appropriate 
measures to evaluate if a larger study was undertaken. 
 
5.1.2 Evaluating disease status in meningioma 
 
Evaluating disease status is particularly challenging in meningiomas because 
the aim of treatments is usually SD on imaging and control of symptoms. They 
do not tend to significantly regress following radiation and symptoms can 
improve/ deteriorate without significant imaging changes. Even the 
categorisation of stable or progressive disease is more challenging in brain 
tumours, particularly meningiomas, than most solid tumours. Various methods 
of imaging analysis exist. Linear criteria are the best established and remain the 
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most common method of categorising results in the majority of brain tumour 
studies. They apply to diameters measured on a single axial section where the 
tumour is largest and are detailed in table 5.1. Cystic or necrotic tumour and 
leptomeningeal lesions are “nonmeasurable” according to RECIST criteria – 
clearly an issue for meningiomas that arise from the dura. This is not specified 
in the WHO/ MacDonald Criteria.  Modified RECIST criteria form the basis of 
radiological evaluation in the current RTOG 0539 meningioma dose escalation 
study and were used in the IMRT study in Chapter 2. These allow changes in 
any diameter to be measured rather than specifically the largest diameter. This 
is likely to be a more appropriate measure in meningiomas as they often grow 
irregularly. Several other relevant categories are included in these modified 
RECIST criteria. 
 
 
Table 5-1 Linear Criteria Used to Assess Disease Status on Imaging 
Disease 
Status 
                                               Criteria 
RECIST (1D)                 Modified RECIST (2D)    WHO/ MacDonald (2D)    
Max Diameter*                   Any Diameter             Product of Max Diameter         
                                                                                  on slice with largest   
                                                                                       tumour area*                                                                   
PD ≥20% ↑ ≥20% ↑ or new nodule ≥25% ↑ 
NP N/A New/ progressive neuro 
symptoms due to 
meningioma but no 
measurable growth 
N/A 
SD All other No growth or growth 
<20% 
All other 
MR N/A ↓size but <20% N/A 
PR ≥30%↓ ≥20% ↓ ≥50% ↓ 
CR Resolution of all 
visible tumour 
Resolution of all visible 
tumour 
Resolution of all visible 
tumour 
CNED N/A No  N/A 
*or sum of maximum diameters if ≥2 lesions 
PD: progressive disease; NP: neurologic progression; SD: stable disease; MR: minor response; 
PR: partial response; CR: complete response; CNED: continued no evidence of disease 
 
Evaluation of changes in tumour volume is now more feasible due to advances 
in radiology software. In malignant gliomas, only the volumetric measurement of 
tumour size was found to be predictive of survival and linear dimensions were 
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not comparable with direct volumetric measurement [401]. Likewise, in 
schwannomas linear measurements were found to underestimate tumour 
growth rate compared to volumetric measurements [402]. However, there are 
no accepted tumour response criteria for volumetric analysis in brain tumours. 
Furthermore, as demonstrated in Chapter 3, defining meningioma tumour 
volume is difficult with significant interobserver variability due to bony 
hyperostosis and dural tails that may represent disease or simply a benign 
reaction to adjacent tumour and post-operative changes.  
 
Analysis of changes in tumour growth rate has been proposed as a sensitive 
indicator of therapeutic potential in early phase studies. Pre-treatment growth 
rates are compared to those during the treatment period. It has been postulated 
that this could substantially improve the assessment of treatment efficacy in 
drug development as linear response is dependent on the natural history of 
tumours [403].  
 
Finally, a novel potential component of a larger study of 177Lu DOTATATE 
would be evaluation of the absorbed dose of the radioisotope into the 
meningioma. This information could be used to formulate individualised 
treatment protocols based upon a desired absorbed dose. I therefore also 
evaluated the feasibility of performing meningioma dosimetry in a larger study. 
 
5.2 Aims 
1. To evaluate outcomes in the first cohort of patients treated on 
compassionate grounds with 177Lu DOTATATE for advanced progressive 
meningioma at my institution in terms of toxicity and response (symptom 
and imaging). 
2. To evaluate the potential to calculate absorbed dose of 177Lu DOTATATE 
for an individual patient.  
3. To establish whether a formal phase 2 study is warranted based on 
experience from this first cohort and what response parameters would be 
most appropriate should further investigation be pursued. 
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5.3 Materials and Methods 
 
5.3.1 Patients 
Six patients with recurrent progressive meningioma were assessed for 177Lu-
DOTATATE therapy between September 2010 and January 2012. Four patients 
came from the local neuro-oncology practice and two were referred from 
elsewhere due to a lack of other treatment options. Patients underwent 68Ga 
DOTATATE PET/CT to establish tumour sstr status. Compassionate treatment 
with 177Lu-DOTATATE in patients with sstr-positive disease and no other proven 
treatment options had been approved by the local ethics committee. The cases 
of all patients were discussed at the neuro-oncology and nuclear medicine 
multi-disciplinary meetings at my institution. All patients had previously 
undergone surgery and/ or radiation therapy. Patients had no other proven 
therapeutic options and the risks of further surgery or re-irradiation were 
deemed too high to pursue at the point of evaluation. Each patient gave written 
informed consent for treatment. For radiation protection purposes, patients were 
excluded from receiving PRRT if they were unable to self-care and they were 
required to have adequate haematologic, renal and hepatic function.  
 
5.3.2 Imaging 
Patients were required to have progressive disease (PD) at baseline on a post-
contrast T1 weighted MRI scan and sstr positivity on 68Ga-DOTATATE PET/CT. 
Nuclear imaging was carried out according to the local protocol. Patients were 
imaged on a Discovery STE PET/CT system (GE Healthcare) 45- 60 minutes 
post intravenous injection of 68Ga DOTATATE (139MBq +/- 35MBq). A low-
dose scout projection (120kVp; 10 mA; pitch 1.75) was used to localise the 
region required for imaging. PET acquisitions incorporated 2 bed positions to 
cover the head and neck regions. PET was performed in 3-dimensional mode 
with 5 min per bed position. Whole-body acquisitions were not routinely 
performed. Iterative reconstruction with 21 subsets was performed with 
attenuation correction derived from the CT. Patients were considered eligible for 
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PRRT if their meningioma showed avid uptake of 68Ga, although no specific 
SUVmax criteria  was set.  
5.3.3 Therapy 
Patients were admitted into a dedicated in-patient radioisotope treatment room. 
177
Lu DOTATATE was obtained commercially (IDB, Holland) and re-constituted 
in the in-house radio-pharmacy.  The planned treatment was four cycles of 7400 
MBq of 177Lu DOTATATE, with 8 to 10 weeks between cycles. An intravenous 
infusion of amino acids (2.5% L-Lysine HCl and 2.5% L-arginine in water for 
injection, 1L over 4 hours) was commenced 30 minutes before 177Lu 
DOTATATE to saturate renal tubular uptake and reduce radiation to the 
kidneys. Ondansetron and a short course of oral dexamethasone were 
prescribed to counteract nausea and prevent acute oedema. 177Lu DOTATATE 
was administered intravenously via a second pump over 30 minutes (400 – 
600ml/hour). Suitability for discharge was based on external dose-rate 
measured at 1m from the patient, with the appropriate restrictions advised 
regarding radiation protection.  
Prior to each cycle, patients were assessed to evaluate symptoms, ECOG 
performance status (PS) and treatment toxicity according to the Common 
Toxicity Criteria of the National Cancer Institute (CTCAE) version 3.0. Full blood 
count (FBC) was monitored weekly for 6 weeks after each administration and 
biochemistry was assessed prior to each cycle. 
 
5.3.4 Imaging Assessment 
All patients underwent post-therapy imaging on Day 2 of each cycle to assess 
uptake of 177Lu DOTATATE. This comprised whole-body imaging followed by a 
single SPECT/CT (on GE discovery 670), bed position (40cm) covering the 
head and neck. All acquisitions were performed using a medium energy general 
purpose collimator. SPECT data was acquired using 2 emission windows (113 
keV and 208 keV) and 3 scatter windows located around the emission 
photopeaks. Projection time was 30 seconds with 120 views. CT was performed 
with 140 kV and modulated mA. Slice thickness was 1.25mm.  
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Patients did not undergo imaging between cycles provided that they were 
clinically stable. Follow-up 68Ga DOTATATE PET/CT and MRI scans were 
performed approximately 3 months following administration of cycle 4. 
The standard imaging reports issued during treatment consisted of assessment 
of metabolic activity on 68Ga DOTATATE PET/CT (pre treatment and after 4 
cycles) by SUVmax and a general evaluation of the tumour mass on MRI by a 
consultant in nuclear medicine/ neuro-radiology as appropriate. More detailed 
evaluation was carried out retrospectively by a single neuro-radiology 
consultant to explore methods of evaluating meningioma response on MRI 
according to the linear criteria specified in table 1 and tumour volume. T1-
weighted MRI post with gadolinium. Tumour volumes were delineated as a 
region of interest using OsiriX Medical Image Software (www.osirix-
viewer.com). Only the soft tissue disease was measured as response in bone is 
difficult to assess.   
Two pre-treatment MRI scans were available for all patients to establish pre-
treatment growth rates and two methods of expressing growth rate were 
explored: a standard percentage tumour volume increase per month and a 
logarithmic transformation to account for exponential growth kinetics [403]:   
GR= log10 (Vt/V0)/dt 
Where Vt and V0 are the tumour volume at time t and time 0, and dt is the time 
in months elapsed between time 0 and time t.  
Statistical evaluation was not carried out due to the small patient numbers. 
 
5.3.5 Dosimetry  
Only Patient 4 had undergone the necessary imaging to allow evaluation of 
tumour dosimetry (cycle 2 only). This consisted of several post-therapy scans to 
evaluate dose to tumour over time rather than just a single scan to assess 
whether there was tumour uptake. With the assistance of a nuclear physicist, I  
evaluated this according to the standard Medical Internal Radiation Dose 
(MIRD) schema [404]: 
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TD is mean absorbed dose (Gy). hA
~
is total cumulated activity (both uptake and 
retention Bq per sec). S is the mean absorbed dose per unit cumulated activity 
(Gy/Bq per second). hA
~
 was established by measuring the total counts in the 
meningioma on SPECT/CT at several time points post-treatment (2.2, 4.8, 21.4 
and 92.6 hrs) and converting these to activity using the SPECT sensitivity factor 
(counts per second/ MBq) specific for our scanner (determined by 177Lu-
DOTATATE phantom imaging). A time-activity curve was plotted and a 
MATLAB program used to fit a biexponential to the curve to derive cumulated 
activity ( hA
~
).S includes consideration of the types and energies of the radiations 
emitted, geometrical aspects such as the size and shape of the source and 
target regions and the distance between them. OLINDA/EXM software was 
used to derive the relevant S factors for the mass of the meningioma region of 
uptake [405].  
 
5.4 Results 
 
5.4.1 Patient features and clinical course 
All six patients had sufficient 68Ga DOTATATE uptake to warrant PRRT. Table 
5.2 details patient demographics and previous treatment history. All had grade 2 
or 3 meningiomas. Due to issues pertaining to production and labelling, the 
mean administered activity of 177Lu DOTATATE was 7.32MBq (range 6490 – 
7800 MBq). The mean interval between treatments was ten weeks (range 8-14 
weeks). The length of in-patient stay required for radiation protection purposes 
was one night, although for logistical reasons patients stayed two nights. Four 
patients completed the full course of four cycles. Two patients continued to 
deteriorate neurologically in relation to their tumour prior to cycle 2 causing 
significant radiation protection issues and did not undergo further cycles. 
 ST
h
hT rrSAD 
~
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During therapy two patients demonstrated objective symptomatic benefit. One 
had significant reduction in seizure frequency (without change in medication) 
and the other had an increase in power of previously weak limb, which 
improved their mobility. 
There were no significant acute toxicities. Two patients reported grade 1 fatigue 
and one patient had grade 1 thrombocytopenia (platelet nadir 103 x109/L 6 
weeks post 4th administration). However, Patient 3 developed acute myeloid 
leukaemia (AML) 15 months post-therapy. The treating haematology team felt 
that the complex karyotype that was found in the bone marrow biopsy was 
typical of a therapy-related AML and PRRT was implicated as he had not 
previously had chemotherapy, although the latency period was very short.  
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Table 5-2 Patient Demographics 
 
 
Patient 
 
Age 
(yr) 
Sex 
PS 
(ECOG) 
Main Site/ 
Symptoms 
Type 
Grade 
Time since 
initial tx 
(months) 
Previous 
surgeries 
Previous RT Other tx and notes 
1 
 
67 
M 
1 Sphenoid 
Proptosis 
Chordoid 
2 
34 1 EBRT: 50.4Gy 28# (IMRT) 29 
months prior 
 
2 53 
M 
1 Parieto-occipital 
Seizures 
Atypical 
2 
240 5 EBRT: 55Gy in 30# (2D) 192 
months prior 
ɣ-knife RS: 14Gy to 45% isodose 
36 months prior 
 
3 60 
M 
1 Sphenoid 
Blind L eye 
Meningothelial 
2 
95 2 EBRT: nil 
ɣ-knife RS: 16Gy to 50% isodose 
58 months prior 
 
4 67 
M 
1 Parafalcine 
Weak leg 
Chordoid 
2 
53 2 EBRT: 50.4Gy 28# (IMRT) 29 
months prior 
Had PRRT immediately 
post debulking surgery 
rather than at further PD 
5 67 
F 
3  Cav sinus 
CN III, IV, V, V1  
unsteadiness 
Atypical 
2 
32 0 EBRT: 50Gy in 25#  
6 45 
M 
3  Temporal 
Blind and deaf (R) 
Anaplastic 
3 
54 2 EBRT: 45Gy in 25# (3D) 30 months 
prior 
ɣ-knife: 16Gy to 50% isodose 9 
months prior 
 
Tamoxifen since 4 
months prior 
Had TBI as a child 
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5.4.2 Imaging Uptake  
Regions of 177Lu-DOTATATE therapy uptake on SPECT scan mirrored regions 
of tracer avidity on pre-therapy 68Ga-DOTATATE scans (figure 5.1).  
                68Ga-DOTATATE               177Lu-DOTATATE        
 
Figure 5-1 Regions of 177Lu-DOTATATE therapy uptake on SPECT scan mirrored 
regions of tracer avidity on pre-therapy 68Ga-DOTATATE scans 
Pt  
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
4 
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5.4.3 Response 
Tables 5.3 and 5.4 detail the disease status and growth rates pre and post 
treatment for each patient. There was at least 12 months between the pre-
treatment and post-treatment imaging due to cycle length and time to post-
treatment MRI, hence disease status “post-treatment” reflects a long time 
period. It was not possible to calculate time to progression as patients had 
significant intervals between imaging. Patients 1-4 completed all 4 cycles. On 
MRI performed 3 months post-therapy, three of these four patients had SD by 
RECIST criteria, two by WHO criteria and one by modified RECIST criteria. By 
volumetric analysis, all had an increase in tumour volume across the treatment 
period, but the extent of this increase varied widely between 2-460%. The only 
patient with SD by modified RECIST criteria had minimal volume increase over 
the treatment period (2%). Tumour growth rate was markedly slower in the post-
treatment period in three patients. Percentage increase in tumour volume was 
7-255% per month pre-treatment versus 0.1–24% per month through treatment. 
Assuming exponential growth, this equates to a growth rate of 0.022-0.388 
versus 0.0006-0.044. Figure 5.2 depicts changes in growth rate. Patient 2 had 
also developed several new intracranial meningioma deposits in the four 
months prior to the baseline scan and no further new deposits occurred in the 
12 months between the baseline and post-treatment scans.  
Patient 5, who terminated treatment after one cycle, actually had a reduction in 
tumour growth rate on MRI performed post cycle 1 compared to pre-treatment 
imaging (14% per month pre-treatment versus 2.5% per month during 
treatment), although the patient had continued to deteriorate clinically and was 
unfit for cycle 2. Both patients who did not complete therapy had a poorer 
baseline performance status compared to those who completed 4 cycles (PS 3 
versus PS 1). 
As detailed in table 5.6, there was no clear association between SUVmax and 
changes in growth rate:  patient 3 had the most striking reduction in both growth 
rate and SUVmax (figure 5.2), but in other patients SUVmax response was 
variable.
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Table 5-3 Disease Status Post PRRT According to Linear Criteria 
Pt Linear assessment Post-PRRT 
RECIST                          Modified RECIST                         WHO 
1 PD PD PD 
2 SD PD SD 
3 SD SD SD 
4 SD PD PD 
SD: stable disease; PD: progressive disease 
 
 
Table 5-4 Disease Status Post PRRT: Volumetric and Growth Rate Analysis 
Pt Vol pre-
PRRT 1 
(ccm) 
Vol pre- 
PRRT 2 
(ccm) 
Vol post-
PRRT (ccm) 
Vol ↑ between pre and 
post-tx MRI (%) 
Time between 
scans  
Pre 1 and 2; 
Pre 2 and 
Post  
(months) 
Growth pre- 
PRRT 
(%↑  per 
month)* 
Growth 
Over PRRT 
(%↑per 
month)* 
Growth Rate 
pre-PRRT** 
Growth Rate 
over PRRT** 
1 1.1 4.2 19.3 460 1.5; 15 255 24 0.388 0.044 
2 17.6 28.8 49.7 70 4; 12 16 6 0.054 0.02 
3 5.1 17.9 18.3 2 12; 16 21 0.1 0.045 0.0006 
4 10.9 20.7 
(but had 
surgery after  
so 8.2 pre-
PRRT) 
 
16.4 
 
 
100 13; 12 7 8.3 0.022 0.025 
5† 14.7 26.8 30.9  N/A 6; 6 14 2.5 0.044 0.01 
6† 96.5 183.7 N/A N/A 1.5; NA 60 N/A 0.186 N/A 
†Performance status deteriorated so patients received only 1 cycle 
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Figure 5-2 Growth rates pre and post PRRT
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Table 5-5 SUVmax values pre and post PRRT 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 Patient 3 was the only patient with a considerable reduction in SUVmax 
after 4 cycles of treatment.    
 
 
  
Patient Pre-PRRT 
SUVmax 
Post-PRRT 
SUVmax 
1 16.6 16.2 
2 9.5 14.6 
3 12.3 5.8 
4 8.6 7.0 
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5.4.4 Outcomes Post PRRT 
Disease progression continued in all patients following completion of PRRT. 
Patient 1 died 18 months after completion of therapy following continued 
gradual disease progression. Further surgery was not pursued as only limited 
debulking would have been possible and was associated with significant risks.  
Patient 2 underwent further debulking surgery 10 months after cycle 4 due to 
PD causing impaired mobility. 18 months following completion of 177Lu (8 
months post-surgery) gradual disease progression had continued but further 
surgery is being reserved until symptoms progress.  
Patient 3 had the best reduction in growth rate and SUVmax during treatment, 
but underwent re-irradiation with EBRT for disease progression 15 months 
following completion to try and prevent loss of vision (accepting the risk of 
reirradiation). As discussed, he was diagnosed with AML shortly afterwards and 
received palliative treatment. 
Disease progression in patient 4 has continued at the same rate in the 12 
months follow-up post PRRT, although only in one specific region of the tumour 
(frontal). Surgery is being reserved for when symptoms develop.   
Rapid disease progression continued in the two patients who terminated 
treatment after one cycle and both died within five months of commencing 
PRRT. 
 
5.4.5 Dosimetry 
The estimated mean absorbed dose of radiation within the meningioma in the 
single cycle evaluated in patient 4 was 33.9Gy. The cumulated activity graph is 
shown in figure 5.4.  
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Figure 5-4 Cumulated activity within the meningioma for patient 4 (1 cycle) 
 
5.5 Discussion 
The purpose of reviewing outcomes in the first patients with progressive 
meningioma treated with 177Lu DOTATATE PRRT at my institution was to 
establish if a larger formal study was warranted, to assess treatment regime 
tolerability and to explore methods of evaluating response and dosimetry in 
meningiomas. The patient cohort was necessarily small and results are 
therefore descriptive.  
The definition of stable or progressive disease in brain tumours, particularly 
meningiomas, is challenging. In this analysis, measuring response by three 
different linear criteria produced three different results. Of the four patients who 
completed therapy, the disease was classified “stable” at 1 year in three 
patients using RECIST criteria and two patients by WHO criteria. Neither 
measure adequately reflected the clinical picture as they did not take account of 
the fact that particular regions of meningioma were growing in most patients, 
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but were not the largest dimensions. Modified RECIST criteria did reflect this 
and seemed the most appropriate linear measure, as the only patient with SD 
according to these specifications also had very little change in volume (Patient 
3). 
 Volumetric measurements offer more information, but no cut-off values exist to 
define stable or progressive disease. Henson et al, extrapolated the RECIST 
and WHO linear criteria to equivalent volume criteria assuming a spherical 
lesion using the formula V= 4/3πr3 [406]. They reported that disease would be 
classed as progressive when the tumour volume increased by ≥73% or ≥40% 
for RECIST and WHO respectively. This large discrepancy indicates that further 
work would be required before volumetric criteria could become standard in 
studies. Volumetric analysis may also not reflect important changes in 
meningiomas where the exact region of disease progression can be more 
relevant than the extent of progression per se, as even minimal growth in 
eloquent areas can result in major symptoms. Conversely, for similar reasons 
objective symptomatic improvements can occur following radiation with very 
little change in imaging (as shown in chapter 2). Another issue previously 
discussed is that meningioma volumes can be difficult to define due to dural 
tails, post-operative changes and bony hyperostosis, although it is likely to be 
the extent of soft tissue disease that dictates prognosis. To try and standardise 
MRI evaluation in this report, only regions of bone positive on 68Ga DOTATATE 
PET were defined as disease and all measurements were performed by one 
consultant radiologist to avoid inter-observer variability.  
Evaluation of growth rate was explored in these patients. Meningioma growth 
rates slowed considerably in three of four patients who completed 4 cycles. 
However, tumour growth continued in all patients and debate is required 
regarding the extent of growth rate reduction that could be considered clinically 
relevant and would justify the cost of therapy. The two methods of expressing 
growth rate (% per month and logarithmic scale) appeared relatively equivalent 
when plotted, although meningiomas may not grow in the same exponential 
manner as most malignant tumours. 
Changes in tumour metabolic activity on PET imaging may have a role in 
assessing response to treatment, although there was no obvious correlation 
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between reduction in growth rate and SUVmax in these patients. A larger cohort 
would be required to formally evaluate this. Patient 3 had a notable reduction in 
SUVmax and growth rate during treatment, but developed progressive disease 
post-therapy at a similar rate to the other patients who completed four cycles. 
Indeed, whether meningiomas reduce sstr expression in response to radiation is 
not known as sstr do not necessarily reflect metabolic or mitotic activity and 
such receptors may not down-regulate following successful treatment. One 
group actually reported an increase in SUVmax values on 
68Ga DOTA PET in the 
majority of patients following one cycle of 177Lu DOTA for meningioma [338].  
The 177Lu DOTATATE protocol used in this cohort of patients was well tolerated 
acutely. It was the same regime as that used in neuroendocrine tumours where 
patients have usually been heavily pre-treated with other marrow-depleting 
therapies. As this is not the case for patients with meningioma, there could be 
scope to increase the dose or frequency/ number of cycles of treatment, but this 
would obviously incur greater cost and potential side effects.  
There were considerable limitations with this analysis, largely due to the fact 
that a pre-defined “pilot study” protocol was not used. Although a defined 
treatment protocol was used, a formal study protocol would have improved 
consistency of imaging and symptom analysis and strengthened outcome 
assessment. Timing between imaging differed considerably (particularly pre-
treatment imaging). This made it impossible to accurately define time to disease 
progression. As such growth rate results are an approximation as they would 
not necessarily have been consistent over the time period between imaging. 
Ideally, in a formal study, two pre-treatment MRIs at a specified interval would 
be required for growth rate evaluation and more frequent MRIs during therapy 
would allow time to progression/ progression free survival rates to be 
established at set time points. This would allow comparison to studies of 
systemic agents. 
Accepting these limitations, overall this outcome analysis in the six initial 
patients with advanced progressive meningioma treated with this PRRT 
suggested limited potential clinical benefit. Recently, the cost of 177Lu 
DOTATATE therapy has risen significantly due to patenting that restricts in-
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house re-constitution. As such, we have decided not to pursue a more formal 
study. 
Furthermore, although treatment was well tolerated in the acute setting, a 
causative relationship between PRRT and the development of AML 18 months 
following treatment in Patient 3 must be considered. It cannot be definitively 
concluded that this was secondary to PRRT, particularly in view of the short 
latency period, but the complex karyotype was indicative of a secondary 
leukaemia. The potential for ionising radiation to induce leukaemias is well 
established, most notably in survivors of the atomic bombs [407]. Although rare, 
an increase in secondary leukaemias has also been reported in patients 
receiving external beam radiotherapy for a wide range of conditions [408, 409] 
and cytotoxic chemotherapy [410]. Overall, therapy-related myeloid neoplasms 
are thought to account for 10-20% of all cases of AML and myelodysplastic 
syndrome [411]. Most reports of leukaemia following PRRT concern the use of 
131I for thyroid cancer and a recent meta-analysis reported a 2.5 fold increased 
relative risk for the development of leukaemia in patients treated with 
radioiodine for thyroid cancer [412]. Case reports exist regarding AML following 
the use of other radionuclides in cancer therapy [413, 414]. Most relevant to this 
case, are reports of acute leukaemia following treatment with 177Lu or 90Y DOTA 
in patients with neuroendocrine tumours, but causation cannot be assumed 
from case reports [415, 416]. Kossman et al, reported two incidences of AML 17 
and 26 months following 89Strontium for metastatic prostate cancer [413], 
although a causative relationship with the radionuclide was questioned in view 
of the fact that the patients had previously received other cancer therapies and 
the relatively short latency period [417].  
 
The potential to induce second malignancies carries more importance if PRRT 
were to be used earlier in the course of meningiomas, particularly as 
radiotherapy/ radiosurgery are generally very effective. Minutoli et al, recently 
reported their experience of using 111Pentetreotide in eight patients with 
meningioma [418]. The treatment schedules varied between patients and 
sometimes combined 90Y DOTA cycles. They reported PR in two patients, 
stable disease in five and progression in one after 2-4 cycles of therapy. 
However, four patients (50%) had stable disease prior to therapy and as the 
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majority had grade 1 disease, PD would not necessarily have been expected in 
that timescale in the absence of any treatment. Furthermore, only one patient 
had previously received radiotherapy (six had surgery) and this certainly 
remains the recommended treatment when effective surgery is not possible. 
Kriessl et al, also evaluated the use of PRRT earlier in the course of 
meningiomas [338]. They carried out a pilot study in 10 patients with 
meningioma (majority grade 1) to establish the feasibility and tolerability of a 
combination of standard EBRT (median 53Gy) with a 7.2Gy PRRT boost 
(177Lu). Treatment was well tolerated and there was a minor reduction in tumour 
size overall. However, whether the PRRT altered outcomes compared to EBRT 
alone cannot be evaluated and it remains unproven whether dose escalation in 
general is beneficial in meningioma, particularly for grade 1 disease.  
All patients in my cohort had G2 or 3 meningiomas with relatively rapid rates of 
progression. Patients 5 and 6, with poor performance status continued to rapidly 
progress and were not able to receive a second cycle of PRRT. Poor outcomes 
in less fit patients are typical in studies of systemic agents, and an ECOG PS of 
≤2 is usually required. Most previous reports of the use of PRRT in 
meningiomas suggested that those with less aggressive disease may gain more 
benefit from PRRT. In Bartolomei’s study of 29 patients treated with 90Y DOTA, 
unsurprisingly patients with G1 disease had a much longer time to progression 
than those with higher grade disease (61 v 13 months) [335]. Likewise, there 
was no response in high grade bulky meningiomas treated with 177Lu octreotate 
in the report by Van Essen et al [337]. However, Sabet et al, reported a 
dramatic improvement in a single patient with very poor PS following PRRT for 
meningioma [336]. In general, large tumour size is reported to limit the efficacy 
of PRRT[419]. It may be that the patients in my cohort had disease that was too 
advanced to achieve substantial benefit from 177Lu DOTATATE therapy or that 
their disease had already become largely resistant to radiation therapy.  
An understanding of absorbed radiation dose following PRRT would help 
evaluate the relative merits of PRRT in meningioma. The ability to perform 
individual dosimetry could theoretically permit personalised dosing of 
radioisotope to achieve a desired uptake. Preliminary evaluation of meningioma 
uptake of 177Lu was carried out in this study to assess whether this would be a 
feasible component of a larger study. The calculated absorbed dose of 33.9Gy 
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with one cycle was greater than expected, although not impossible as reported 
absorbed doses for neuroendocrine tumours vary between 0.9 to 42Gy/MBq 
following a single administration of 90Yttrium DOTATOC therapy [420, 421]. 
However, there are substantial inherent inaccuracies with dosimetric evaluation 
of PRRT uptake. Most significantly, there is a rapid uptake or ‘wash-in’ phase of 
177Lu into the tumour and a longer clearance or ‘wash-out’ phase (half-life 6.7 
days). Therefore the accuracy of the cumulative time activity curve is dependent 
on the number of time points used to create the curve.  Imaging was performed 
at four time points to create the curve used but there was a large gap between 
point 3 and 4. More imaging time points would have increased certainty 
regarding the shape of the curve.  A small degree of error may also have been 
introduced by the fact that the CT component of the SPECT/CT was used to 
calculate the tumour mass when MRI is the optimal imaging modality to define 
meningiomas, although the patient’s tumour was clearly visible on SPECT/CT. 
Accurate mass is required to determine the appropriate S factor. Furthermore, 
the pre-calculated standard S factors provided by OLINDA/EXM software 
assume that tumours are isolated unit-density spheres with a uniform activity 
distribution and do not take into account individual patient/ tumour morphology 
or cross dose between tumour and normal tissue. However, the effect of this for 
177Lu in the brain will be minimal as there is little uptake outside the pituitary. 
Finally, when data are acquired shortly after isotope administration the gamma 
camera may be unable to accurately process the high activity, although a dead-
time correction can be applied.   
 
The only other published work evaluating PRRT uptake in meningiomas comes 
from the previously mentioned pilot study of combined EBRT/ PRRT by Kriessl 
et al, and a subsequent paper by the same group correlating pre-treatment 68Ga 
DOTA SUVmax  and PRRT uptake in the same patients [338, 422]. Patients 
remained in hospital for 4-5 days after PRRT and underwent daily nuclear 
imaging. They reported absorbed doses of 0.2-30.6 Gy (median 7.2Gy) and a 
strong correlation between pre-treatment 68Ga DOTA SUVmax and 
177Lu DOTA 
retention in the voxels with the highest uptake. However, the limitations in 
accuracy of tumour dosimetry must be considered when interpreting results and 
further study would be required before conclusions could be drawn.                     
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Unfortunately, more accurate assessment of meningioma dosimetry in a larger 
study would be extremely costly and onerous for patients due to the number of 
scans required. In view of the apparent limited efficacy of PRRT in patients with 
advanced progressive disease, such evaluations may not be feasible.  
 
5.6 Conclusion 
There are no effective treatment options for patients with advanced, progressive 
meningiomas previously treated with radiotherapy. The abundant expression of 
sstr on meningiomas provided scientific rationale to explore the use of PRRT 
with 177Lu-DOTATATE in such patients. Assessment of treatment response is 
challenging in meningiomas and standard linear criteria do not appear to 
accurately reflect disease status. Modified RECIST criteria appeared the most 
useful and simple to assess of the linear criteria. Volumetric analysis is 
appealing, but reproducibility within large studies may be difficult and impair 
response evaluation.  
In the first six patients with meningiomas treated with 177Lu DOTATATE on 
compassionate grounds at my centre, growth rates did appear to slow. 
However, tumours continued to grow during treatment and only one patient had 
obviously stable disease over the treatment period. In view of the recent 
increase in cost of 177Lu-DOTATATE, we did not feel that it was feasible to 
pursue further study in this patient population.    
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6 Chapter 6: Conclusions 
 
6.1 Introduction 
 
The purpose of this thesis was to explore the feasibility and potential of 
advanced radiation planning and delivery techniques in the treatment of 
meningioma. Meningiomas are the most common non-glial brain tumour and 
radiotherapy is a well established treatment, with case series indicating ten year 
local control rates following radiotherapy of approximately 90% for benign 
disease (Table 1.5). In view of these excellent control rates, minimising 
treatment toxicity is of significant importance. Advanced radiation planning/ 
delivery techniques such as IMRT (including VMAT) and protons have the 
potential to reduce toxicity as they theoretically better spare normal tissue 
compared to 3DCRT. These techniques may also permit dose escalation for 
non-benign meningiomas where long-term reported tumour control rates post-
radiation are generally ≤50% (Table 1.5). Although the theoretical potential of 
such techniques to improve outcomes is clear, they are expensive to 
implement, require extreme precision of delivery and robust quality assurance 
protocols. Furthermore, questions remain regarding the low-dose radiation bath 
associated with IMRT. As highlighted in Chapter 1, the majority of reports 
detailing outcomes following radiotherapy for meningioma are retrospective 
case series which limit the estimation of local control, symptom improvement 
and toxicity rates. Careful clinical evaluation within prospective studies is 
required.  
Newer radiation techniques carry a greater potential for error than 3DCRT due 
to the conformity of the high dose region around the target. Translating their 
theoretical advantages into true clinical benefit will be highly dependent on 
accurate target delineation. Paradoxically, the use of advanced radiation 
techniques could be detrimental to outcomes if the target is poorly contoured. 
The definition of the appropriate target volume in meningiomas has not been 
established. Even the delineation of GTV is contentious as differentiating post-
operative changes from viable meningioma can be challenging and the 
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appropriate extent of bone, dural tail and venous sinuses to include can be 
unclear on CT/MRI. Therefore, research into techniques that could clarify GTV 
is attractive. In Table 3.1 I detailed several reports that described alterations in 
the meningioma target volume defined in relation to the addition of 68Ga 
DOTATATE PET/CT imaging to CT/MRI. This is appealing as 68Ga DOTATATE 
is relatively specific to meningioma within the skull (outwith the pituitary). 
However, although there are reports of clinicians altering target volumes in 
relation to PET information, whether this improves the accuracy of contouring 
and whether PET/MRI offers any benefits over and above PET/CT has not 
previously been evaluated.  
Whilst more accurate target definition will maximise the benefits of all newer 
radiation planning and delivery techniques, the unique characteristics of the 
proton Bragg Peak has led many to consider whether protons could provide 
additional benefit in treating meningiomas over even the most conformal of 
photon techniques. As described in Chapter 4, several older planning studies 
indicated that protons improve normal tissue sparing in the treatment of 
meningiomas and many proton centres in other countries routinely treat 
meningiomas. This is of particular relevance as the first UK proton centres are 
being commissioned and appropriate treatment indications need to be defined. 
However, the recent advances in photon technology confer a need to evaluate 
whether the proton techniques to be used initially in the UK are likely to improve 
radiation treatment planning parameters against the current gold standard 
photon therapies for meningiomas.  
Unfortunately, despite impressive local control rates following radiotherapy, 
meningioma progression is encountered in clinical practice due to their relatively 
high prevalence. Currently, there are no established treatment options for 
patients with meningiomas that have progressed following radiotherapy. They 
appear unresponsive to cytotoxic chemotherapy. As for other tumour types, 
advances in treatments for meningiomas that recur following surgery and 
radiotherapy are likely to lie with receptor-targeted agents. The same 
somatostatin receptors exploited diagnostically with 68Gallium DOTATATE PET 
offer an appealing target for peptide receptor radionuclide therapy (PRRT) with 
177Lutetium DOTATATE. Such therapy had been introduced at my institution on 
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a compassionate basis and evaluation of patients treated was required to 
establish whether a larger study was warranted. 
IMRT/ VMAT, PET-based planning, proton therapy and PRRT all carry the 
potential to improve outcomes for patients with meningioma. However, the cost 
implications associated with their use must be justified and it is essential to 
identify where they may offer most significant clinical benefit. Large scale 
studies themselves require considerable resources and should be supported by 
feasibility study evidence.  
Therefore, the specific aims of this thesis were: 
1. To evaluate IMRT as a treatment for meningiomas within a prospective 
observational study in terms of toxicity, clinical and imaging response, 
quality of life and local control rates.  
2. To assess the feasibility of integrating simultaneous 68Gallium 
DOTATATE PET/MRI into meningioma radiotherapy target volume 
definition and to establish whether this impacted upon interobserver 
variability in contouring in relation to CT/MRI alone and PET/CT plus 
MRI. 
3. To compare dosimetric parameters from optimal VMAT photon 
radiotherapy plans to SFUD proton plans for the treatment of 
meningioma and identify practical issues with SFUD proton planning. 
4. To evaluate whether a formal phase II study of 177Lutetium DOTATATE 
therapy for advanced progressive meningioma is warranted based upon 
outcomes in the first cohort of patients. 
 
6.2 Important findings 
 
In Chapter 2 I demonstrated that IMRT is feasible for meningiomas and 
provided excellent target coverage/ OAR avoidance. This resulted in medium 
term tumour control rates of >90% in benign disease and provided more robust 
toxicity data than previous studies. Objective measures of toxicity were low. 
Improvements in visual symptoms were documented in a significant proportion 
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of patients and usually occurred without significant change in tumour 
dimensions on MRI. Analysis of non-visual symptoms and quality of life were 
more subjective and subject to confounding, but a substantial number of 
patients did report improvements. Longer follow-up and a larger patient cohort 
are required to strengthen these findings. As such, I would advocate IMRT/ 
VMAT as the radiation method of choice to treat meningiomas.  
However, in Chapter 3 I identified very high rates of interobserver variability in 
meningioma target volume definition. This requires further evaluation if more 
highly conformal radiotherapy techniques are to be widely adopted. Significant 
levels of IOV indicate over/ undertreatment of the true target depending upon 
the contouring physician. I found that analysing the Kouwenhoven Conformity 
Level highlighted the extent of IOV far more than the absolute volumes and 
would suggest that analysis of conformity with a method such as the KCL be 
analysed in all future studies of IOV. It would be useful if this were standardised 
to allow interstudy comparisons. Although the incorporation of simultaneous 
PET/MRI into treatment planning was feasible, it resulted in only a very small 
reduction in IOV compared to the standard CT/MRI and there was no clinical 
advantage to PET/MRI over PET/CT when all three modalities were co-
registered. There was one case (of ten) where the PET information clearly 
assisted two of the observers in identifying meningioma that had unexpectedly 
extended into the soft tissue below the base of skull. However, on reflection, 
this could be identified on MRI with careful evaluation. Therefore, although there 
may be specific situations where PET could add valuable information, I would 
not advocate the routine use of PET (from MRI or CT) in meningioma 
contouring without more evidence to indicate a significant benefit.  
Thus, the theoretical potential of 68Ga DOTATATE PET to improve meningioma 
contouring did not appear to translate into a substantial benefit in real clinical 
cases. In a similar manner, despite the favourable dose deposition 
characteristics of the proton Bragg Peak, I did not find a notable advantage for 
SFUD protons compared to an advanced photon IMRT technique (Truebeam 
VMAT) in the planning study in Chapter 4. This was largely due to the high 
quality of the photon plans that left little room for improvement and the 
significant uncertainties associated with protons that necessitated optimisation 
to a larger proton target volume. I did identify a slightly lower V10-30% for 
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normal brain with protons which could become more significant if advances in 
knowledge of proton dose deposition characteristics reduce the need for the 
addition of extra margins to guarantee target coverage. Overall, my findings in 
Chapter 4 do not support the clinical introduction of SFUD protons for 
meningioma treatment currently.  
In my analysis of 177Lu DOTATATE therapy for advanced meningiomas 
presented in Chapter 5, I again found that the theoretical promise of advanced 
radiation techniques did not necessarily translate into substantial clinical benefit. 
Although meningioma growth rates appeared to slow during 177Lu DOTATATE 
therapy, the tumours did generally progress during treatment. The cost of 
embarking upon a larger study would be substantial and the magnitude of 
benefit and relevant patient population relatively small. Therefore, although 
177Lu DOTATATE appeared to confer some anti-meningioma activity, further 
study was not feasible. This chapter also highlighted the challenges associated 
with defining imaging criteria that reflects the response of meningiomas to 
treatments. It was clear in Chapter 2 that many patients experienced objective 
symptomatic improvement following IMRT despite no obvious change on MRI 
and the converse is no doubt true. The “modified RECIST criteria” appeared the 
most useful and practical of the linear criteria as it includes a “neurological 
progression” category to reflect this. Growth rate/ volumetric analysis seemed 
more sensitive to identify meningioma growth and may be useful for future 
studies evaluating treatments particularly in advanced meningioma, but 
clinically relevant changes in growth rate would have to be debated and would 
vary depending upon tumour location. Furthermore, the IOV in contouring 
meningiomas noted in Chapter 3 would also be likely to affect volume analysis 
by reporting radiologists.  
 
6.3 Implications of thesis 
 
Chapter 2 provided preliminary clinical evidence to support the more 
widespread use of IMRT rather than 3D CRT in the treatment of meningiomas. 
In addition, it demonstrated that introducing an advanced radiation technique to 
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clinical practice within an observational/ phase 2 study can be an effective tool 
to increase patient access to advanced treatments whilst ensuring quality 
assurance and allowing prospective data collection. I would argue that 
randomised studies are unnecessary and indeed unethical to evaluate 
advanced radiation techniques in situations where the dose distributions 
achievable are significantly superior to the standard technique, particularly for 
meningiomas where it would take many years to evaluate outcomes.  
Randomised trials of radiation techniques for meningiomas have previously 
failed due to poor accrual. These are particularly unlikely to succeed in benign 
meningioma as extended follow-up would be required to establish tumour 
control rates and clinical outcomes, which are themselves highly dependent on 
tumour location, baseline features and previous interventions. Even for non-
benign meningiomas, treatment decisions are highly influenced by individual 
tumour features such as the tumour location and clinician/ patient preferences 
hamper randomisation. Currently, a phase 3 multi-centre RCT (ROAM Study) is 
in set-up in the UK with the aim of evaluating the impact of adjuvant 
radiotherapy on recurrence rates following complete resection of atypical 
meningiomas. This is a relatively clean question and a randomised study could 
succeed, although the feasibility/ acceptability of the study to eligible patients 
and clinicians will be initially analysed to determine whether the full study can 
proceed. Whilst in specific circumstances RCTs may therefore remain 
appropriate to study radiotherapy for meningiomas, more novel trial design must 
be considered. The IMRT study in Chapter 2 will provide robust long-term 
outcome information that is far more reliable than retrospective case series in 
the largest patient population possible within a single centre. However, such an 
approach could potentially be extended to include multiple centres and the 
robust radiotherapy quality assurance required would in itself improve the 
quality of radiotherapy delivered. As was apparent throughout this thesis, the 
support of professionals outside of the radiotherapy department is essential to 
implement advances in technology and to accurately monitor clinical outcomes 
(such as ophthalmology) and a trial setting appeared to facilitate 
interdepartmental support.  
In Chapters 3-5 I found that the theoretical advantages of advances in radiation 
planning/ delivery techniques do not necessarily translate into likely clinical 
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benefit.  Clearly a balance must be struck between early implementation of new 
technologies for the benefit of current patients and a need to delay widespread 
clinical use whilst supporting evidence is obtained. Nevertheless I would 
advocate the need to obtain evidence in support of a technology from feasibility/ 
planning studies prior to embarking upon expensive large studies or 
incorporating the technique in routine clinical practice. Contouring protocols 
have been changed in some centres on the basis of reports that the integration 
of a new imaging modality alters target volume definition, but, as demonstrated 
in Chapter 3, this is not necessarily evidence that the new imaging improves 
contouring. Although evaluation of IOV is only a surrogate for improved target 
definition, it is more meaningful than change alone. Methods of evaluating IOV 
vary widely throughout the literature and it would be helpful if a standardised 
approach could be endorsed by bodies such as the EORTC/ RTOG to allow 
comparison between different studies in the future. In the UK, direction from the 
NCRI CTRad group can help standardise studies and provide appropriate 
software, such as that used to analyse IOV in Chapter 3. 
Although the number of patients who received PRRT for advanced 
meningiomas in Chapter 5 was very small and there were considerable issues 
with data analysis, the apparent minimal activity of the radioisotope therapy 
suggested radioresistance in meningiomas that progress following previous 
radiation treatment (EBRT, RS or both). Future research efforts for this patient 
group should concentrate upon systemic targeted non-radiation therapies. The 
recent publication of promising phase 2 data reporting outcomes following the 
use of sunitinib, a tyrosine kinase inhibitor targeting vascular endothelial growth 
factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR), 
to treat surgery and radiation refractory grade 2 and 3 meningioma offers an 
avenue for future randomised study [423]. Thirty-six patients were enrolled and 
six month PFS rates were 42% with a median PFS of 5.2 months and overall 
survival of 24.6 months. However, the rate of progression pre-treatment was not 
stated and radiological outcome measures were limited by the use of the 
MacDonald (2D) response criteria as previously discussed. Expression of 
VEGFR2 appeared predictive of PFS, although this could just be a marker of 
more favourable tumour biology. Considerable toxicity was also noted with 60% 
experiencing ≥grade 3 side-effects.  
225 
 
6.4 Future Research 
 
The ability of IMRT to sculpt radiation dose demonstrated in Chapters 2 and 4 
raise the question of whether other regions of the brain, particularly those 
known to be associated with higher mental function, should become organs at 
risk. The hippocampus has an important role in short term memory and has 
been shown to be extremely radiosensitive. As shown in appendix 3, doses to 
the hippocampus can be significantly reduced with IMRT by specifying this as 
an avoidance structure. However, many other regions of the brain responsible 
for functions such as attention and information processing are likely to be just 
as important as the hippocampus and clinical study with formal 
neuropsychology testing is required to establish whether reducing dose to the 
hippocampus reduces toxicity and if so what the appropriate dose constraint 
should be. Indeed, neuropsychological impairment following brain radiotherapy 
is very poorly characterised and will be significantly influenced by other factors 
such as tumour location, previous surgery, anti-seizure medications and co-
morbidities such as depression. The true incidence and nature of 
neuropsychological impairment following brain radiotherapy have been very 
poorly studied and this should be a priority for future clinical study. 
Strategies to reduce the high baseline level of IOV in meningioma contouring 
identified in Chapter 3 require evaluation. Clinical judgement regarding areas at 
risk appeared to be a significant factor determining IOV and simple clarification 
of the location of meningioma recurrences/ progressions may help to 
standardise physicians’ views on what constitutes the target. Due to the efficacy 
of radiotherapy, multicentre observational/ non-randomised phase 2 studies 
would be required to generate this information. Although I did not find that PET 
information significantly reduced IOV, further work aiming to clarify the 
sensitivity of PET tracers to identify small volume meningioma may improve 
confidence to reduce volumes in relation to PET information. This may make it 
more likely to assist in standardising contours. The most appropriate way of 
studying this would be pathological examination of tissue in patients undergoing 
surgery for meningioma from regions that appear suspicious on pre-operative 
CT/MRI but are PET negative. It would be impractical to attempt biopsy in 
patients undergoing primary radiotherapy.  
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Although I did not find a notable improvement in meningioma plan dosimetry 
with SFUD protons, range uncertainty necessitated optimisation to larger target 
volumes for protons than photons which compromised their potential to improve 
radiotherapy plans. However, in view of the excellent results achievable with 
modern photon techniques, I do not feel that further research into the use of 
protons to treat meningioma is a priority, but more general research into proton 
dose deposition characteristics and biology would allow better exploitation of 
their potential clinical benefit. Development of proton-based imaging is an 
important area of research that is likely to advance our understanding of 
absorbed dose and reduce uncertainties. It is likely that additional avoidance 
structures in the brain will be proposed in the coming years, particularly for 
aspects of higher mental function and it is possible that protons may become a 
useful treatment option if more certainty regarding the location of the Bragg 
Peak can be achieved. 
 
6.5 Conclusion 
 
The likely clinical benefits associated with some advanced radiation techniques 
in meningioma are clear, such as IMRT versus 3DCRT. However, throughout 
this thesis I have found that the theoretical benefits of some technologies do not 
necessarily translate into dosimetric/ clinical improvements in real cases. 
Planning studies and early feasibility assessments are essential to focus 
radiation research in the most appropriate areas and to identify technical 
challenges prior to embarking upon expensive large scale studies or routinely 
introducing complex techniques into clinical practice.  
The RCT is not necessarily the most appropriate form of study for research into 
advanced radiotherapy techniques, particularly for slow-growing tumours like 
meningiomas. Technology develops far faster than results of studies would take 
to mature. However, other carefully planned and executed prospective 
approaches, such as non-randomised observational/ phase II studies, can 
provide strong evidence for the dosimetric advantage, safety and clinical 
effectiveness of new techniques. Radiotherapy confers excellent long term 
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control rates for meningioma and therefore research focused on minimising 
long-term toxicity rates is important. Such studies require a co-ordinated 
multidisciplinary approach both in design and execution.     
A raft of quality assurance procedures to ensure optimum treatment planning 
and delivery has accompanied the implementation of modern highly conformal 
radiation techniques. However, the largest variable influencing outcomes is 
likely to be delineation of the target by the treating clinician. This appears to be 
a particular issue for meningiomas, although it is undoubtedly a feature in many 
other tumour types. Research to establish variables in target definition between 
clinicians and strategies to improve consistency should be seen as a priority to 
allow the theoretical promise of advanced radiation therapies to be translated 
into real clinical benefit.  
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7 Appendices 
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7.1 Appendix 1 EORTC Quality of Life Questionnaires 
 
EORTC QLQ - BN20 © Copyright 1994 EORTC Quality of Life Group 
Patients sometimes report that they have the following symptoms. Please 
indicate the extent to which you have experienced these symptoms or problems 
during the past week. 
______________________________________________________________ 
 
 
 During the past week: Not 
at all 
A 
Little 
Quite a 
bit 
Very 
much 
31 Did you feel uncertain about the future? 1 2 3 4 
32 Did you feel you had setbacks in your condition? 1 2 3 4 
33 Were you concerned about disruption of family life? 1 2 3 4 
34 Did you have headaches? 1 2 3 4 
35 Did your outlook on the future worsen? 1 2 3 4 
36 Did you have double vision? 1 2 3 4 
37 Was your vision blurred? 1 2 3 4 
38 Did you have difficulty reading because of your 
vision? 
1 2 3 4 
39 Did you have seizures? 1 2 3 4 
40 Did you have weakness on one side of your body? 1 2 3 4 
41 Did you have trouble finding the right words to 
express yourself? 
1 2 3 4 
42 Did you have difficulty speaking? 1 2 3 4 
43 Did you have trouble communicating your thoughts? 1 2 3 4 
44 Did you feel drowsy during the daytime? 1 2 3 4 
45 Did you have trouble with your coordination? 1 2 3 4 
46 Did hair loss bother you? 1 2 3 4 
47 Did itching of your skin bother you? 1 2 3 4 
48 Did you have weakness of both legs? 1 2 3 4 
49 Did you feel unsteady on your feet? 1 2 3 4 
50 Did you have trouble controlling your bladder? 1 2 3 4 
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EORTC QLQ-C30 (version 3) 
We are interested in some things about you and your health. Please answer all of the questions 
yourself by circling the number that best applies to you. There are no "right" or "wrong" answers. 
The information that you provide will remain strictly confidential 
  Not at all A little Quite a 
bit 
Very 
much 
1 Do you have any trouble doing strenuous 
activities, like carrying a heavy shopping bag 
or a suitcase? 
1 2 3 4 
2 Do you have any trouble taking a long walk? 1 2 3 4 
3 Do you have any trouble taking a short walk 
outside of the house? 
1 2 3 4 
4 Do you need to stay in bed or a chair during 
the day? 
1 2 3 4 
5 Do you need help with eating, dressing, 
washing yourself or using the toilet? 
1 2 3 4 
      
 During the past week:     
6 Were you limited in doing either your work or 
other daily activities? 
1 2 3 4 
7 Were you limited in pursuing your hobbies or 
other leisure time activities? 
1 2 3 4 
8 Were you short of breath? 1 2 3 4 
9 Have you had pain? 1 2 3 4 
10 Did you need to rest? 1 2 3 4 
11 Have you had trouble sleeping? 1 2 3 4 
12 Have you felt weak? 1 2 3 4 
13 Have you lacked appetite? 1 2 3 4 
14 Have you felt nauseated? 1 2 3 4 
15 Have you vomited? 1 2 3 4 
16 Have you been constipated? 1 2 3 4 
      
 During the past week:     
17 Have you had diarrhoea? 1 2 3 4 
18 Were you tired? 1 2 3 4 
19 Did pain interfere with your daily activities? 1 2 3 4 
20 Have you had difficulty in concentrating on 
things, like reading a newspaper or watching 
television? 
1 2 3 4 
21 Did you feel tense? 1 2 3 4 
22 Did you worry? 1 2 3 4 
23 Did you feel irritable? 1 2 3 4 
24 Did you feel depressed? 1 2 3 4 
25 Have you had difficulty remembering things? 1 2 3 4 
26 Has your physical condition or medical 
treatment interfered with your family life? 
1 2 3 4 
27 Has your physical condition or medical 
treatment interfered with your social 
activities? 
1 2 3 4 
28 Has your physical condition or medical 
treatment caused you financial difficulties? 
1 2 3 4 
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For the following questions please circle the number between 1 and 7 that 
best applies to you 
 
29. How would you rate your overall health during the past week? 
 
1  2  3  4  5  6  7 
Very poor      Excellent 
 
 
 
30. How would you rate your overall quality of life during the past week? 
 
1  2  3  4  5  6  7 
Very poor      Excellent 
 
 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved.  
 
 
  
232 
 
7.2 Appendix 2 EEG Neuropsychology Pilot Substudy  
 
7.2.1 Protocol 
 
Background 
In the standard IMRT Study protocol we now use clinical neuropsychology 
testing to evaluate whether there are any changes in higher mental functions 
such as memory, attention etc. following radiotherapy for meningioma. 
Measuring event related potentials (ERP) with electroencephalogram (EEG) 
recording during neuropsychology testing is a more complex assessment 
protocol for neuropsychology assessment used in research into dementia and 
other cognitive disorders. Many groups have reported that such testing has 
allowed a better understanding of why patients develop deficits and in some 
situations can identify abnormalities before they clinically manifest. More 
information about electrical changes in the brain following radiotherapy would 
permit a better understanding of the cause of any cognitive changes and the 
sensitivity of various brain regions to radiotherapy. Currently there are no 
reports of using such technology to study patients following radiotherapy. 
 
Objectives 
We will carry out a pilot study to establish whether EEG –monitored 
neuropsychology testing is practical for patients undergoing radiotherapy, 
whether patients find the protocol acceptable and how it would best be 
incorporated into the main IMRT study. We will assess what changes are seen 
on the EEG in patients who have neuropsychology test scores that have 
reduced following radiotherapy. 
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Patient Selection Criteria 
Inclusion 
 Patients should already have undergone neuropsychology testing in the 
main IMRT study with scores in any domain below the 50% percentile on 
the most recent test or with a drop of ≥25% from their baseline. 
Exclusion 
 Patients deemed unlikely to be able to participate in the full 2 hour 
assessment. 
 
Patient Numbers 
Five patients will undergo EEG testing to assess the feasibility of testing and 
potential value of including it for other patients. 
 
Withdrawal 
Patients will be free to stop the session and withdraw from the study at any 
point. 
 
Trial Design 
This is a pilot study to evaluate acceptability of EEG neuropsychology testing to 
patients, practical issues regarding the feasibility of carrying out such testing 
and is hypothesis generating in terms of what EEG features may be seen in 
patients following radiotherapy. If this pilot substudy indicates that a larger study 
of EEG testing is warranted then before and after treatment testing may be 
incorporated into the main IMRT study (following study amendment). 
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Interventions 
Patients will have one session of neuropsychology assessment with EEG 
recording. The EEG will be measured using 24 electrodes, which are applied to 
the subject’s scalp by means of an electrode cap. Reference electrodes will be 
placed on the left and right mastoids, and a ground electrode will be placed on 
the sternum. After application of the electrodes, a water soluble electrode paste 
is applied to the electrodes. The application of the electrodes, will take about 30 
minutes in total.  
A variety of neuropsychology tasks relating to different cognitive processes 
will be carried out with EEG recording. These are used frequently in EEG 
studies. The tasks are presented in the visual modality on a computer 
screen which will display varying commands. Patients will respond by 
pressing different computer keys as instructed with either left or right hand 
or with different fingers of the same hand. The following tests will be 
undertaken: 
1. Information processing: S1-S2 Test (stimulus/ response) 
2. Memory processes: Relational and Item Specific Encoding Task 
3. Response related information processing: Eriksen Flanker Task 
A mental fatigue and patient opinion questionnaire will be completed at the 
end of the session. 
Total testing time will be around two hours (including short rest periods).  
 
Criteria of Evaluation 
Behaviour analysis  
During the experiment, computer key presses of the subject will be recorded. 
Average response accuracy and reaction times will be used as a measure of 
performance during each task. 
EEG analysis  
EEG analyses will be performed, using Vision Analyzer (Brain Products GmbH).  
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Statistical Considerations 
Behavioural data will be analysed using repeated measures ANOVA. Analyses 
will be performed using SPSS. The univariate approach for repeated measures 
will be used. Mean amplitudes will be entered as dependent variables into 
SPSS. In the ERP analyses, erroneous responses will be rejected from the 
analyses. 
 
Ethical Issues 
The substudy will be conducted in accordance with the declaration of Helsinki. 
A patient information sheet specific to the substudy will be given to the patient. 
The patients are already enrolled in the main IMRT study so that information 
sheet will not be given again.  Any questions arising from the patient information 
sheet will be discussed before the patient gives written informed consent to be 
entered into the substudy. GPs of patients that have consented should be 
informed in writing. 
 
 
 
 
7.2.2 Analysis 
Five patients took part in the substudy. Feasibility data was obtained. All 
patients completed the tasks, but found them onerous and tiring. They would 
not have been willing to undertake such assessment on a regular basis. The 
results could not be further analysed due to technical issues. 
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7.3 Appendix 3: Can doses to the hippocampus be 
reduced for patients treated with IMRT for 
meningioma? SGDMLC IMRT versus VMAT  
 
Background 
Preclinical evidence suggests that radiation dose to neurogenic stem cells in the 
hippocampus is central to radiation-induced memory impairment [424, 425]. 
Recently, preliminary work has postulated that a dose of >7.3Gy (EQD2) to 
40% of the bilateral hippocampus (D40) is a predictor of memory impairment 
[345]. Such effects are particularly significant in patients with benign histology, 
such as meningiomas. One of the main benefits of IMRT is that dose to specific 
OARs can be reduced compared to older radiation delivery methods. The OAR 
maximum dose has to be specified in the IMRT optimiser at the start of 
planning. Standard OARs in the brain where optimiser limits are set are the 
optic structures and brainstem. However, the use of IMRT may permit reduced 
dose to other OARs, including regions responsible for higher mental functions. 
VMAT is increasingly favoured as the method of IMRT delivery, mainly due to 
its efficiency. However, it is unclear whether static gantry dynamic MLC IMRT 
(SG DMLC) where the field position can be manipulated or VMAT would offer 
the best hippocampal sparing or how low the dose to the hippocampi could be 
kept. I therefore explored the feasibility of reducing doses to the hippocampi 
using IMRT and VMAT.  
 
Aim 
Preliminary study of the ability of SG DMLC IMRT and VMAT to reduce dose to 
the hippocampi. 
 
Methods 
Five meningioma cases from the IMRT study described in chapter 2 were 
replanned with the addition of specific hippocampus dose constraints. Tumours 
in varying locations were specifically chosen. Two tumours were anterior, two 
central and one posterior. All planning was performed using Eclipse Treatment 
Planning System (Varian). The original IMRT plans had been delivered with a 
SG DMLC technique and had been optimised for PTV coverage with limitation 
of dose to optic structures and brainstem. The prescribed dose to PTV was 
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50.4Gy in 28#. Hippocampi were contoured on co-registered MRI according to 
the guidelines by Chera et al [426] (although MRI slice thickness was 3mm). No 
attempt had been made to spare the hippocampus. IMRT plans were re-
optimised and VMAT plans created aiming to reduce mean hippocampi dose 
with a bilateral D40% ≤12Gy (equivalent to ≤7.29Gy in 2Gy #, α/β=2) whilst 
meeting the original plan objectives (specified in section 2.3.2).   
 
Results 
It was possible to reduce the dose to the hippocampi in all cases whilst 
remaining within the other standard dose constraints. The mean bilateral 
hippocampal dose with was 21.5Gy (range: 17.8-26Gy) with original SGDMLC 
IMRT; 14.3Gy (range 10.5-19.3Gy) with optimised SG DMLC IMRT and 9.8Gy 
(range 5.8-13.7Gy) with optimised VMAT. 
 
None of the original non-optimised SGDMLC plans met the proposed bilateral 
hippocampi constraint of D40% of ≤12Gy. This constraint was met by four of the 
VMAT plans (13.1Gy for the other) and one of the optimised SG DMLC IMRT 
plans.  
 
Compared to the original SGDMLC IMRT plan the bilateral hippocampi D40% 
was reduced by 26-54% (mean 39% reduction) for the optimised IMRT plan and 
53-77% (mean 64% reduction) in the VMAT plan.  
 
These doses were achieved without significant changes in PTV coverage or 
dose to OAR (increase in lens dose in one patient with VMAT). Hippocampal 
doses were higher for central lesions. The mean doses to the hippocampus and 
brain-PTV are shown in figure 7.1. The dose distributions for each patient are 
shown in figure 7.2. 
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Figure 7-1 Mean doses to the bilateral hippocampus and whole brain-PTV 
comparing the original SG DMLC plan to the SG DMLC optimised for the 
hippocampi and the optimised VMAT plan 
 
Conclusions 
Doses to the hippocampi can be significantly reduced for meningioma patients 
by optimising for this structure in the treatment planning process. VMAT delivery 
appears more effective at reducing hippocampal dose than SGDMLC IMRT. 
The clinical impact of hippocampal dose reduction should be evaluated within 
prospective studies.  
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Figure 7-2 Axial CT slices of 5 meningioma cases comparing hippocampal dose 
distribution: original SGDMLC IMRT plan (not optimised for hippocampus), versus 
reoptimised SGDMLC IMRT plan versus optimised VMAT plan. PTV in red. 
Hippocampus in green. Doses >12Gy visible in colour wash. 
  
Patient 1 
Patient 2 
Patient 3 
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Figure 7.2 continued 
 
 
 
 
 
 
 
Patient 4 
Patient 5 
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7.4 Appendix 4: Local Baseline Evaluation of 
Meningioma Recurrence Rate and Target Volume 
Definition 
 
Aims 
1. To establish my institutions rate of meningioma progression following 
EBRT and the percentage of central versus marginal recurrences. 
2. To establish the interobserver variability (IOV) in meningioma target 
volume definition at the institution. 
3. To make a preliminary assessment of whether the addition of 68Gallium-
DOTATATE PET/CT information alters target volume definition  
 
Materials and Methods 
Recurrences 
I performed a retrospective evaluation of the location of meningioma 
progression in patients treated with radiotherapy since 2004 when co-
registration of MRI to planning CT became standard. All appropriate patients 
were identified on the ARIA radiotherapy management system. Confirmation of 
diagnosis and information regarding subsequent relevant clinical history was 
accessed on the institution’s clinical document database. Demographic 
information and radiotherapy details were recorded for patients with disease 
progression and their radiotherapy target volumes  accessed on the Oncentra 
planning system. MRI scans from the time of recurrence were co-registered to 
the original planning images and site of recurrence analysed. Progression/ 
recurrences clearly originating within the original CTV were deemed “central” 
and those outwith the CTV “marginal.” Dose distributions were reviewed. 
 
Baseline IOV in target definition 
Ten patients from the IMRT study planned by the same observer were selected 
(Observer A). GTV, CTV and PTV were delineated by Observer B (without 
reference to Observer A’s volumes). Both observers were clinical oncologists 
certified by the Royal College of Radiologists and with an interest in 
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neurooncology. Departmental guidelines for meningioma delineation were 
followed by both observers as per Chapter 3.  
Absolute volumes for each observer and percentage difference between 
observers were measured and displayed on Bland Altman plots showing mean 
difference in agreement and 95% limits of agreement (+/- 1.96 SD). Spearman’s 
correlation coefficient was calculated as other papers assessing IOV have 
reported this statistic [294]. The conformity level (CL) (Jaccard coefficient) was 
calculated to reflect the volume of intersection in contours (figure 3.4).  
It could be argued that only differences in GTV need be measured, but 
differences in GTV, CTV and PTV were all evaluated at this stage to explore 
whether the addition of CTV and PTV margins negates the clinical impact of 
GTV differences.   
 
Does 68Ga-DOTATATE PET/CT information change target volume definition? 
Three patients due for meningioma IMRT underwent a 68Ga-DOTATATE 
PET/CT in addition to planning CT and MRI (with institutional board approval). 
In two patients this was because it was not clear whether extensive base of 
skull abnormalities on CT/MRI represented tumour or post-operative change. 
The other patient had clinical features suggestive of progression of ONSM but 
minimal visible tumour on MRI/CT. Patients underwent planning CT scan in the 
PET/CT scanner as described in Chapter 3. A nuclear medicine physician 
contoured the BTV (Advantage Windows GE workstation). MRI was available 
on an adjacent screen (co-registration not possible). The BTV contour was 
transferred to Oncentra for radiotherapy target volume contouring with co-
registered MRI.  GTV1 was contoured by Observer A using CT/MRI, followed by 
GTV2 formed from a composite of GTV1 and BTV. Absolute volumes, 
percentage differences, volume of intersection and percentage of BTV not 
covered by GTV1 were analysed.  
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Results 
Recurrences 
90 patients were treated with radiotherapy for meningioma from 2004-2012. 
Eleven patients developed PD. Patient characteristics are detailed in table 7.1. 
Another patient developed progression of a separate meningioma (not 
included). Eight patients with PD progression had non-benign disease (73% of 
PD). All patients underwent radiotherapy following previous surgery. Median 
time until progression was 24 months. Three patients had recurrences that were 
clearly marginal as there was a space between new tumour and original CTV. 
There was clear central progression in five patients who had general expansion 
in the whole tumour volume. In three patients it was difficult to differentiate 
whether the progression was central or whether tumour had grown inward from 
the CTV margin and coalesced with the treated tumour.  Of the three patients 
with benign disease who progressed, one recurrence was clearly central, one 
clearly marginal and one unclear.  All patients had adequate target coverage 
(>95% receiving 95% of dose). 
Baseline IOV in target definition 
The absolute volumes for the contours drawn for Observer A and B and the 
volume of intersection (IS) are detailed in table 7.2. In general Observer B drew 
larger contours. Table 7.3 details the absolute GTV and CTV between 
observers in relation to the volume of intersection between the two observers. 
The level of agreement between observers in absolute volumes (GTV) and % 
volumes (GTV and CTV) compared to the mean is depicted in the Bland Altman 
plot (figure 7.3). The mean difference in GTV was -9.6% (observer A was 9.6% 
smaller) with a 95% limit of agreement of -57.3 to 38% (mean +/- 1.96 SD). 
Similar differences were noted with CTV (mean -15.3%, 95% limit of agreement 
-50 to 19.3%). Spearman’s correlation coefficient between observers was 
r=0.976 (p<0.0001) suggesting that this measure is not very informative (it is 
very likely that volumes will correlate in size). 
The CL for GTV, CTV and PTV are shown in table 7.3. The median CL for GTV 
was 0.66 (range 0.47-0.82); CTV 0.67 (range 0.56-0.77); PTV 0.735 (0.63-
0.82). The region of discord between observers mainly concerned inclusion/ 
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exclusion of bone and dural tail (although dural tail comprised little percentage 
volume). 
 
Table 7-1 Characteristics of patients with PD following radical RT 
Variable Characteristic 
Sex Male: 9 
Female: 2 
Age at RT Median 64.5 yrs (range 46-77) 
Median Volume (cc) GTV: 64cc (range 23-106) 
CTV: 90cc (range 23-208) 
Histological Grade at RT 
  
WHO G1: 3 
WHO G2: 6 
WHO G3: 2  
Note: 3 patients with G2 disease at 
time of RT had G3 disease at 
recurrence 
Radiotherapy Setting 
 
Primary: 0 
Following STR: 7 
Following GTR: 4 
Recurrences Prior to RT  
 
0: 6 
1: 4 
>1: 1 
RT technique: 
 
3DCRT: 4 
IMRT: 7 
Dose 50.4Gy: 10 
60Gy: 1 
Region of PD Skull base: 2 
Frontal: 3 
Parasagittal: 4 
Occiput: 2 
Time from RT until PD Median 24 months (range 3-70 
months) 
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Table 7-2 Absolute volumes of contours by observer A and B (in cc) and % difference (- sign indicates Observer A smaller than 
B).  
IS = intersection 
 
Patient GTV A GTV B GTV 
IS 
CTV A CTV B CTV 
IS 
PTV A PTV B PTV 
IS 
     % Difference A versus B 
GTV              CTV              PTV 
1 41.7 73 41.1 47.9 73.6 44.2 118.3 159.1 111.6 -75.1 -53.7 -34.5 
2 9.4 9.4 8.3 11.2 13 10.1 41.1 45.1 37.1 0 -16.1 -9.7 
3 28.5 31.1 23.8 39.7 41.5 34.4 100.3 110.6 92.9 -9.1 -4.5 -10.2 
4 139.7 200.5 133.2 175 236.2 161.4 352.2 449.6 313.4 -43.5 -35 -27.7 
5 10.3 7.9 6.9 16.6 16.1 12.1 61.1 52.4 45.4 23.3 3 14.2 
6 24.8 34.8 23.7 34.1 49.7 32.3 84.4 114 80.9 -40.3 -45.7 -35.1 
7 81 82.4 69 186.3 179.9 159.7 315.5 302.6 275 -1.7 3.44 4.1 
8 21 20.6 13.2 81.2 83.3 71.7 157.1 153.3 139.5 1.9 -2.6 -2.4 
9 20.5 18.6 13.3 33.5 44.6 28.1 90.1 109.5 77.1 9.3 -33.1 -10.4 
10 14.9 14.9 12.2 14.9 14.9 12.2 39.3 41.8 33.8 0 0 8.9 
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Figure 7-3 Bland Altman Plots of (top) % volume differences GTV, (bottom) % 
volume differences in CTV between Observers A and B 
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Table 7-3 Conformity Level (CL) between Observers 
 
Patient GTV 
CL 
CTV 
CL 
PTV 
CL 
1 0.56 0.57 0.67 
2 0.79 0.72 0.75 
3 0.66 0.74 0.79 
4 0.64 0.65 0.64 
5 0.61 0.59 0.78 
6 0.66 0.63 0.69 
7 0.82 0.77 0.8 
8 0.47 0.77 0.82 
9 0.75 0.56 0.63 
10 0.69 0.69 0.72 
Median 
Mean 
0.66 
0.67 
0.67 
0.67 
0.74 
0.73 
 
Can 68Ga-DOTATATE PET/CT information change target volume definition? 
BTV was smaller than GTV1 in two patients and larger in one (figure 7.4). 
 
Figure 7-4 GTV with and without PET (Observer A only) 
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Conclusions 
In my institution: 
1. At least 12% of patients treated with radiotherapy for meningioma 
experienced PD (with CT/MRI defined target volumes). The figure is 
likely to be higher due to short follow-up in some patients. 27% were 
clearly marginal recurrences. 
2. There is considerable IOV in target definition of meningiomas despite the 
use of a defined protocol (approx. 65% conformity). Bone is a main area 
of contention. The difference is maintained between GTV and CTV, but 
the addition of volumetric standard PTV margin reduces the IOV. 
3. The use of 68Ga-DOTATATE PET altered target definition in the small 
group of patients studied (substantial changes in 2/3). All regions 
suspicious for disease on CT/MRI are not positive on PET and vice 
versa. 
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7.5 Appendix 5: PET MRI of meningiomas for 
radiotherapy planning Work Instruction 
 
SCOPE 
This document includes all protocols and work instructions to facilitate the 
scanning of head patients in their treatment position on the PET MRI scanner in 
the Macmillan Cancer Centre. 
 
INTRODUCTION 
MRI is being increasingly used in oncology for staging, assessing tumour 
response and also for treatment planning in radiotherapy. Intensity-modulated 
radiotherapy requires improved means of defining target volumes for treatment 
planning in order to achieve its intended benefits. Ga68 DOTATATE PET 
scanning identifies meningiomas by binding to somatostatin receptors and when 
combined with simultaneous MRI may add to the radiotherapy treatment 
planning process by providing improved characterization of tumours. 
 
PET MRI LOCATION & CONTACT DETAILS  
 The  PET MRI is in the basement of the Macmillan Cancer Centre 
 Extension number - 76826 
 Bookings contact - Take form directly to PET MRI radiographer 
 PET MRI superintendent – Celia O’Meara 
 Nuclear Medicine Radiologist - Dr Jamshed Bomanji– email from global 
address book 
 Radiologist - Dr Irfan Kayani – email from global address book 
 Nuclear Medicine Physics – John Dickson – email from global address 
book 
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RADIOTHERAPY PLANNING RADIOGRAPHER’S AND CLINICIANS 
CONTACT DETAILS 
 
 Radiotherapy Planning – Bleep 1127, Ext 73789/73750/73751. Lead 
Planning Superintendent Kevin Sullivan 
 Dr Jillian Maclean – email from global address book 
 Dr Naomi Fersht - email from global address book 
 Radiotherapy Physics – Chris Stacey ext 4955 
 
MRI CONSIDERATIONS FOR STAFF 
 All radiotherapy radiographers that enter the PET MRI scanner room 
must have completed a MRI screening questionnaire before attendance 
and have shown it to a MRI radiographer 
 All staff entering the MRI scanner must remove all pocket contents and 
ensure that they are wearing no metal accessories e.g. hair clips. 
 
PET CONSIDERATIONS FOR STAFF 
 No pregnant staff should accompany the patient to PET-MR. 
 All staff working with the radioactive patient must limit their time and 
increase their distance when in the scan room. 
 
SCANNING A PATIENT IN PET-MRI  
PET 
The isotope used is Gallium68 which has a half life of 68 minutes. The 
patient will be injected with this prior to their MRI scan without the shell on. 
The uptake time of Ga68 is 45 minutes.  
MRI (no shell) 
 The patient will undergo a research MR protocol of approximately 45 
minutes immediately following the administration of Gallium
68
.  
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 The sequences within this protocol are as follows: 
 Axial T2,3 B value Diffusion, 3D SWI (susceptibility weighted imaging), 
multi high B value diffusion, Sagittal 3D FLAIR.  
 
MRI (with shell) 
 The patient will then be taken off the scanner and the MRI compatible 
baseboard will be placed on the couch. The MRI compatible baseboard 
is kept in the MRI scanner on P2.  
 The baseboard rests on the rails of the couch. Ensure that the spine coils 
are placed underneath the baseboard and that the baseboard is in a 
suitable position for the coils. 
 Planning radiographer to position the patient on the MRI couch as per 
set-up instruction in treatment card.   
 Position bridge device over the patient in their shell and place body coil 
over the bridge using the velcro attachments. 
 
  
 
 MRI radiographers will select the Radiotherapy Brain MRI protocol.   
This will include: 
Localiser, MRAC, T1MPRAGE Sagittal pre contrast, dynamic 
contrast, T1 MPRAGE post contrast, UTE. 
 A simultaneous 15 minute PET acquisition will be acquired at this time. 
 The patient will then be taken directly to PET/CT and scanned as per 
work instruction 9.1 without any further tracer injection. 
252 
 
PATIENT CONSIDERATIONS 
 The MRI radiographer’s will complete a MRI screening questionnaire to 
ensure patient is eligible for MRI scanning. 
 
PATIENT PATHWAY 
 Radiotherapy booking form is submitted by the clinical oncologist 
requesting PET MRI planning.  
 RT bookings clerk will book the RT as per protocol. Patient to be 
informed that appointment could take up to 4 hours. 
 MRI screening questionnaire to be completed for the patient. 
 Planning radiographer to position the patient on the MRI couch with the 
MRI radiographers. 
 
IMAGE REGISTRATION  
As per WI 9.1.13 
 
VOLUME DELINEATION  
Nuclear Medicine Physician 
BTV 
PET positive region on PET/CT and PET/MRI 
Clinical Oncology Physician 
For the first 10 patients who undergo PET/MRI, volumes should be drawn 
with and without PET information to allow us to evaluate the extent of 
change in volumes with the addition of PET information. 
DO NOT LOOK AT PET BTV. GTV1 and CTV1 to be drawn using CT/MRI 
information only. 
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Volumes to be drawn on planning CT fused with postoperative MRI (T1 plus 
Gadolinium axial, sagittal and coronal views as required). Fused pre-
operative MRI may help to differentiate post-operative changes from tumour. 
Non-enhanced T1 images can be fused if required. Hyperostotic bone 
present on pre-operative CT should be included. Hyperostotic bone from 
planning CT should be included if there is no pre-operative CT. 
 
GTV1 
Residual Disease: 
 GTV is residual meningioma, hyperostotic bone and dural extension. 
 
No Residual Disease: 
 GTV equivalent = Use pre-operative MRI to define largest extent of 
dural/bone thickening and the tumour bed if there was brain invasion 
 
CTV1 
Residual Disease: 
 Add 1cm in plane of dura for CTV 
 Add 1cm into brain at brain/meningioma margin in presence of brain 
invasion 
 Add 1cm into bone where bone invasion/thickening 
 
No Residual Disease: 
 Add 1cm in the plane of the dura  
 If documented brain invasion add 1cm into brain from tumour bed  
 
GTV2 AND CTV2 TO BE DRAWN USING BOTH PET AND MRI/CT DATA 
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GTV2 
 BTV + GTV1. If GTV1 is larger than BTV re-evaluate whether such 
regions should be included in GTV2 – clinicians decision 
 
CTV2 
 GTV2 + 1cm in plane of dura  
      1cm into brain at brain/meningioma margin in presence of brain invasion 
      1cm into bone where bone invasion/thickening 
 
Where hyperostotic bone is included in GTV2 but not within BTV (PET 
negative), CTV2 should include the PET negative hyperostotic bone with no 
additional margin (because no gross disease in bone if negative on PET). 
 
PTV  
 CTV2 + 3mm  (no additional margin required for CT/MRI/ PET fusion) 
 
Note: Only one PTV is formed (from combined PET/ MRI/ CT data) and patient 
will be treated using this. DO NOT USE CTV1 TO FORM PTV PRIOR TO 
PATIENTS TREATMENT AS THIS MAY LEAD TO CONFUSION FOR 
PLANNERS. 
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